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ABSTRACTS 
ABNORMAL REGULATION OF TGFB EXPRESSION BY PERIPHERAL BLOOD LYMPHOID CELLS IN PATIENTS WITH 
SCLERODERMA. G. Aichinger'. M. Gruschwitzl. G. Bockl, N. Seop+, G. Wickl. Dept. of Internal Medicine', Dept. of Dermalology+, 
and Inslitute for General and Experimental Pathology!, University of Innsbruck, Innsbruck, AusVia 
It has been hypothesized that cellagen and proteoglycan synthesis in scleroderma is driven by cytokines produced by 
inflammatory cells accummulating in the perivascular area. TGF has been shown to stimulate cellagen and proteoglycan synthesis 
and to inhibit epithelial cell growth in vitro. Theretore, we were interested in studying the expression of TGFB by unstimulated and 
PHA activated peripheral blood lymphocytes (PBL) from patients with scleroderma and healthy blood donors. For that purpose, 
unstimulated and PHA activated PBL from 5 patients with scleroderma and 5 healthy donors were double stained tor the ceex-
preSSion of TGFB with T cell antigens, activation and monocyte markers. Phyceerythrin cenjugated monoclonal antibodies (Leu 2a, 
Leu 3a, anti-HLA-DR, anti IL-2 receptor, and Leu M3, Becton Dickinson) and a polyclonal rabbit anti TGFB antiserum (British 
Biotechnology) were used in direct and indirect immunofluorescence. The results obtained by flow cytometric analysis were 
expressed as per cent positive cells. The following results were obtained: 1. In centrast to our findings in healthy centrols, which 
showed a decrease of TGFB positive cells after mitogene exposure, 25.6 vs. I 1.6 %. Such a reduction was not observed with PBL of 
patients with scleroderma, 17.6 vs. 19.4 %. 2. TGFB expression was increased predominantly in the activated HLA-DR and IL-2 
receptor, CD4 or CD8 positive cell population from patients with scleroderma after PHA stimulation. Although this effect was also 
seen in PBL from healthy donors it was significantly lower. 3. Monocytes in both groups showed a high percentage of TGFB ex-
pression. 4. No difference in the distribution of T cell subpopulations and the expression of activation markers, HLA-DR and IL-2 
receptor, was noticed between unstimulated PBL from patients and centrols. In cenclusion, the results of our studies indicate an 
abnormal regulation 01 TGFB expression in peripheral blood T cells from patients with scleroderma. Furthermore, our tindings 
provide indirect evidence for a pathogenetic role of TGFB in this disease, possibly related to immunologicaf abnormalilies and 
disturbed cennective tissue melabolism, This study was supported by the Austrian Research Council (Proj. S4 105). 
TNFALPHA LEVELS IN CUTANEOUS LEISHMANIASIS. H.S.Z. Aksu' , H.R. Memisoglu", M. GaWk", A. Acar", 'Departmenl of 
Infeclious Disease, "Departmenl of Dermatology, t;:ukurova University, School of Medicine, Adana, Turkey 
Serum TNFALPHA (cachectine) levels were measured in 23 patients with cutaneous leishmaniasis (CL) and in 13 healthy 
centrols. All of patients had active culaneous lesions. Blood samples were cellected from the patients before therapy adminislration. 
Human TNFALPHA is a polypeptide hormone (cytokine) mainly produced by macrophages. High cencentrations of TNFALPHA are 
linked to various toxic manifestations ot infections, neoplastic, or autoimmune disease. TNFALPHA levels were found in patients with 
visceral leishmaniasis in previous studies. Our patient group represents the first study of TNFALPHA levels in CL. Since TNFALPHA 
is known to have toxic effects on parasites, it might playa pathogenic role in CL. TNFALPHA levels in patients with CL (mean value 
= 19.21 +/- 17.41 pglml , median = 18.5 pglml) were found to be significantly higher than that of centrols (mean value = 9,64 +/- 2.76 
pglml, median = 1 f.O pglml), p < 0.0006. In cenclusion, elevatio~ of TNFALPHA levels in CL could be due to active infection. Further 
studies, such as effect of treatment of CL on TNFALPHA levels should also be considered. TNFALPHA levels may also be of 
therapeutic significance in CL. 
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INTRALESIONAL 1 HUMAN LEUKOCYTE INTERFERON TREATMENT IN THE EUROPEAN KAPOSI'S SARCOMA. M. Alecu. G. 
Ghyka. F. Halalau. A. Calugaru. G. Coman; Berceni Hospital for Dennatology, Bucharest, Romania 
Eight patients with European Kaposi'S sarcoma have been treated by intra- and peri-tumoral injections 01 human alfa 
leukocyte interteron 50,000 IU per dosis, twice a week during 7 - 8 weeks. The treated tumors were clinically followed-up in 
comparison with similar non-treated nodes and the after-treatment biopsies of the treated as well as untreated nodes have been 
histologically examined for each patient. In the treated nodes the skin colour changed to brown (BIB cases), the consistency 
decreased (818), the tumor thickness decreased (5/8) and the surface of the lesions diminished (3/8 cases). Histologically, the typica, 
Kaposi aspect totally disappeared (218 cases), fibrosclerous modifICations were obvious (3 /8) and abundant lymphocyte infiltrations 
were observed (618) in the interferon treated nodes. None of these modifications were observed in the untreated tumors. Noteworthy, 
the interferon inoculated nodes were gradually cured even in four cases where some other tumors progressed or even new lesions 
appeared during the treatment. 
IMMUNOPHENOTYPIC ALTERATIONS INDUCED BY IMMUNE INTERFERON IN HUMAN SKIN. M.J. Allen, J.N.W.N_ Barker, D.M. 
MacDonald, Laboratory of Applied Dermatopathology, Guy's Hospital, London, U.K. 
The inflammatory dennatoses are characterized by a dennal infiltrate rich in T lymphocytes. These cells produce the 
immunomodulatory cytokine interieron-gamma (IFN-y) which, in turn, is thought to be responsible lor manyol the 
immunopathOlogical features observed in these disorders. The precise effects of IFN-y on nonnal skin in vivo, are, however, 
unknown. Adult male volunteers received intradennal recombinant IFN-y (Biogen Inc.) to a total dose 01 30 ug (n=9) over 3 
consecutive days. Biopsy was obtained on day S and snap Irozen. 5 um cryostat sections were cut and incubated with a panet of 
monoclonal antibodies to a range of surtace detenninants. Positive labelling was visualized by the sensitive peroxidase 
antiporoxidase assay. IFN-y produced a significant perivascular lymphocytic infiltrate with the ratio of helper to suppressor cells of 
3: t . Overlying the dennal infiltrate keratinocytes expressed HLA-DR in all cases studied and HLA-DP in 3 cases. HLA-DO was not 
observed. IFN-y also induced keratinocyte expression of intercellular adhesion molecule-t (ICAM-t ) with LFA-l+ve (CDlla+ve, 
CD1B+ve) lymphocytes present along the basement membrane zone, suggesting adherence to basal keratinocytes. Epidermal 
OKTS+ve Langerhans cells were markedly reduced by IFN-y while OKT6+ve cells appeared within the dermal infiltrate. Langerhans 
cells expressed CD18 weakly in control specimens with absent COIl a, but after IFN·y both were positively expressed. Our studies 
demonstrate that IFN-y induces many of the immunophenotypic changes observed in inflammatory cutaneous disease, implying that 
it may be an important mediator in the pathogenesis of these discrders. Furthermore, its marked effects on epidermal adhesion 
molecule expression suggests that IFN-y is important in the regulation of keratinocyteAymphocyte and keratinocyte/Langerhans cell 
interactions, in vivo. 
ALPHA 2 INTERFERONS IN METASTASES OF MALIGNANT MELANOMA. St. Antonescu, I. Nedelcu, Dept. of Dennatology, 
Central Hospital, Bucharest, Romania 
Recombinant alpha 2 interferons were used in the treatment of 5 patients, i.e. 3 women and 2 men, with malignant 
melanoma of Clark level IV on the thorax. 4 patients had ganglionic and 3 cases local metastases. The patients received either rlFN 
a1pha-2a - 9 million IUldail y s.c. was administered. Metastases regressed in volume within 20 - 120 days, but the progression of the 
disease was not brought under control: 3 patients died 30 - 270 days after start of therapy due to mesenteric metastases with an 
occlusive syndrome and generalized cerebral and pleuropulmonary or visceral metastases. All patients had flu-like symptoms, the 
severity of which depended on the interferon-dosage and route of administration. Discrete areas of liver cell destruction were 
observed in 1 subject. Leucopenia and an increase of NK cell activity were observed in 3 patients. When given at an advanced stage 
of the disease, after the development of metastases, recombinant alpha 2 interferon reduced the volume of the metastases but did 
not prevent the spread of the disease and did not prolong the patienfs survival time. 
BCG-STIMULATED LYMPHOCYTES INDUCE MICROVASCULAR ENDOTHELIAL CELL INJURY BY lAK ACTIVITY. T. Asai', M. 
Masuzawa", K. Nishioka' and S. Nishiyama', Dept. of Dennatology, 'Kitasato University School of Medicine and "The Kitasato 
Institute Medical Center Hospital, 'Kanagawa and "Saitama, Japan. 
Varying numbers of lymphocytes infiltrate around the damaged microvascular vessels in many skin diseases. In the 
present study we demonstrate the cytolytic activity of antigen-stimulated lymphocytes against human dennal microvascular 
endothelial celis (DMECs) in vitro. Lymphocytes as effector cells were obtained Irom PPD-positive healthy volunteers and cultured 
for five days with respective concentration of BCG of recombinant interleukin-2 (rIL-2) (TGP-3, Takede-chemical industries, LTD, 
Osaka). They reacted to 51 Cr labeled DMECs and also to Daudi cells for assay of LAK activity. Cytolytic injury was assessed by 
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51Cr release. BCG-stimulated lymphocytes as well as r1L-2 stimulated lymphocytes induced lysis of DMECs, and they also had 
cytolytic activity to kill Daudi cells. The maximal cytolytic activity was achieved by the lymphocytes stimulated with 0.1 mgtml BCG. 
These results suggest that the optimum concentration of BCG can induce LAK activity on lymphocytes of PPD-positive population 
and thus induced LAK cells can injure DMECs. We supposed that endogenous IL·2 from antigen-stimulated lymphocytes plays an 
important role to promote appearance of LAK cells to damage microvascular vessels in allergic inflammatory skin diseases. 
CLINICAL IMMUNOPATHOLOGY OF PORPHYRIA CUTANEA TARDA. N.S. Asfandijarova, Ch.Ch. Mansurov, G.K. Mirodzov, 
T.Ch. Rasulova, M.A. Manijazova, L.I. Tkalicheva, Institute of Gastroenterology, Dushanbe, Soviet Union. 
In order 10 detect the causes of liver lesions in porphyria cutanea tarda we examined 53 patients with alcohol liver 
diseases: liver cirrhosis in 32 (3 with acute alcohol hepatitis), acute alcohol hepatitis in 6, steatofibrosis or haemosiderosis in 15. 
Immune status characterized the peripheral blood lymphocytes response degree to PHA, liver specific lipopritein, HBSAg, and 
functional activity of shortliving suppressor cells (3H-thymidine incorporation). Porphyrin exchange disorder (porphyrin accumulation 
in hepatocytes, coproporphyrinuria, uroporphyrinuria) was detected in 17 patients. Porphyria cutanea tarda was noted in 10 patients, 
liver cirrhosis in all, but one. Comparative analysis of immune system indices let us detect the reduction of proliferative activity in re-
sponse to PHA, disorder in function of shortliving suppressor cells, lymphocyte sensibilization to liver specific lipoprotein in 
porphyrine exchange disorder, that indicates an obvious role of autoimmune reactions in the development of pathological process in 
liver tissue in patients with porphyria cutanea tarda. Conclusions: Porphyrins equally with alcohol may lead to development of liver 
cirrhosis in patients with porphyria cutanea tarda as a result of autoimmune reactions inductions. 
ANTITUMORAL ACTION OF INTERFERONS. F.R. Balkwill, Imperial Cancer Research Fund, London, U.K. 
Interierons, IFNs, were the first cytokines to be tested as cancer therapy. Purified cell derived or recombinantlFN-ALPHA 
has been used extensively in phase 1/11 clinical trials over the past 10 years. Low dose IFN-ALPHA therapy induces partial or 
complete remissions in a majority of patients with hairy cell leukemia, chronic myelogenous leukemia and is also useful in some 
patients with myeloma, lymphoma, carcinoid and Kaposi's sarcoma. A minority, approximately (5-25 %), of melanoma patients 
achieve a partial or complete response although response rates are higher with local therapy. Intralesional IFN-ALPHA has been 
reported to be effective in treatmenl of large basal cell carcinomas where surgery of radiotherapy is not possible. Trials with the other 
2 IFN types, B & y, have not been so extensive. IFNs ALPHA, B. and yare members of the cytokine family of pleiotropic protein cell 
regulators. Their antitumor action could be due to a number of different mechanisms. In some human and experimental cancers IFN-
ALPHAs appear to be directly cytostatic for the tumour cells possibly replacing defective negative regulation of growth. IFNs could 
also act by stimulation of host responses to the tumours, or by perturbing the host tumour relationship by some non-immune 
mechanism. Further progress in the use of IFNs and other cytokines in cancer therapy will depend on a more complete 
understanding of their mechanisms of action, and understanding alterations in the production of peptide cell regulators during the 
malignant process. 
ANTITUMOR EFFECTS OF NATURAL AND RECOMBINANT INTERFERONS ON TRANSFORMED HUMAN KERATINOCYTES. 
C. Bangemann, R. Stadler; Dept. of Denmatology, University Medical Center Steglitz, The Free University of Berlin, Bertin (West), FR 
Genmany 
The aim of this study was to investigate the antitumor effect of interierons (IFNs), which are partly based on the immune 
system. HaCaT cells (kindly donated by Boukamp, DKFZ, Heidelberg). a spontaneously transfonmed human keratinocyte cell line, 
were cultured in DMEM and treated for 1 - 7 days with 10 - 5000 IUlml natural and recombinant interieron alpha, beta and gamma. 
Cell prolileration was detenmined by cell counting, 3H-thymidine incorporation and DNA content. The expression of class II antigens, 
transferrin receptor and ICAM-l was examined after treatment with the 25% and 50% inhibitory dose of IFNs by the APAAP method 
according to Cordell. The inhibition of cell proliferation of all IFNs was dose and time dependent. 50% inhibition was found at a dose 
of 100 IU/ml for IFN-y, 500 IU/ml for IFN-B and a dose of 100 IUIlnI for IFN-ALPHA. HLA-DR expression was induced by allIFNs, 
however, the number of positive stained cells was 2 - 3 times higher with IFN-y than with alpha and beta IFN. HLA-DQ and -DP 
showed minimal expression under IFN-y treatment, while ICAM-t was induced on 50 - 60% of the transfonmed keratinocytes. There 
was no significant change of transferrin receptor induction by all interferons. After 4 hrs respectively 6 hrs of IFN-y treatment HaCaTs 
expressed ICAM-l at a minimal dose of 25 IU/ml. This effect was reversible within 24 hours after removal of the drug. HLA-DR was 
not expressed before 24 hours. Reversibility was observed 72 hours after cessation of the drug. In conclusion, IFN-y is playing an 
important role in tumor immunology including inhibition of cell growth as well as induction of cell surface antigens. A remarkable fact 
is ihatthe concentration necessary for induction of HLA-DR and ICAM-l represents only 50 % of the minimal growth inhibitory dose. 
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REGULATION OF KERATINOCYTE-DERIVED MONOCYTE AND T CELL CHEMOTACTIC FACTORS BY GAMMA INTERFERON 
(IFN-y) & TUMOR NECROSIS FACTOR-ALPHA (TNF). J.NW.N. Barker. V. Sarma. V. Dixit. B. Nickoloff. Univ. 01 Michigan, Ann 
Arbor, Mich., USA 
Studies in our lab have suggested lt1at keratinocytes (KCs) play an active role in the accumulation of blood mononuclear 
cell (BML) subsets in the epidermis. During our adhesion assays where IFN·y Ireated KC expressed ICAM· t, and bound LFA- t 
expressing BML, it became apparent lt1at IFN-yand TNF also induced KC elaboration of chemoattractant molecules, since 30 % 01 
BML bound to the bottom of wells containing treated KCs. Because this adherence reaction was restricted to monocytes and certain 
T cell subsets we sought to determine il lt1is was related to chemoattractant molecule production which was differentially regulated 
by IFNy & TNF. Cultured KCs were incubated with IFN·y (100 U/ml) and TNF (500 U/ml) alone or in combination. KC total cellular 
RNA was extracted at varying times and RNA extracted and hybridized with c DNA probes specific for IL-8 and monocyte 
chemotactic and activating factor (MCAF). These probes were chosen since IL-S is a potent chemoattractant lor T cells, and MCAF 
induces monocyte chemotaxis. IL-B mRNA, not present in untreated KCs, was induced by TNF wilt1in 30 mins. Pretreatment \\i1t1 
cycloheximide (CHX) produced superinduction. IL·8 transcription was maximal at 60 mins. and still detectable at 18hrs. IFN-yalone 
had nol effect, but together with TNF greatly increased IL·8 rRNA synergistically. KC constitutively expressed MCAF mRNA, and 
TNF alone had no effect, even alter CHX exposure. IFN-y alone weakly increased MCAF at 2 hrs, and lt1e combination of IFN-y and 
TNF greatly upregutated MCAF rRNA levels. These molecular studies demonstrate lt1at IFN-y and TNF differentially regulate KC 
synthesis of PBML chemoattractant lactors, specific lor monocytes and T cells with marked synergism. Detection of KC mRNA lor 
IL-8 and MCAF after cytokine exposure suggests that KC elaborated factors are important not only in the adhesion of BML to KCs, 
but also in lt1e initial chemotaxis of these intlammatory cells to It1e epidermis. These studies extend our concepl of lt1e KC as a 
'master' cell type which can intluence olt1er cell types such as endothelial cells and BML to enhance tratfiC\\ing of specific T celt 
subsets and monocytes into lt1e dermis and epidermis. 
THE QUANTITATIVE IMMUNE STATUS DURING INTERFERON THERAPY. R. Bauer, I. B6hm, HW Niedecken, J.A. Stefan, Dept. 
of Dermatology, The Rheinische Friedrich-Wilhelms·University 01 Bonn, Bonn, FR Germany 
Interferons are gaining more and more importance in lt1e treatment of viral and malignant diseases. Allt10ugh the complex 
inHuence 01 interferons in the cellular and molecular lields has been analysed to a great extend in lt1e last years, only few information 
about their immunopharmacologiCal effects is available in clinical use. Therefore we would like to present some 
immunopharmacological data. Seven male patients between 28 and 58 years of age, suffering from recurrent condylomata 
acuminata, were treated \\i1t1 recombinant interferon alta-2 subcutaneously with doses 01 3 million IUldie five times per week lor 2 
weeks. As some patients were treated repeatedly we were able to document 10 treatment cycles in toto. Before the administration of 
interferon and on It1e last day of each treatment cycle relative and absolute values of circulating mononuclear cells were measured 
ltow-cytometrically (FACS-Analyser , Fa. Becton·Dickinson) with monoclonal antibodies. (Fa. Becton·Dickinson). We observed that 1. 
absolute values of leukocytes, lymphocytes and monocytes dropped significantly (p < 0.05) during interferon therapy, 2. absolute 
values of circulating lymphocyte subpopulations (CD3+, CD4+ , CD8+, CDI6+, CDS7+, CD3+ HLA-DR+, CD8+ CD" -) were 
significantly (p < 0.05) reduced after lt1erapy, 3. relalive values of circulating subpopulations and CD4/CD8 ratio showed no 
significant changes, 4. It1e clinical response of monotherapy wilt1 interferon was poor, no improvement of disease could be seen. We 
conctude that a main effect of an immunopharmacological treatment with interleron alta in lt1is schedule is resulting in a quantitative 
immune depression in blood. 
SEQUENTIAL THERAPY OF INTERFERON-ALPHA AND INTERLEUKIN-2 IN ADVANCED MALIGNANT MELANOMAS -
PRELIMINARY RESULTS OF A COOPERATIVE PHASE II STUDY. L Bergmannl, U. Keilhola, E. Weidmannl, U. RunneQ. H.H. 
BartscM. C.R. FrankS§, P.S. Mitrou, 1 Div. of Haematol.,2 Dept. Int Med. and 3Dept. Dermato!., JW. Goethe University, Heidelberg, 
FR Germany; 4Dept. Int. Med. GOttingen, 5EuroCetus, Amsterdam; The Nethe~ands 
In advanced malignant melanomas (MM) It1ere is still a lack 01 sufficient It1erapeutic approaches. Recentty, biological 
response modifiers (BRM) as interteukin-2 (IL-2) and in part interteron-alpha (IFN'alpha) were shown to have some efficacy in MM. 
Additionally, in vitro studies suggest a synergistic effect of IFN·alpha on the induction 01 Iymphokine activated killer (LAK) cells by IL· 
2. Therefore, we initiated a phase-II trial combining IFN-alpha with IL-2. The patients receive 106/m IFN·alpha s.c. (Essex Pharma, 
Munich, FRG) day 1-7 followed by 2 blocks of r1L-2 CIVI (EuroCetus, Amsterdam) from day 8-21 with a rest on day 14. This total 
cycle will be repeated after 2 weeks rest and in case of SO or better as maintenance bimonlt1ly. Up to now, 15 pts. have been 
included. 11/15 are evafuable at time. In 3/10 pts. a partial remission (PR) could be induced \\i1t1 a remission duration of 2.2 and 4+ 
mths. In one of It1ese pts. brain metastasis and in It1e 2nd pI. a generalized relapse occurred. 2111 pts. had SO (2.2 mths) and 6/11 
PGR. The side-effects of It1e combination of IFN-alpha and IL -2 was not more pronounced than It10se of single agents alone. Despite 
It1e study Is still in progress, the results demonstrate that (1) remissions can be induced in advanced MM by IFN·alpha+IL-2, (2) IFN· 
alpha does not increase It1e side-effects of IL·2 in this protocol. 
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SHORT-TERM KELOID TREATMENT IN VIVO WITH HUMAN INTERFERON ALFA-2B RESULTS IN A SELECTIVE AND 
PERSISTENT NORMALIZATION OF KELOIDAL FIBROBLAST PHENOTYPE. B. Berman and M.R. Duncan. Univ. of California, 
Davis and VA Medical Center, Martinez, CA, USA 
In as inferferons (IFNs) normalize the hypercollagen producing phenotype of scleroderma fibroblasts after short-term in 
vitro exposure we examined the clinical efficacy of short-term treatment of keloid with IFN-alfa-2b and determined whether such 
short-term in vivo exposure results in a persistent, de-activated keloid fibroblast phenotype. Two intralesional injections of IFN-alfa-
2b (1.5 million Ulinjection) into a progressively enlarging keloid rapidly (9 days) resulted in a 41 % reduction in lesional area. 5 
additional injections following biopsy-induced keloid enlargement resulted in a persistent 45 % reduction in area. Rbroblasts cultured 
from the keloid prior to (pre-IFN keloid) and 5 days after the initial set of IFN injections (post-IFN keloid) were compared with 
fibroblasts cultured from the patient's normal skin with respect to proliferation and production of certain connective tissue matrix 
components and collagenase. There were no significant differences in the in vitro doubling times of pre-IFN keloidal (p > .2), post-
IFN keloidal (p > .5) and normal fibroblasts in subconfluent cultures. Multiple passages of pre-IFN keloidal fibroblasts in confluent 
cultures produced more collagen (171 %, 187% and 204%) and more glycosaminoglycans (GAGs) (153% and 141%) and less 
collagenase (26% and 31%) than the patienrs own normal fibroblasts. In contrast, post-IFN keloidal fibroblasts persistently produced 
normal or sub-normal amounts of collagen (107%, 73% and 64%) and GAGs (97% and 96%) and normalized levels of collagenase 
activity (96% and 86%). Normal amounts of fibronectin were produced by pre· and post-IFN keloidal fibroblasts. The addition of IFN-
alfa-2b in vitro, in concentrations attainable in vivo, to pre-IFN keloidal fibroblast cultures suppressed the hypercollagen and GAG 
production and normalized collagenase activity without affecting fibronectin production. These data suggest that transient in vivo 
exposure to low dose IFN-alfa-2b resulls in an anti-fibrotic effect following normalization of the keloidal fibroblast phenotype. 
EFFICACY OF INTERFERON ALFA-2B FOR CUTANEOUS SQUAMOUS CELL CARCINOMA. B. Berman, D.A. Whiting, L. 
Edwards and K.A. Smiles, Univ. of California, Davis CA, Dallas TX, Arizona Health Sciences Center, Tucson AZ, Schering Corp., 
Kenilworth NJ, USA. 
Recent reports of the efficacy of interferon alfa-2b in the treatment of basal cell carcinomas and actinic keratoses prompted 
us to determine the safety and effectiveness of intralesional interferon alfa-2b treatment of cutaneous squamous cell carcinoma 
(SCC). A single biopsy proven in situ or invasive SCC, on sun-exposed skin, with a greatest linear dimension of> 0.5 < 2.0 em was 
infiltrated with 1_5 million IU of interferon alfa-2b in 0.15 cc three limes a week for three weeks. The patient was clinically evaluated 
during and for 18 weeks following the course of 9 injections (total dose of 13.5 million IU). At the final visit (week 21) the entire 
treated area was excised and examined histologically for residual SCC at least every 0.5 mm along the specimen's longest 
dimension. Twenty four patients have completed the 21 week study. A mild, localized erythematous reaction without erosion 
developed during the treatment period, which resolved, often as a minimally hypopigmented macule. The majority of patients had no 
side-effects, however, some experienced mild to moderate flu-like symptoms lasting several hours, usually following the initial doses. 
No persistent or serious clinical laboratory value abnormalities were found. By week 21, clinical resolution of the SCC was achieved 
in 23 patients with histologiC examination confirming the absence of SCC, for an observed cure rate of 95.8 %. The one patient with 
a partial clinical response had residual SCC histologically. These data suggest intralesional interferon alfa-2b to be a safe and 
effective treatment of cutaneous squamous cell carcinoma. 
TOPICAL APPLICATION OF INTERFERON BETA AS AN ADJUVANT IN THE TREATMENT OF RECURRENT GENITAL WARTS: 
RESULTS OF A PLACEBO-CONTROLLED DOUBLE-BLIND STUDY. J. Berthold.!, E. Schbpfl W. Volckerss J. Brzosk~. 
1 Department of Dermatology, University of Freiburg, FR Germany; 2Department of Dermatology, Municipal Hospital, Dortmund, FR 
Germany; present address: SOdstr. 38, Hamm, FRG; 3Bioferon, Laupheim, FR Germany. 
Several clinical studies have shown that interferons are effective in the therapy of genital warts. Pilot studies indicate that 
interferon gels or ointments may be useful adjuvants to conventional therapy to prevent disease recunrence. To prove the 
effectiveness of an interferon beta gel preparation (FibiaferonR-Gel: 0.1 x lQ6IU1g) a double-blind placebo-controlled clinical trial is 
currently being performed. After electrocautery of recurrent genital warts lhe adjuvant self -applied topical therapy is started within 24 
hours. The gel is applied 5 times daily over 3 to 4 weeks. Observation period is 6 months unless the warts recur earlier. Up to now 
more than 20 patients have been recruited. No side-effects have been reported. Because of the double-blind character of this study 
no statements concerning efficacy of the treatment can be given yet. However, the code will be broken at the beginning of October 
so that the results are available by the time the symposium takes place. 
CACHECTINfTNF: THE BIOSYNTHETIC CONTROL OF A MEDIATOR OF INFLAMMATION AND SHOCK. B. Beutler, Howard 
Hughes Medical Institute, U.T. Southwestern Medical Center, Dallas, TX, USA 
CachectinfTNF is a macrophage-<ierived hormone which may be produced in large quantities by cells that have been 
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activated with lipopolysaccaride (LPS) or other invasive stimuli. Through its effects on neutrophils, vascular endothelial cells, and 
other ossues, cacheconlTNF evokes many inflammatory changes. It is also responsible for the induction of a catabolic state, and is 
widely believed to be an important mediator of shock in sepsis and cachexia in chronic disease. We have examined the mechanisms 
by which cachectinlTNF biosynthesis is controlled in macrophage, and have observed that cachectinlTNF gene transcription is 
augmented approximately 3-fold following activation of the cell by endotoxin. However, the quantity of cachectinlTNF mRNA rises by 
about lOO·fold, and at the protein level, a 10,000·fold increase in the rate of synthesiS is observed. We now report that 
cachectinlTNF regulation occurs largely at the level of translation in permanently transformed mouse macrophages of the cell line 
RAW 264.7. Using a series of post-transcriptional reporter conslructs, in which a chloramphenicol acetyttransferase (CAT) gene is 
transcribed under the influence of a constutively active promoter, we have been able to show that the 3'-untranslated region of 
cachectinlTNF mRNA strongly suppresses translation of the CAT coding sequence. This translational blockade, which seems largely 
attributable to the action of a conserved UpA·rich 3'·untranslated sequence element, is relieved by endotoxin activation. 
Derepression of cachectinlTNF translation is modulated by mRNA sequences flanking the UpA-rich element. Up to 200·fold 
induction of CAT activity may be observed based upon the presence of sequences downstream from the terminalion codon. Control 
conslructs containing irrelevant stretches of cDNA, did not conler inducibility. Control 01 cachectinlTNF synthesis may model the 
regulation 01 synthesis operating in many other inducible genetic systems. Familiarity with the mechanisms 01 induction may allow for 
a bener understanding of the inHammatory response. 
INTERFERONS IN SERA FROM PATIENTS WITH PSORIASIS. J.R. Bjerke 1 , M. Tigalonowaf, H. Gallati3. M. DeqrEj4~ 
Jablons~, S. Majewsk§. R. Matrei! 
1 Dept. of Dermatology, Ullev~1 Hospital, Oslo, Norway, 
2Dept. of Dermatology, University of Bergen, Norway, 
3Hoffmann-La Roche Laboratories, Basel, Switzerland, 
4Dept. of Virology, National Hospital, Oslo, 
5Dept. of Dermatology, Academy of Medicine, Warsaw, Poland, 
6Broegelmann Research Laboratory for Microbiology, University of Bergen, Bergen, Norway 
Sera from 52 patients with psoriasis and 106 healthy controls were tested for IFN- and IFN-ALPHA using an ELISA method 
based on monoclonal antibodies, and for total IFN activity using an infectivity inhibition micromethod. The patienls were divided into 
3 groups according to the disease activity, i.e. stationary plaque psoriasis (A=, n=(6), peripherally spreading psoriaSiS (AI , n=22), 
acute disseminated guttate pSOriasis (A2, n=(4). Serum IFN- levels were decreased for the whole pSOriasis group compared with the 
control group, median 0.10 ng/ml vs. 0.16 nglml (p=O.OI ). The highest median serum levels were found in group AI , 0.1 nglml, and 
A2, 0.09 nglml. Group AO showed significantly lower IFN-y leve~ (median 0.0) as compared with other forms of psoriasiS or with 
blood donors (p=0.OOO3). Only sera from 2 of the psoriatic patients had detectable levels of IFN-ALPHA, which did not differ from the 
control group. Neither did the total lFN activity in the psoriatic sera differ from the control group. 
The results indicate that serum IFN-y levels in patients with pSOriasis may reflect the activity of the inflammatory process. 
THERAPY OF METASTATIC MALIGNANT MELANOMA: PHASE II·STUDY USING CRYOTHERAPY IN COMBINATION WrrH 
LOCAL APPLICATION OF NATURAL INTERLEUKIN 2. A. B6hm, U. Wever, L. Kowalzick, E.w. Breitbart, Universitats-Haulklinik 
Eppendort, Hamburg, FR Germany. 
The results with previous treatment regimens of malignant melanoma stage IV using mono- or polychemotherapy were nol 
encouraging. Therefore, attempts with new therapeutic means have to be performed. Recently Rosenberg has reported bener 
results with an immunotherapy supplying LAK-cells and IL-2, although this regimen showed strong toxic side-effects. 
We have found evidence for an immunostimulating effect of cryosurgery of primary malignant melanoma. Therefore we have made 
an attempt to treat metastatic malignant melanoma using local administration of natural IL-2 following cryosurgery of cutaneous 
metastatic lesions. Four palients are yet available for preliminary evaluation. Follow-up of immunological parameters in the 
peripheral blood under therapy using immunohistochemistry revealed an increase of IL-2 receptor positive and transferrin receptor 
positive cells. All four patients showed progressive disease. 
TREATMENT OF BASAL CELL CARCINOMAS WITH INTRALESIONAL ALPHA 2B RECOMBINANT INTERFERON. V. Boneschi. 
L. Brambilla, N. Mozzanica, A. Cattaneo, A.F. Finzi. 2nd Department of Dermatology, University of Milan, Milan, Italy. 
27 patients (mean age 67 years) with one basal cell carcinoma (BCC) each (mean size 9.5 mm, range 7.22) were treated 
with intralesional alpha 2b recombinant interferon (alpha 2b IFN), 1.5 x lOS IU, 3 times a week for 3 weeks. Histological diagnosis: 
14 BCC of the superfiCial type (S), 13 of the nodular type (N), 6 of them ulcerated (U). Clinical and histological assessments were 
made 4 months after the end of therapy, with complete clinical and histological resolution in 14 patients (9S, 4U, I NJ, clinical 
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improvement> 50 % in 9 (4S, 5N) and 50 % in 4 (IS, 3N) observed. All the treated ulcerated BCC of the face (4) disappeared 
completely, clinically and histologically with good aesthetic results. No hematochemicai abnormali ties were detected. Side-effects 
observed: 2 cases of flu-like syndrome, 15 cases of hyperthermia alone up to 381C, asthenia without fever in 3 cases. We 
investigated immunohistologically the peri tumoral infiltrates for 6 BCC (4S, 2N) with a series of monoclonal antibodies. The study 
was done before and 12 days after the start of the therapy (total injected dose: 7.5 x 106 IU). Before therapy, the infiltrate consisted 
mainly of T (CD3+) cells, with discrete %s of monocyte-macrophages (CDI4+) and Langerihans (CD1+) cells. There were more CD4 
than CD8 positive cells (CD4/CD8 ratio: 1.4); very few NK (Leu7+) cells and B (CD20+) cells were presenL After therapy there was a 
remarkable increase in infiltrating cells, with predominance of T cells (CD4 > CD8). The % of activated T (CD25+DR+) cells and 
Langerhans cells was slightly reduced, with a small rise in monocyte-macrophages. The number of NK and B cells did not change. 
INTERFERONS (IFNs): CURRENT STATUS FOR VIRAL AND NEOPLASTIC DISEASES. E.C. Borden, University of Wisconsin 
Clinical Cancer Center, Madison, USA 
In more than 20 disease states including more than a dozen malignancies, IFNs resulted in amelioration of the disease 
process. Although extent of therapeutic usefulness has yet to be defined in all diseases, improvemenl in quality of life for patients 
with some of these conditions has been established. Only 4 of the more than 25 IFN types have been clinically evaluated. In 
addition, IFNs with specific amino acid substitutions and hybrid ~teins, designed for specifIC desired biological effects, have been 
introduced. The research challenge for IFNs in the 1990s is to define the full therapeutic potential of this family of cell regulatory 
proteins. A reasonable working hypothesis is that each IFN will have a unique spectrum of therapeutic application. We have utilized 
cell proteins, induced by IFNs to assess host biological response modification to different IFNs. Proteins were assessed at 24 hrs by 
enzymatic assay (2-5 A Synthetase), radioimmunoassay (HLA Class I component, serum 62 microglobulin) or by gating by lighl 
scatter on the ftow cytometer for monocytes with HLA Class II (HLA-DR, HLA-DQ). All IFNs resulted in significant (p<O_05) increases 
in 2-5AS; IFN y was < 2x as effective as IFNs ALPHA and B. All IFNs were also effective in significantly (p<O.05) stimulating serum 
B2m; in contrast to 2-5 AS, INF B was < 2x as effective as IFN ALPHA and IFN y. HLA-DR and HLA-DQ, evaluated only after IFN B 
and y, were increased in both ; IFN y was significanlty more effective in increasing numbers of monocytes positive for HLA-DQ and 
IFN B for HLA-DR. Lower doses of IFNs effectively stimulated all induced proteins; only modest additional augmentation occurred 
with higher doses. Results provide a basis for design of therapel1ic trials based upon modulation of a desired IFN and dose specific 
response. IFNs have already met the promise expected of them by the inlernational research community of IFN scientists. They are 
lhemselves effeclive therapeutic modalities and are serving as prololype molecules to slimulate basic and clinical research on other 
cytokines. It seems probable that their therapeutic impacl will even exceed ear1y expectations. 
OUR EXPERIENCE OF THE TREATMENT OF SELECTED DERMATOSES WITH INTERFERON ALPHA 2A. N. Botev, N_ Berova 
and V. Andreev, Institute of Dermatology, Academy of Medicine, Sofia, Bulgaria 
Ear1y in 1988 we started using rlFN alpha 2a in the treatment of a number of dermatoses, mostly of viral or suspected viral 
origin or associated with immunodeficiency syndromes. The number of patients treated was 15_ The indications comprised: Mycosis 
fungoides plus T-cell lymphoma - 7 patients; Kaposi's sarcoma (not associated with AIDS) - 4 patients; condylomata acuminata - 3 
patients; endogenous eczema with immunodeficiency, generalized verrucosis and molluscum contagiosum - 1 patient. The treatment 
of these patients was carried out as foliows: 
Mycosis fungoides: 18 Mill IU once weekly for 8 weeks. After this periiod and if there was any improvement, the weekly dose was 
reduced to 9 Mill IU for another 8 weeks. The maintenance dose was 9 Mill IU every second week_ Results: Improvement to 
complete disappearance of lesions in all patients. Recurrences in 3 patients after 4, 7 and 8 months. 
Condylomata acuminata: 3 Mill IU rlFN alpha 2a daily subcutaneously for 5 days; then an interruption for 2 - 3 days and continuation 
with the same regimen the next week. Total duration of treatment: 4 weeks. Results: Complete disappearance of condylomata in 2 
patients and partial improvement in 1. 
Kaposi's sarcoma (not associated with AIDS): Treatment the same as in mycosis fungoides. Results: Complete disappearance of 
infiltrations in 1 patient. Significant improvement in the remaining 3_ For the time being the treatment continues with 18 Mill IU. One 
patient developed eczema which quickly disappeared with corticosteroid treatment. 
Endogenous eczema: 18 MiIIlU rlFN alpha 2a for several months. Results: Complete disappearance of lesions, no further itching. 
MEDITERRANEAN KAPOSI'S SARCOMA: INTERLEUKIN PRODUCTION AND HLA ANTIGENS. L. Brambilla', M. Vanoli", G. 
Chiappino " S. Della Bella", C. Coppola", V. Boneschi' and A.F. ROli' ; '2nd Dept. of Dermatology, University of Milan, Milan, Italy; 
"Institute of Internaf Medicine, Infectious Diseases and Immunopathology, University of Milan, Milan, flaly_ 
The HLA antigens of 91 patients with Medilerranean Kaposi's sarcoma (KS) have been typed, In untreated patients (n = 
31) lymphocyte proliferation and interteukin-l (IL-l), interteukin-2 (IL-2), gamma interteron were also evaluated in vitro in primary 
mixed aliogenic culture. Our results show thaI: 
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I . lhere is a significant association between DRS and the disease 
susceptibility with a relevant increase in DRwI2(S) ; 
2. there is no significant difference between KS and control 
subject in vitro lymphocyte proliferation or interleukin 
production; 
3. in both patients and control there is a significant 
association between DRS phenotype and 100 character of: 
a) low gamma inlerferon producer 
b) high IL-I producer 
c) IL -I inhibitor(s) producer. 
This behaviour seems to characterize a particular histo-clinical subgroup of patients. 
THE JOURNAL OF INVESTIGATIVE DERMATOLOGY 
SYSTEMIC TREATMENT OF MELANOMA PATIENTS WITH INTERFERON ALPHA (I FNALPHA) INDUCES CHANGES IN THE 
TUMOR CELL PHENOTYPE AND THE LOCAL IMMUNE RESPONSE OF SKIN METASTASES. E.B. Brocker!' M.v. Depka-
Prondzinskil . U.v. Stamml. D.J. Ruiterf. C. Soral; I Dep1. of Dermatology, MOnster, FR Germany; 2Dep1. of Pathology, Nijmegen, 
Netherlands, for the EORTC melanoma cooperative group. 
The influence of INFALPHA-therapy on melanoma metastases was studied. Nineteen patients with metastalic melanoma 
were treated treated subcutaneously with escalating doses of recombinantlFNALPHA. Skin metastases were excised before (n=40), 
and during IFNALPHA-treatment (n=49). Fresh frozen samples were studied immunohistochemically with monoclonal antibodies 
directed against melanoma-associated antigens including progreSSion and proliferation markers, and functional subset of 
tymphocytes and macrophages. Comparing 100 metastases excised during IFNALPHA-treatment with those before treatment, we 
found a decreased expression of the proliferation-associated nuclear antigen Ki 67, an increase of HLA-DR antigen 
expression, and increased numbers of intratumoral macrophages of the RM3/1 + phenotype. 
Antigen 
Ki 67' 
HLA-DR' 
RM3/1" 
before IFN-ALPHA 
13 
3 
22 
during IFNALPHA 
3 
10 
48 
• median %age of 
+ tumor cells 
•• median cell 
number per HPF 
The data suggest that IFNALPHA in vivo, though of limited clinical efficacy in metastatic melanoma, modulates markers of 
proliferation (Ki 67) and progression (HLA-DR), and induces an influx of macrophages into the tumor. 
REGRESSION OF KAPOSI'S SARCOMA AND IMPROVMENT OF PERFORMANCE STATUS BY A COMBINED INERFERON B 
AND ZIDOVUDINE THERAPY IN AIDS PATIENTS. N.H. Brockmeyer, L. Mertins, R. MaleBa, R. Biniek. M. Goos; University of 
Essen, Essen, FR Germany 
Eleven HIV-infected patients with Kaposi 's sarcoma (KS) (stadium WR6) were treated with human fibroblast interferon B 
and zidovudine for a period of four months. KS were histologically verified and localized at the hard palate, gum, at the plantar side 
of the feet, abdomen and on the arms. In the last two months before lherapyall patients had 10SI 4 - 10 kg b.w. i.v. daily for 1wO 
periods of 14 d each wilh an interruption of 14 d. After the second course we administered a constant dose of lOS U/kg b.w. every 
third day. Only minimal side-effects were observed. Zidovudine (4 x 200 mg) had been given daily three months before and during 
treatment with IFN-B. All patients showed a significant and persistant regression of the number and diameter of KS atter the first 
treatment period. The KS lesions in the mouth and at the plantar side of the feet disappeared, the other lesions became smaller and 
changed their colour from dark to bright red, similar to 100 initial stages of KS lesions. There was a weight gain in all patients and a 
small increase in helper cells to a mean value of ISO/ul ; the Karnovski index changed from 20 - 40 % to 80 %. Our findings with IFN-
B lherapy clearly show the effectiveness of IFN therapy. Indeed the number and diameter of the KS lesions were definitely reduced 
and the performance status improved. 
EFFICACY OF SUBCUTANEOUS INTERFERON ALFA 2A IN THE TREATMENT OF CHRONIC THERAPY-RESISTANT 
CONDYLOMATA ACUMINATA: CORRELATION WITH HPVTYPE AND IMMUNITY. F.G. Bruins. A.J.C. van den Brule, R. Mullnik, 
J.M.M. Walboomers. C.J.L.M. Meijer, R. Willemze; Dep1. of Dermatology, Free University, Academic Hospital, Amsterdam, The 
Nelherlands. 
VOL 93, NO. " OCTOBER 1989 ABSTRACTS 545 
In this study the efficacy of subcutaneous administration of human recombinant interleron alia 2a was assessed in 22 
patients (I S males, 7 females; age 23 - 42 yrs) with condylomata acuminata (CA), that had been present for 14 to 204 months 
(median: 30 months) and that had been refractory to previous conventional therapies. In total 36 million IU interferon alfa 2a were 
administered: 12 injections of 3.0 million IU during 4 weeks with a follow-up of 8 weeks. The results show complete remission in I 
patient and a partial remission in 3 patients. 18 patients showed no response. Progression of disease dunng treatment was not 
observed. Altogether, 4 of 22 patients (18 %) showed a greater than 50 % reduction of previously therapy-resistant CA. In additional 
studies we investigated cellular immunity and human papilloma virus (HPV) type in these 22 patients as well as in 23 patients with 
CA of short duration (I to 9 months; median 4 months). However, abnormalities in cellular immunity, as determined by CD4/CD8 
ratios in peripheral blood and intradermal tests with recall antigens, were not seen. HPV typing, using in situ DNA-hybridization as 
well as the polymerase chain reaction on smears and biopsies of CA, showed a rather high frequency of HPV 16 and HPV 18, both 
in the study group and the control group. 
In conclusion, subcutaneous administration of interleron alfa 2a has a beneficial effect in some patients with chronic CA, refractory to 
conventional therapies. However, in order to obtain higher response rates, further studies using higher doses of interleron alfa 2a or 
a combination of interleron alfa 2a and other treatment modalities are necessary. 
TREATMENT OF CUTANEOUS T CELL LYMPHOMAS WITH INTERFERON AND MONOCLONAL ANTIBODY Tt01. P.A. Bunn, K. 
Foon, D.C. Ihde and S. Rosen; University of Colorado, Denver CO; Northwestern University, Chicago IL ; and National Cancer 
Institute, Bethesda MD, USA. 
We have conducted three trials employing recombinanl interleron alpha (rIFN2ALPHA), one trial employing recombinant 
interferon gamma, one tnal of the combination rlFN2ALPHA and PUVA, one tnal of unlabeled monoclonal antibody TlOl , and one 
tnal of 1131-TlOI in patients with cutaneous T cell lymphomas (mycosis fungoides and the Sezary syndrome). For advanced stage 
CTCL patients, high dose rlFNALPHA (50 x 106 MU 1M TIW) gave a response rate of 45 % (9/20). a median response duration of 6 
months, a complete response (CR) rate of 15 % with a median CR duration> 3 years. An alternative high dose schedule (10 MU day 
1, 50 MU day 2 -5 every 3 weeks) gave a response rate 01 29 % (7/24 ) and a median response duration of 8 months. In less 
advanced patients we compared low dose (3 x 106 MU 1M qd) to intermediate dose rlFN2ALPHA (3 escalating to 36 MU 1M qd) for 
10 weeks. The overall response rale was 64 % (14/22) with a 27 % complete response rate and a mean duration of 6 months. The 
intermediate dose therapy gave better results. In advanced stage CTCL patients, rlFNy (.25 mglm SO TIW) gave a response rate 
of 31 % (5/16) with a median duration of 10 months. The combination of rlFN2ALPHA and PUVA gave a 100 % response in 20 early 
stage patients with a median response duration exceeding 6 months. Unlabeled Tl 01 monoclonal antibody given intravenously twice 
weekly in doses of I fo 500 mg gave no response in 12 patients. However, 113 1-Tl 01 gave short minor or partial responses in 5/6 
patients despite considerable dihalogenation in vivo. We conclude that both rlFNa2ALPHA and rlFNy are active in cutaneous T cell 
lymphomas. The combination of rlFNa2ALPHA and PUVA is extremely active and well tolerated in early stage patients, though 
longer follow-up is required to determine its ultimate role. Further studies ot combinations of interlerons ALPHA and y and interferons 
with other agents are needed. Radiolabeled monoclonal antibodies need further evaluation. 
LEUKOCYTE CHEMOATIRACTANT CYTOKINES OF THE EPIDERMIS: CHARACTERISATION AND RELEVANCE. R.D.R. Camp, 
K.B. Bacon and J.S. Ross; Institute of Dermatology, SI. Thomas's Hospital, London SE1 , U.K. 
Material similar or identical to the potent inflammatory cytokine, interteukin (IL) 1, has been isolated in biologically active 
amounts from normal human epidermal samples, probably being retained intracellularly under normal conditions and therefore 
inducing no adverse effects. Pre-formed epidermal IL I may, however, be released by a vanety of events associated with membrane 
perturbation, causing inflammatory reactions which may in part be due to its direct, potent T -helper cell chemoattractant effects. In 
vivo, injected IL I also induces pronounced neutrophil and monocytelmacrophage infiltrates in human skin, presumably by indirect 
mechanisms as it appears not to be directly chemotactic towards these cells in vitro. These potent effects on leukocytes may be 
important in a range of inflammatory diseases. The potent inhibitory effect of cyclosporin A on IL I -induced in vitro lymphocyte 
migration may also explain in part the apparent therapeutic efficacy of this drug in certain inflammatory dermatoses. The neutrophil 
infiltrates provoked by IL I may be a result of the rapid in vivo induction of the synthesis of IL 8, a cytokine with direct neutrophil 
chemotactic properties in vitro. We have also found recombinant IL 8 to be the most potent lymphocyte chemoattractant we have yet 
tested in vitro. IL 8 and homologous peptides have been identified in epidermal samples from psoriatic lesions and, as for IL 1, may 
become important therapeutic targets in inflammatory skin disease. In addition to IL 1, we have identified a small, polar, non-peptide 
lymphocyte chemotactic compound in stratum corneum, chamber fluid, and suction blister fluid samples from normal skin. Similar or 
identical material, which we have termed plasma associated lymphocyte chemoattractant (PALC), has been identified in normal 
plasma. This compound, together with the low level release of IL I from normal epidermis, may serve to promote physiological 
lymphocyte trafficking in normal skin, and may constitute a new target for immunosuppressive therapy. 
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PATHOGENESIS OF SYSTEMIC SCLEROSIS. E. Carwile LeRoy, Medical University of South Carolina, Charleston SC, USA 
Exoessive production of collagens (types I and III), fibronectin, hyaluronate, and proteoglycans are characteristic of the 
lesional dermal fibroblast from patients with systemic sclerosis. These matrix components are overexpressed al the Iranscriptional 
level. In addition, the SCleroderma fibroblast is resistant to in vitro synchronization of the oell growth cycle. These oell growth 
abnormalities are associated with a persistent expression of the competence gene c-myc, suggesting a defect of gene regulation to 
explain the scleroderma fia-oblast phenotype. Ample evidence exists for a role of T oells and monocytes in the panern of endothelial 
injury and fibroblast activation which precede fibrosis in scleroderma. On the hypothesis that a cascade of cytokines can explain 
these oellular abnormalities, the role of three cytokines, transforming growth factor beta and tumor necrosis factor alpha and beta will 
be discussed in detail. The immune basis for unregulated fibrosis in scleroderma may lead to specific immunomodulatory therapy. 
Therapeutic strategies will be discussed. 
INTERFERON STRATEGIES IN MALIGNANT MELANOM: PROMISES, PERILS, AND PERSPECTIVES. E.T. Creagan, D.J. 
Schaid, D.L. Ahmann, S. Frytak; Mayo Clinic, Rochesler, Minnesota, USA 
We have performed 7 phase II trials with recombinant inlerferons (IFN) involving 191 patients with biopsy-proven, 
measurable disseminated malignant melanoma. The regimens and numbers of patienls have included IFN-ALPHA2A, 50 x lOS 
Ulm subcutaneous (SO) TIW (Regimen A, 31 patients); IFN-ALPHA2A, 12 x lQ6 Ulm SO TlW (Regimen B, 30 patients); IFN-
ALPHA2A with cimetidine as an immunorestorative agent (Regimen C, 35 patients); IFN-y (Regimen D, 29 patients); IFN-ALPHA2A 
with IFN-y (Regimen E, 20 patients); IFN-ALPHA2A with bis-cllioroethyinitrosourea (BCNU) (Regimen F, 30 patients); and IFN-
ALPHA2A with the biochemical modulator, difluoromethylornithine (DFMO) (Regimen G, 16 patients). Most study participants had 
ECOG performance scores of 0 or 1, visceral dominant disease, and no prior chemotherapy. The objective regreSSion rates were as 
follows: A, 23 %; B, 20 %; C, 23 %; D, 10 %; E, 5 %; F, 7 %; G, 0 %. Despite the higher response rate from regimen A, there was no 
survival advantage from any of these programs. The median time to progression was 1 month with a median survival time of 6 
months. These distributions are frustratingly reminiscent of results from conventional chemotherapeutic programs. Most regressions 
involved soft tissue disease, were partial, and occurred within 2 - 3 months of treatment. Four palients reoeived IFN for 
approximately 6 months and have manifested extraordinarily durable regreSSion of > 4.5+ years. The ALPHA-regimens produoed a 
flu-type illness and anorexia which were dose-related. Leukopenia was most noteworthy with regimens containing y-interferon. There 
were no consistent hepatorenai, cardiac, or neurologic sequelae with these programs. However, fulminant disease progression in 
most individuals precluded an accurate assessment 01 long-term complications. Our experienoe does not portend great promise for 
the interferons in the management of malignant melanoma. Objective regreSSions were ephemeral and without a meaningful 
therapeutic impact in most patients. Ongoing trials involving alternative immune-related modalities are awaited with trenchant 
interest. 
TUMOR NECROSIS FACTOR-ALPHA (TNF) DIFFERENTIALLY MODULATES INTERFERON-GAMMA INDUCED ANTIGEN 
EXPRESSION OF HUMAN KERATINOCYTES. M. Delmar, C.E. Orfanos; Dept. of Dermatology, University Medical Center Stegmz, 
The Free University ot Be~in, Berlin (West), FR Germany. 
Interferon-gamma (IFN gamma) is known to induce the expression ot class II antigens and of interoellular adhesion 
molecule ICAM-l in cultured human keraJinocytes. To investigate whether TNF can modulate IFN gamma-induoed effects, second 
passage normal human keratinocytes grown in serum-free KGM were treated with IFN gamma and TNF either alone or in 
combination (0.1-10,000 U/ml) tor up to 6 days. Antigen expression was examined by APAAP immunocyto-chemistry using 
monoclonal anlibodies against HLA-DR, HLA-DO, HLA-DP and ICAM-l, and by immunoelectron microscopy. In addition, oell 
proliferation was measurd using a reoently developed ftuorometric assay. IFN gamma and TNF both inhibited the keratinocyte 
proliferation. The combination ot both cytokines led to synergistic growth inhibition. HLA-DR expression was only moderately induced 
by TNF alone while TNF did not increase expression ot HLA-DO and HLA-DP. In contrary, TNF led to a strong induction of ICAM-l. 
Combination 01 TNF and IFN gamma resulted in increased ICAM-l positivity, while TNF dose-dependently inhibited the IFN gamma-
induced expression 01 HLA-DR, -DP and DO. Immunoelectron microscopy confirmed these findings. Our results demonstrate that 
TNF differentially modulates IFN gamma-induced activities in cultured human keratinocytes and they suggest a potential role lor TNF 
in the regulation 01 inflammatory skin disorders. 
EFFECTS OF TUMOR NECROSIS FACTOR-ALPHA (TNF) ON CULTURED MICROVASCULAR ENDOTHELIAL CELLS DERIVED 
FROM HUMAN DERMIS. M. Detmar, E. Imcke, Z. Ruszczak, C.E. Orfanos; Dept. 01 Dermatology, University Medical Center 
Steglitz, The Free University 01 Berlin, Berlin (West), FR Germany. 
Vascular endothelium is a major target for the biological actions of TNF in vivo. To further characterize the effects of TNF 
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on skin vasculature, we investigated the eHects of TNF on the morphology, proliferative behaviour and antigen expression of cultured 
endothelial cells derived from human dermal microvasculature. Endcthelial cells were isolated from the foreskin of neonatals or 
children by trypsin treatment and continous Percoll gradient centrifugation and were cultured on fibronectin-coated plates, using 
Iscove's medium with 20 % FCS, EGF and hydrocortisone. Second passage endothelial cells were treated with recombinant TNF 
(0.1-10,000 U/ml) alone or in combinalion with IFN gamma for up to 6 days_ Growtll was assessed by cell counts, thymidine 
incorporation and by a recently developed fluorogenic assay. Antigen expression was studied by APAAP immunocytochemistry using 
monoclonal antibodies againsl HLA-DR, -DO, -DP and intercellular adhesion molecule ICAM-I. Treatment with TNF altered the 
morphology of the epithelioid endothelial cells into arrays of fibroblastoid cells. Moreover, TNF dose-dependently inhibited the growtll 
of human dermal endothelial cells_ In addition, TNF (1000 U/ml) induced expression of HLA-DR and, in concentrations from I Ulml 
on, ICAM-I , but not HLA-DO and -DP. Combination with IFN gamma acted synergistically on ICAM-I expression, but not on HLA-
DR. These results demonstrate a profound effect of TNF on the growth and activation of dermal microvascular endothelial cells and 
suggesl a major role of TNF in the mediation of leukocyte adhesion to endothelial cells in the skin. 
SYNERGISTIC EFFECTS OF SPLENOPENTIN AND RECOMBINANT HUMAN GRANULOCYTE/MACROPHAGE COLONY 
STIMULATING FACTOR ON MYELOPIOESIS. W_ Dieze!, S_ Gruner, H. Weber, J. Maciejewski and H.-D_ Volk; Department of 
Dermatology and Institute of Medical Immunology, Medical School (Charite), Humboldt University Berlin, Berlin, GDR 
Splenopentin (SP-5) is a pentapeptiae corresponding to the amino acid sequence 32-36 (arg-lys-vaHyr) of the splenic 
hormone splenin. The pentapeplide acts as a costimulant for recombinant human granulocytelmacrophage colony stimulating factor 
(rhu G/M-CSF) and for IL-3 in the induction of human bone marrow derived colony formation in vitro. Number of colonies per lOS 
bone marrow cells after addition of 200 Ulml rhu GM-CSF: 46 +1- 9, rhu GM-CSF + SP-5: 102 +1- 23; IL-3: 40 +1- 8; IL-3 + SP-5: 62 
+1- IS. In agreement with this, SP-5 injected in a dose of I mg/kg 3 times per week, stimulated the recovery of bone marrow colonies 
in mice treated with sublethal dose of X-rays (SOO cGy). The number of colony forming cells in their bone marrow was normalized 
significantly earlier (21 versus 35 days). Furthermore, SP-5 accelerated the recruitment of ATPase and la-antigen expressing 
decreased epidermal Langerhans cells in mice treated with dexamethasone_ Based on these results a clinical trial of SP-5 in 
immunocompromized patients, especially with HIV-infection, was initiated. 
INTRALESIONAL INTERFERON THERAPY IN NON-AIDS ASSOCIATED DISSEMINATED KAPOSI'S SARCOMA. A. Dobozy, S_ 
Husz and J. Hunyadi ; Albert Szent-Gyorgyi Medical University, Departmenl of Dermatology, Szeged, Hungary 
Five patients with disseminated Kaposi 's sarcoma are presented in whom both the mucosa membranes and the intemal 
organs were affected ; the patients did not have AIDS. The immunological parameter were evaluated with those ten heatthy men 
older than 70 years, and in ten patients with Kaposi's sarcoma of classical type of Central Europe. The patients with disseminated 
Kaposi's sarcoma manifest immunological characteristics: a) very marked depletion of the OKl 4+ cell population; b) relative increase 
in the proportion of OKl8+ cells; and, c) fall in the OKT8+ ratio below 1.0. Skin tumors of three patients with disseminated Kaposi's 
sarcoma were intralesionally treated with alfa2-interleron. Regression of the lesions was observed both clinically and histologically_ 
EFFECTS OF THE IMMUNOREGULATIVE NEUTROPHILOKINES ON THE INFLAMMATORY REACTIONS IN INJURED SKIN_ 11 
Dolgushin, A.V. Chukichev, A.v. Zurochka, S_1. Marachev, A.V. Kshivo; Medical Institute, Chelyabinsk, USSR 
The neutrophil products - neutrophilokines (NK) are determined to have a wide range of action on immunity_ These cells 
secrete substances capable both to stimulate and suppress the functions of the neutrophils or macro phages, immune response, 
resistance of the organism to infection. The products of stimulated neutrophils influence the course of inflammatory and reparative 
reactions in injured skin. The introduction of NK to the animals is sure to stimulate the healing eHect of skin wounds, considerably 
different peptide fractions of NK possessing no identical effect on inflammation and reparation. The findings of our research suggest 
the possible role of NK on reinforcement of the reparative process in injured skin, 
LEUII and MY7 USEFUL INDICATORS OF EFFICIENCY OF INTERFERON ALPHA IN CUTANEOUS T CELL LYMPHOMA.!h 
Dreno, S. Valard, A_ Huart, B. Bureau, P. Litoux; Dept. of Dermatoloy, Hotel Dieu, Nantes, France 
Several studies suggested the efficiency of interleron alpha in the treatment 01 cutaneous T Cell lymphomas (CTCL). 
However, most often an objective response was only noted in about 45 % of patients and the median duration of response was 
between 5 and 8 months. In this context, the aim of this study was to investigate the expressivity of different membranous antigens 
on keratinocytes and lymphocytes in cutaneous lesions of CTCL during treatment with interleron alpha and to compare the results 
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obtained with the clinical response in order to determine immunological criters of efficiency. Cutaneous biopsies were pertormed 
from affected areas of 15 patients with CTCL treated with low doses of interteron 2a (6 x 106 U per day during 2 months by 
intramuscular injection, then 6 x lOS U three times weeky during 10 months) before treatment and every 2 months during 10 months. 
An indirect immunfluorescent technique on cutaneous frozen sections was used with different monoclonal antibodies: CD1, CD2, 
CD3, CD4, CDS, COO, CD16 (My7), HLA-DR and Leul1 (Anti-N Killer). We found that interferon alpha modulated the expressivity of 
My7 and Leull monoe/onal antibodies wnich respectively reacted with basal cells and granular layer in normal epidermis. Indeed 
My 7 and Leu 11 were expressed in epidermis of cutaneous lesions during interteron alpha 2a therapy only in patients with a good 
ciirical response. Their expressivity was absent or weak in epidermis of patients without clinical response, furthermore, the labelling 
disappeared before a relapse. This results strongly suggest that My7 and Leull have a prognostic value to determine the elriciency 
of interferon afpha during the treatment of CTCL. 
ANTIBODIES TO INTERFERON (IFN)-8 INHIBIT T-CELL ACTIVATION IN VIVO DURING ADJUVANT TREATMENT WITH IFN-8 
AND IFN-y FOR HIGH RISK MELANOMA. R. Dummer, W. MOiler; Dept. of Dermatology, University of WOrzburg, WOrzburg, FR 
Germany 
The prognosis of metastatic malignant melanoma stil remains poor. Therefore, it is necessary to develop adjuvant 
therapeutic regimens for high risk melanoma patients. In vitro IFN-6 and -y show synergistic effects on tumor growth inhibition. But 
IFNs also modulate the immune system in vivo. We developed an adjuvant immunotherapy for high risk melanoma patients using 
IFN-8 and -yand monitored antibody formation 10 IFns and T-cell activation by determination of soluble inteneukin-2-receptor (sIL-2-
R) and CDB protein (sCOO) levels. The study included patienls with at ieast T3 tumor (TNM classification) with or without 
involvement of the locoregional lymph nodes aher surgical removal of all clinically detectable tumor manifestations. Patients with 
tumor location on head, neck or trunk received 3 Mill. IE IFN-8 3 times weekly. All patients were pulsed by 50 x 10-3 mg IFN-y for 3 
days every 4 weeks. Antibody formalion was measured by coincubation of IFNs and patients' serum and determination of inhibition 
of the cytopathiC effect 01 a virus suspension. sll-2-R and sCOO levels were determined by ELISA technique. Of 7 patients receiving 
intravenous IFN-8 1 developed antibodies to IFN-8. Of 9 patients with s.c. application of IFN-8, 6 formed antibodies. No antibody 
formation against IFN-y was observed. Before starting therapy. sIL-2-R and sCDB levels were found in the normal range. No 
significant change was seen for sCD8, but sIL-2-R was elevated during therapy. sIL·2-R were found significantly higher in patients 
without antibody formation compared to patients with antibodies to IFN·B (802 +1- 27B versus 585 +1- 123 Ulml). Neutralising 
antibodies to IFN-8 do not only block the antiviral effect in vitro. but also inhibit T-cell activation, which might be an important 
pathway for the anti-tumor effect of IFNs. 
EFFECT OF HUMAN RECOMBINANT INTERLEUKIN 6 ON THE BIOSYNTHETIC FUNCTIONS OF CULTURED ADULT DERMAL 
FIBROBLASTS. M.R. Duncan and B. Berman; Dermatology Department, Univ. of California, Davis School of MediCine, Davis CA 
and VA Medical Center, Martinez CA. USA 
Fibrotic repair of injured dermal connective-tissue is dependent on the ordered growth and differentiation of dermal 
fibroblasts in response to the orchestrated release of paracrine cytokines by infiltrating inflammatory cells. One recently 
characterized cytokine, inteneukin 6 (IL 6), has been shown to inhibit the growth of cultured fibroblasts. In order to determine if IL 6 
modulates fibroblast functions in addition to growth. we measured the production of collagen, glycosaminoglycan. fibronectin and 
collagenase activity by confluent dermal fibroblasts microcultures exposed to 1 - 1000 Ulml of IL 6 for 48 hours. Collagen and 
glycosaminoglycan production were assessed by product specifIC incorporation of 3H-proline for 3H-glucosamine. fibronectin 
production by immunoturtbidimetric assay, and collagenase activity by solubilization of 14C-labeled collagen fibrillar ges. IL 6 
treatment of fibroblasts cultured in the absence of fetal calf serum (FCS) caused increases in the production of glycosaminoglycan 
(41%,67%, 179% at la, 100 and 1000 U/ml) and collagenase activity (46% at 1000 Ulmt) and fibronectin (55% at 1000 Ulml). 
Rbroblasts cultured in the presence of 10% FCS were a log-fold less sensitive to the effects of IL 6 treatment. Although IL 6 
modulated the biosynthetic activities of confluent fibroblast microcuhures without affecting cell number, IL 6 did inhibit the growth of 
asynchronous subconnuent fibroblasts (21%, 37% at 100 and 1000 U/ml) cultured in 10% FCS. Therefoe.IL 6 differentially regulates 
normal human fibroblast functions and may pfay a significant role in controlling fibrotic responses. 
MODULATION OF TGF-ALPHA AND EGF RECEPTOR GENE EXPRESSION BY INTERFERON GAMMA IN NORMAL AND 
PSORIATIC HUMAN KERATINOCYTES.J .T. Elder. R.S. Mitra, J.J. Voorhees. and B.J. Nickoloff; Dept. of Dermatology, University 
of Michigan, Ann Arbor MI, USA 
Human keratinocytes (KC) cuhured from psoriatic lesions dispfay a blunted response to the antiproliferative effects of 
interferon gamma (IFN-y). Transforming growth factor-ALPHA (TGF-ALPHA) is markedly overexpressed in psoriatic lesions and 
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appears to be the endogenous ligand for the KC epidermal growth factor receptor (EGFR). To test whether IFN·y might exert its 
antiproliferative effects via the interaction of TGF·ALPHA and EGFR, we have used RNA blot hybridization, radioimmunoassay, and 
immunoprecipitation to assay the expression of these two genes as a function of time after IFN·y treatment. Keratinocytes were 
grown from normal skin (NN) and psoriatic lesions (PP) in keratinocyte growth medium (KGM, Clonetics). TGF·ALPHA mRNA levels 
were increased 2.5 . /- 0.3 (NN) and 2.4 . /- 0.2-lold (PP) 48 hours after IFN-y treatment. Moreover, NN and PP KC did not differ in 
basal or in unstimulated TGF-ALPHA mRNA levels relative to the control gene, cyclophilin, In contrast, EGF receptor mRNA levels 
and 35S·labelied immunoprecipitable EGFR (1 80 kd) were both reduced after 24 hours of IFN-y treatment. The reduction in EGFR 
expression cannot be explained by increased EGFR internalization, since TGF·ALPHA may both be concomitants of KC 
differentiation. Since TGF-ALPHA stimulates KC growth in vitro, TGF-ALPHA released by more differentiated KC may regulate the 
growth of less differentiated KC via a paracrine mechanism. The results also suggest a molecular link between IFN-y·producing 
epidermal T cells and epidermal hyperplasia in inflammatory dermatoses, including psoriasis. 
TREATMENT OF CUTANEOUS T CELL LYMPHOMA WITH RECOMBINANT ALFA 2B INTERFERON. T. Estrach, R. Marti. M. 
Lecha, J.M. Mascaro; Hospital Clinic i Provincial , Barcelona, Spain 
Alia 2b interferon has been used in the treatment of 7 cases of CTCL. The median age was 65 (range 45 - 69), 4 were 
males and 3 females. Two patients had Sezary syndrome and 5 patients mycosis fungoides (2 plaque stage and 5 tumor stage). 
Interferon was initially administered Lm. at a dose of 5 x 106 IU three times a week during 1 months, and the dose increased to 10 x 
106 IU three times a week for five months more. After three months two patients were dropped from the study for progression of the 
disease. The improvment was dramatical in three cases (with> 80% remission of the lesions) and mild in three cases with 25 . 50% 
remission of the lesion). Side-effecs were a major problem and consisted of flu·like symptoms and leukopenia. Our preliminary data 
indicate a potential usefulness of recombinant alfa 2b interferon in CTCL but a prolonged follow·up is necessary to define the long· 
term interferon response. 
TREATMENT OF VISCERAL AND DIFFUSE LEISHMANIASIS BY INTERFERON GAMMA. R. Falcoff, R. Badaro', E. Falcoff; Unite 
196 INSERM, Institute Curie, Paris, France; and 'Universidad Federal da Bahia, Salvador, Brazil 
T cells from patients with either visceral or diffuse leishmaniasis do not recognize specific antigens. In vivo, intradermal 
injection with specific leishmanial antigen (Montenegro 's test) fails to induce a local inflammatory reaction and, in vitro, cultures of T 
cells from these patients are not stimulated by this antigen. These clinical forms were chosen for an open therapeutic trial with 
recombinant interferon gamma (rIFN-y) provided by Roussel -Udaf (Paris - France). 15 out of 17 visceral leishmaniasis patients 
responded completely, as measured by the disappearance of parasites in splenic aspirates, dramatic reduction of splenomegaly, 
improvment of hematological and clinical symptoms, and the Montenegro's test and in vitro blastogenic responses reverting to 
positive. In the other 2 visceral leishmaniasis patients, a full response was also achieved when rlFN-y treatment was followed by 
amphotericin B. One patient with diffuse cutaneous leishmaniasis, a very uncommon clinical form of leishmaniasis, who presented 
with persistent nodules also completely responded. Thus, although the results of a current double· blind study are not yet available, 
we can conclude that rlFN·y is an effective drug in this infectious disease. 
MORBUS BEHCET: TREATMENT WITH INTERFERON GAMMA. G. Rerlbeck, G. Rassner; Dept. of Dermatology, University of 
TObingen, TObingen, FR Germany 
In a clinicallong·term study 10 patients with Morlbus Behcet were treated with subcutaneous injections of interferon (IFN) 
gamma. Patients were treated with doses of 100 microg IFN gamma daily for the first two weeks and three times per week for the 
following months. After three months of treatment evaluable documentation was available for 10 patients and after 9 months for 7. 
After three months of treatment 9 out of 10 patients responded to IFN gamma. Oral and genital ulcers, erythema nodosum, 
thrombophlebitis and polyanthritis became less pronounced and less painful or cleared completely. However, uveitis and papillitis 
failed to respond to the treatment. In one patient treatment had to be discontinued because of a deterioration in his state after four 
months. One patient dropped out after 5 months and one is just now 7 months under therapy. In 7 patients after nine months of 
treatment, various improvements occurred depending on the main manifestation, the mucocutaneous symptoms responded well to 
therapy, whereas ocular symptoms did not. Clinical hematological investigations were carried out over the entire duration of the 
study. Raised erythrocyte sedimentation rates decreased, and the serum triglyceride values and the lactate dehydrogenase activity 
increased under therapy. The tolerance at low dosage was good, only mild influenza-like symptoms were recorded. A short time after 
discontinuation of the 9 months IFN-therapy, the clinical symptoms recurred, and the clinical test values returned to those before 
treatment with IFN gamma. 
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ACTIVATION OF 2'-5'Ol\GOADENYLATE SYNTHETASE AND NATURAL KILLER CELL FUNCTION DURING TREATMENT WITH 
INTERFERON GAMMA. G. Fierlbeck, M. Gombert, R. Handgretinger, G. Bruchelt; Dept. of Dermatology, University of TObingen, 
TObingen, FR Germany 
Patients with genital warts were treated with recombinant interteron (IFN) gamma subcutaneously. 15 patients with a single 
dose of 200 microg and 14 patients with 200 microg IFN gamma daily for 7 days. We used IFN wittl a specific activity of 2.5 x 10 
U/mg protein (Bioferon, Laupheim, FRG). The activity of 2'-5' oligoadenylate synthetase (2'-5' OAS) in peripheral blood cells and ttle 
natural killer cell (NK cell) activity were monitored as indicators of interteron biological activity in vivo. In addition we determined the 
serum interteron (IFN) levels by a commercial available kit. 2'-5' OAS activity was detected by Schattner-assay in mononuclear blood 
cells and NK cell activity against K 562 target cells in the CrSl release assay. Mer a single administration of 200 microg IFN gamma 
a significant increase of the serum IFN level could be observed after 6 hours, of 2'-5' OAS after 24 hours and of NK cell activity after 
72 hours. 168 hours after injection the NK cell activity and 2'-5' OAS decreased below ttle initial levels. 216 hours after injection ttle 
IFN serum level, ttle NK cell activity and the 2'-5' OAS were higher ttlan before treatment. After one week of treatment with daily 
injections of 200 microg IFN gamma the serum level of IFN gamma were elevated and an induction of bottl 2'-5' OAS and NK cell 
activity was seen in all patients at the seventh day of treatmen!. Compared wittl the single dosage the serum level of IFN gamma 
was threefold higher, the stimulation of 2'-5' OAS and NK cell activity greater. We conctude ttlat a single dosage of 200 microg IFN 
gamma is able to stimulate ttle 2'-5' OAS and the NK cell activity. The biological effect of a continuous treatment with IFN gamma 
over one week is higher, the serum titer of IFN seems to accumulate. 
TOPICAL lIPOSOME-ENCAPSULATED INTERFERON ALPHA FOR THE TREATMENT OF GENITAL PAPILLOMAVIRUS 
INFECTIONS. M. Foldvari', A. Moreland" and M. Mezei"' ; College of Pharmacy" and Department of Medicine", University of 
Saskatchewan, Saskatoon, Canada; College of Pharmacy"", Dalhousie University, Halifas, Nova Scotia, Canada 
Human papillomavirus (HPV) infections of the ano-genital tract are one of the most commonly diagnosed viral sexually 
transmitted diseases. The frequent progression of HPV infections to malignant tumors urges intensive researCh in ttle ttlerapy of 
genital warts. The success rate ot conventional therapy is low, and ttle more effective systemic interteron (IFN) treatment appears to 
be promising for visible lesions but not for latent or subclinical infections. The purpose of ttlis study has been to formulate and test 
liposomes as a selective topical drug delivery system for IFN in the treatment of genital HPV infections. For ttle formulation of stable 
and dermatologically acceptable liposomal IFN, various lipid compositions and preparation techniques have been evaluated. The 
liposomes were characterized by electron microscopy. The encapsulation efficiency and stability of IFN in liposomes was determined 
by centrifugation and polyacrylamide gel electrophoresis of the proteoliposome fractions. Intron A (IFN alpha-2b, Schering Canada 
Inc.) has been successfutly encapsulaled inlo large multilamellar liposomes prepared trom soya 
phosphatidylcholine :cholesterol:steariC acid 2:1 :1.4 molar ralio; by a modified solvent evaporation method (protein to phospholipid 
ratio 7 x loJ IU/mg). The liposomes were in a size range of 0.5 - 2 microm as determined by electron microscopy. The incorporation 
of IFN into liposomes was greater ttlan 90 %. The developed product has proper meological properties for topical appl ication. It was 
concluded ttlat ttlis liposome preparation is suitable for preliminary clinical investigations, which have already been iniliated wittl ttle 
described formula in patienls diagnosed to have genilal warts by HPV typing. 
PRESENCE OF ICAM-I ON MELANOMA CELLS IN VITRO AND ENHANCEMENT OF ITS EXPRESSION BY INTERFERONS. C. 
Garbe', K. SChrOder', K. Krasagakis:, Ch. C. Zouboulis', S. KrOger:, R. Schwarting!. University-Depts of 'Dermatology and 
fPathology, Urnv. Medical Center Steglitz, The Free University of Berlin, Bertin (West), FR Germany 
Intercellular Adhesion Molecule-I (ICAM-I) is a B9-KDa cell surtace glycoprotein which direcUy binds to Lymphocyte 
Function Associated Antigen-I (LFA-I ), an adhesion glycoprotein broadly expressed on cells of the haematopoietic lineage 
mediating leukocyte adhesion. ICAM-I (identical to P .3.58 antigen) is detectable in situ on advanced human melanomas but not on 
benign melanocytes or early melanomas and was ttlerefore designated as progression associated melanoma antigen. The purpose 
of this study was to determine the in vitro expression of ICAM-I on melanoma cells and its modulation by interterons. ICAM-I 
expression was investigated in 5 metastatic malignant melanomas in situ, in melanoma cell cultures derived from these tumors (cell 
lines StML 21-25, 5th subculture) and in 3 established melanoma cell lines (StML II , 12 and SKMel-2B). Antigen expression was 
determined by the APAAP-technique in tissue sections and in cytospins of cultured cells as well as by FACS-analysis. To investigate 
the IFN-effect, cell cultures were incubated with rIFN-alpha-2a, nlFN-beta and rlFN-gamma (100-1000 IU/ml) for 2-4 days and were 
evaluated in comparison to untreated controls. ICAM-I was found present in 4/5 metastatic melanomas in tissue sections. All 8 
melanoma cell lines investigated expressed ICAM-I including ttle cell line derived Irom the ICAM-l-negative tumor. rIFN-aipha-2a 
intensified the fCAM-I expression on cultured melanoma cells as detected by APAAP, whereas in FACS-analysis no significant 
changes were assessed. nlFN-beta caused a slight increase of ICAM-I expression detected by FACS-analysis in 1/3 cell lines. On 
the contrary to type I IFNs, rlFN-gamma caused a remarkable enhancement at ICAM-' expression on cultured melanoma cells, 
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detected by both APAAP and FACS-analysis. In conclusion, ICAM-t is expressed on melanoma cells in vitro, even on the cells 
derived from a ICAM-l -negative tumor. As ICAM-l is characterized as a marker of tumor progression in situ, its remarkable 
enhancement by rlFN-gamma in vitro arises the question if IFN-gamma induces a more malignant phenotype of melanoma cells. 
BETA- AND GAMMA-INTERFERON IN MALIGNANT MELANOMA. C. Garbe, R. Stadler, Ch. C. Zouboulis, K. Krasagakis, K_ 
Schroder,s. Kruger, Dept. of Dermatology, Univ. Medical Center Steglitz, The Free University of Berlin, Berlin (West), FR Germany 
The antitumor effect of interierons is based on several mechanisms; (a) direct cytostatic effect, (b) tumor cell differentiation 
and (C) modulation of the immune response. In our studies, the direct cytostatic effect of various interierons on melanoma cells in 
vitro was remarkably different. The 50% growth inhibitory concentration tested in 3 established melanoma cell lines (StML-" , StML-
12 and SKMel-28) was 20-40 IUlml for nIFN-beta, 600-1.200 IUlml for rlFN-gamma and 7.000->50.000 IUlml for r-IFN-alpha-2a_ 
IFN-beta and IFN-gamma induced a synergistic antiproliferative effect on melanoma cell proliferation. The differentiation of cultured 
melanoma cells as recognizable by their immunophenotype was different for type I (IFN-alpha, beta) and type II IFNs (IFN-gamma). 
Type I IFNs markedly enhanced HLA-I expression, whereas the expression of the progression associated melanoma antigen 
A.l0.33 (PAMA) was reduced. IFN-gamma Significantly increased the expression of the PAMA A.l.43. Furthermore IFN-gamma 
remarkably enhanced HLA-II antigens and ICAM-l characterized as progression associated antigens in situ. All IFNs tested 
activated and enhanced the antitumor activity of natural killer (NK) cells, macrophages and sensitized T-cells, but IFN-gamma was 
significantly more efficient in enhanCing NK- activity and in activating macrophages than type IIFNs. Treatment with rlFN-gamma in 
a high dosage (0,5mglm2 daily) caused 3 partial remissions among 27 patients with disseminated melanoma. No data on treatment 
with nlFN-beta in disseminated melanoma are available_ A combined treatment with IFN-beta (3x 5 Mill IU per week) and IFN-
gamma (5x O,lmg per week) revealed no response among 16 patients. A similar trial in our dept. with a low dose combined 
treatment (IFN-beta 1 Mill IU per week and IFN-gamma 0.05 mg 5 days every 4th week) resulted in 1 partial response (11 months) 
among 10 patients. No improvement in survival was observed by adjuvant treatment with IFN-gamma or with the combination of IFN-
beta and IFN-gamma in stage II malignant melanoma. In spite of the remarkable effects of nlFN-beta and rlFN-gamma on the 
proliferation and differentiation of melanoma cells in vitro, no superior therapeutic results were obtained so far by rlFN-gamma or the 
combination of nlFN-beta with rlFN-gamma on disseminated malignant melanoma when compared to previous studies with rIFN-
alpha mono therapy. 
THYMIC FACTORS (TACTIVIN) IN THE TREATMENT OF CHRONIC ECZEMATOUS DERMATITIS IN AGED. F. Garib, R. 
Kapkaev, N_ Talanin, V_ Dvatyan; Tashkent Medical Institute, TashKent, USSR 
Thirty aged patients with eczematous skin reactions received tactivin in addition to traditional treatment. Twenty-four 
patients in the control group were treated traditionally_ Before treatment the subsets of circulating lymphocytes in patients were 
studied using sensitive rosette technique. Sharp decrease in total T-Iymphocytes, helper T-cells and suppressor T -cells was noted. 
The level of total B-cells was normal. Slight increase of B-cells bearing Fc y-receptors and antigen-binding lymphocytes were marked 
(normal human skin membrane antigen was used). After a month of treatment the lymphocyte subsets in the control group were at 
an abnormal level. In the test group the percentage of all subsets except B-cells bearing Fc y-receptors was normalized as a result of 
tactivin action. The normalization of immune status was accompanied by marked clinical effect. No major side-effects were 
observed. Tactivin is an effective drug in the treatment of chronic eczematous dermatitis in aged. 
THE PHARMACOLOGY OF INTERFERON ALFA-2A. L. Gauci, Hoffmann-La Roche, Basle, Switzerland 
Interieron aUa-2a is a recombinant produced subtype of human alpha interieron expressed in E. coli. It displays similar 
broad spectra of antiviral and antiproliferative activities as preparations containing mixtures of alpha interierons such as leukocyte 
and Iymphoblastoid preparations. It is virtually non-toxic in most mammalian species tested. Systemic administration in human 
subjects is aSSOCiated with typical interleron toxicity. Its pharmacokinetic behaviour following intramuscular, subcutaneous and 
intravenous administration is very similar to the profile seen in non-human mammals. Some of the acute flu -like effects can be 
prevented or reduced in severity by paracetamol and aspirin. The antiviral effects, however, are not abolished. Similarly co-
medication with predisone does not appear to adversely affect tumor response. Interieron alfa-2a has a remarkably broad potential 
therapeutic applications. As monotherapy it is active against a variety of advanced haematological and non-haemato-Iogical tumors 
when evaluated in the classical chemotherapeutic way. Factors critical to optimalizing therapeutic success include dose and duration 
of therapy. Many months of therapy may be required to induce disease regression. Adjuvant maintenance therapy represent 
important applications in oncology. tnterteron alla-2a can also be used to enhance the activity at chemolhera-peulic agents such as 
5-FU and cis-platinum which may even reverse so-called resistance. The drug is active in chronic viral diseases such as hepatitis-B, 
hepatitis-C, SSPE, HIV and HPV infections etc. It is also active in acute viral disease such as respiratory viruses. Japanese 
encephelatis, herpes zoster etc. Both in oncology and virology there are diseases which do not respond to therapy. Patients who 
respond 10 primary interleron alfa-2a therapy and relapse at a later date have a good chance of responding again to therapy. 
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MEDIATORS OF IMMUNITY 1M PEMPHIGUS AND PEMPHIGOID BLISTER FLUIDS. SA Grando. BT. Glukhenky; 
Immunodermatology Unit and Dept. 01 Dermalo-Venereology, KSATID, Kiev, USSR 
Blister fluids from 39 primary palienls witl1 pemplligus vulgaris (PV) and 28 palients with bullous pemphigoid (BP) were 
tested for the presence of immunity mediators. H was found that blister fluid from PV and BP patients featured interleukin 2- and 
interleukin 2·like activities (IL 1·1 a and IL 2·1 a) and contained prostaglandin (PG) E2, F1ALPHA, F2ALPHA, thromboxane B2 
(TB2), leukotriene (L T) B4 and C4, serine esterase and proteotysis inhibitors. Pemplligus blister fluid was distinguished by high IL I-
I a, proteolytic activity, high concentration of TB2 and L TB4 while pemphigoid blister fluid was characterized by higher IL 2·1 a, 
antiprotease activity and high PGE2 concentration. We also established that the immunity mediator content varied depending upon 
the duration of blister development. Botl1 in PV and BP, the initially high IL 1-1 a, amount of serine proteinase and concentration of 
PGF2ALPHA, T82, L TB4 and L TC4 decreased by the 5th day of blister existence whereas antiproteinase activity and PGE2, 
PGF1ALPHA concentration gradually increased during blisler development. These findings enabled us to suppose tI1at there exist 
certain differences between the character of skin blistering inllammatory processes in pemphigus and pemphigoid. 
SOLUBLE PUTATIVE FACTOR OF EPIDERMAL ORIGIN IN PEMPHIGUS AND PEMPHIGOID INHIBITS INTERLEUKIN 
CASCADE REACTIONS. SA Grando; Unit of Immunodermatology KSATID, Kiev, USSR 
To establish the causes of immunocompetent cell activity inhibition in autoimmune bullous dermatoses, we studied tI1e 
influence of culture supematants of epidermocytes from involved and uninvolved skin of 28 patients with pemphigus vulgaris (PV) 
and 19 patients with bullous pemphigoid (BP) on the ability of donor peripheral blood mononuclears (DPBM) to lectin-dependent 
proliferation and participation in interleukin cascade reactions. When asseSsing the results, suppression index (SI) was calculated: SI 
= (I - with supematantlWithout supernatant) x 100. It was found that supematants of cultures of spinous cells, obtained from involved 
and uninvolved skin of acute PV patients, as well as basal cells of involved skin of acute BP patients, produced equal inhibitory 
effects on DPBM proliferation in response to PHA (SI varied from 67 to 93%), Con A (71 -89%), production of interleukin 1 (63·82%), 
interleukin 2 (59-81 %) and absorption of exogenous interleukin 2 (66-87%). Culture supernatants of epidermocytes from uninvolved 
skin of acute BP patients as well as PV and BP patients in remission stage did not inhibit the DPBM activity. The obtained results 
show that keratinocytes in PVand BP acquire the ability to produce a putative soluble factor marking immunosuppressive effects. In 
PV, such transformation is observed in epidermocytes of entire skin, in BP only in perilesional skin. Interierence of epidermocytic 
factors into interleukin cascade reactions is probably the cause tor the immunodeficit developement in patients with autoimmune 
bullous dermatoses. 
INTERFERON AND COLLAGEN PRODUCTION. R.D. Granstein, T.J. Flotte, and E.P. Amento; Dept. of Dermatology, 
Massachusetts General Hospital and Genentech, Inc., South San Francisco, CA, USA 
The immunoregulatory, antiviral, and antiproliferative agents known as the interferons have profound effects on collagen 
synthesis. Interferons ALPHA, 8, and y suppress collagen synthesis by dermal fibroblasts. In addition, interferon-y (IFN-y) inhibits the 
constitutively increased collagen synthesiS characferistic of fibroblasts derived from lesions of patients with scleroderma. IFN-y also 
inhibits collagen synthesis by myofibroblasts and synovial fibroblast-like cells. Inhibition of collagen protein synthesis by IFN·y is 
associated with a coordinate inhibition of transcription for types I and III collagens. In addition, IFN-y suppresses levels of 
procollagen mRNA and type II collagen synthesis in human articular chondrocytes. In vivo studies in mice have demonstrated that 
IFN-y inhibits collagen synthesis associated witl1 the fibrotic response to an implanted foreign body, bleomycin-induced pulmonary 
fibrosis and the healing response to cutaneous tI1ermal burns. In the latter case, while collagen content of the wound scar was 
decreased, hyaluronate was increased in mice receiving IFN-y compared to controls. Of interest, acute inflammation at sites of 
thermal injury, or when elicited by proinflammatory agents in separate experiments, also was suppressed in mice treated with IFN-y. 
Interferons of all tI1ree classes inhibit collagen synthesis with varying degrees of potency. The means by which IFN·y inhibits 
collagen synthesis involves transcriptional regulation. Since IFN-y can inhibit collagen synthesis in vivo, further studies may be 
warranted to evaluate the usefulness of this agent in the treatment of disease states characterized by abnormal fibrotic responses, 
as well as its potential lor allering the healing response associaled with particular therapeutic inlerventions. 
BIOLOGIC EFFECTS OF INTERFERONS. I. Gresser, Centre National de la Recherche Scientifique (UPR 274), Villjuif, France 
H one were to review articles on IFN publisined between 1957 and 1967 it would become apparent that virtually none of the 
tenets held then are still valid today. Whereas IFN was long considered to be a specific antiviral substance without any effect on 
normal cellular metabolism, we accept today tI1at it affects normal cell division and many specialized cellular functions. In this respect 
it is not unique; IFN is a prototype of a family of similar substances now called cytoilines which all appear 10 function as regulatory 
molecules. II was held that the production of IFN constiMed a specifIC response to a viral infection. Today we believe that IFNs are 
an integral part of a cytokine network and that they and other cytokines may be produced constilutively al low levels. These 
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substances exert multiple effects on virtually all cells. They play an important role in host delense against viral and parasitic 
infections, and in fhe resistance fo experimental tumors. IFNs can be shown to exert effects on the immune system and on 
lymphocyte circulation. Lastly, because of the multiplicity of their biologic effects, they may even contribute to the pathogenesis of 
certain diseases. Thus, when large amounts of IFNs are administered or induced in newborn mice they can cause liver, kidney and 
pulmonary disease. The field of IFN and cytokine research continues to expand and there is an increasing number of therapeutic 
applications. Twenty years from now, scientisls and clinicians may be surprised that we understood so little of how IFNs acl and how 
inadequately we used fhem to treat diseases. 
EFFICACY OF INTERFERONS ON BOWENOID PAPULOSIS AND OTHER PRECANCEROUS LESIONS. G. Gross and A. 
Roussaki; Dept. of Dennatoloy, University of Hamburg, Hamburg, FR Germany 
Both genital bowenoid papulosis (BP) and Bowen's disease (BD) have been associated with a HPV 16 infection using DNA 
hybridization. In contrast to genital BD presenting a high risk 01 malignant conversion especially at the vulva, BP, being also an 
inlraepilheliaJ neoplasia, is a disease seen in younger adults with a more benign course. In view of the possible spontaneous 
regression of SP, vulvectomy should be avoided in young women and Ireatment with interferon (IFN) should be of particular interest. 
As shown previously in cervical intraepilhelial neoplasia, in a limited number of studies IFN alia and beta gel showed fo be active 
also in vulvar and in penile BP. Using fhe syslemic approach, 6 out of 7 patients (515 males and 1/2 women) treated cyclically with 
low doses of rlFN alia 2c (Boehringerllngelheim; 5 x 106 IU) and 2 out of 4 patients (1/2 males and females, respectively) treated 
with low doses of rlFN gamma (Bioferon/Laupheim, FRG; 2 x t06IU) showed complete response. Inferestingly. the response of BP 
to rlFN alia seems to be superior to that to rlFN gamma. Duration of freatment was shorter and the number of therapeutic cycles was 
smaller in Ihe IFN alfa 2c treated group in comparison to the IFN gamma treated group. Furthennore, the data suggest that male 
patients suffering from BP respond better than do female patients. An additional approach to prevent relapse of intraepithelial 
neoplasia after C02-laser or electrocautery is the adjuvant postsurgical therapy with rlFN alia 2c or rlFN beta gel. Thus far 4 women 
suffering from vulvar BP have been treated successfully with rlFN beta gel (tollow-up 2 months). 
RECOMBINANT INTERFERON-GAMMA IN GENITAL WARTS: RESULTS OF A MULTICENTER PLACEBO-CONTROLLED 
CLINICAL TRIAL. G. Grossl, W. Degeng, M. Hilgarth3, L. Kowalzick.1, A. Roussakil, Th. Rufli4, H. Schofer5 and J. Brzoska2; 
Departments of Dennatology of the University of Hamburgl (FR Gennany), Basei4 (Switzer1and), FrankfurtS (FR Gennany), 
Departments of Gynecology of Dusseldorf2 and Freiburg3 (FR Gennany) and Bioferon6, Laupheim (FR Germany) 
44 patients with recurrent genital warts (average age 25-29 years, average duration of disease 8-9 months) entered a 
comparison of SUbcutaneously administered recombinant interferon (IFN)-gamma (n=20; 50 microg (about I mill ion IU) daily for 7 
days followed by 4 weeks without therapy (= I cycle) up to 4 cycles)) with placebo (n=21 ; human serum albumin). Side-effects were 
mild and similar in the two groups (62% in the group receiving verum and 61% in the placebo-treated group) consisting of flu-like 
symptoms. 4 I patients completed the study; 3 were withdrawn from the placebo group. Responders were defined as patients with 
complete or partial (> 50%) remission without fonnation of new lesions. There were 12 responders (60%) in the IFN"9amma group 
compared with 7 responders (33%) in the placebo group (x = 2.93 , p< 0.05 ', one-tailed). These data indicate that low doses of IFN-
gamma given cyclically have a therapeutic potential in genital warts. 
ADJUVANT POSTSURGICAL INTERFERON ALFA-GEL THERAPY FOR RECALCITRANT GENITAL WARTS IN 
IMMUNOCOMPROMISED PATIENTS. G. Grossi, A. Roussakil, H. Pfister2; 1 Dept. of Dennatology, University of Hamburg, 2Dept. 
of Virology, University of Erlangen (FR Gennany) 
Women suffering from both genital papillomavirus infections and defects of the cell -mediated immunity cannot respond 
proper1y to interferon which has been shown recently to be effective in immunocompetent patients wifh anogenital HPV disease. A 
lack of response has been reported in asymptomic patients with HIV, in patients suffering from Hodgkin's disease and in drug 
addicts. Herein, an alternative therapy is presented which leads to complete cure without relapse of severe anogenital warts in 
immunocompromised patients. Recombinant interferon alia 2c (Boehringer-Ingelheim, FRG) is given as a hydrogel (containing I 
million IU per gram) 3 times daily during 4 weeks after complete surgical removal by C02-laser, electrocautery or liquid nitrogen. The 
only side-effect noticed was prolonged wound-healing. Using this approach, so far 2 immunocompromised women and 2 men with 
severe anogenital HPV disease were treated successfully. One woman suffered from Hodgkin's disease and the other had a 
reduced number of NK~lIs. One of the male patients was HIV-positive and suffered from ARC and the other was 
immunosuppressed for renal transplantation. In all cases no relapse was seen during a follow-up of at least 14 months. In confrast to 
the systemic interferon therapy, the action of the topical adjuvant therapy using interferon hydrogel is independent of the cellular 
immunity of the host. II is suggested that interferons given directly to the targel basal cells of HPV inlection, acl in protecting the 
keratinocyte against the penetration of the virus by inducing an antiviral state. 
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TRANSCRIPTION AND EXPRESSION OF TGF-B IN HEALTHY AND DISEASED SKIN_ M_ Gruschwitz. G. Wick; Institute for 
General and Experimental Pathology. University of Innsbruck. Medical School. Innsbruck. Austria 
Transforming growth factors-Bt and -B2 bind to common glycoprotein receptor complex with similar affinity to mediate 
equipotentially the inhibition of epithelial cell proliferation and the induction of fibronectin and collagen expression. TGF-B can be 
produced by neoplastic and normal cells including platelets. activated T cells. macrophages and kerafinocyles. Therefore. we were 
interested in the role of these mediators in dermatological disorders with prominent mononuclear cell infiltration (contact dermatitis. 
chronic discoid LE) and cutaneous fibrotic reaction (scleroderma). We investigated the distribution of TGF-BI12 messenger RNA and 
the final proteins in frozen skin sections by means of in situ hybridizafion and indirect immunfluorescence. Our studies revealed TGF-
Bl and -B2 mRNA in dermal and subcutaneous infiltrating cells in scleroderma. but also in the other inflammatory skin disorders. 
Interestingly. we could also demonstrate abundant expression of TGF-Bl /2 in the epidermal keratinocytes of the germinative layers 
in diseased and normal skin. Immunofluorescence studies revealed the same distribution pattern of the TGF-B proteins. Our data 
indicate that TGF-B expression of mononuclear infiltrating cells is not a specific feature of scleroderma and seems to be associated 
with proliferating cells in general. perllaps functioning as a mediator of cell regulation with special importance for negative control of 
cell growith. Furthermore. TGF-B2 may serve as aulocrine or paracrine regulatory molecule for keratinocyte growith and 
differentiation. necessary for epidermal homeostasis. 
URUSHIOL DIRECTLY INDUCES KERATINOCYTE (KC) INTERCELLULAR ADHESION MOLECULE-t (ICAM) EXPRESSION IN 
RHUS DERMATITIS. C.E.M Griffilhs. B.J. Nickoloff; Dept. of Dermatology. Univ. of Michigan. Ann Arbor. Michigan. USA 
We have previously observed that phorbol ester. via a protein kinase-C dependent pathway. can directly induce KC ICAM 
expression. The small hapten urUShiol. responsible for rIlus dermatitis is a known PK-C agonist. and we asked whether urushiol 
could directly induce KC ICAM. 5 volunteers with a positive history of rhus dermatitis were patch tested for periods up to 5 days with 
a 1:50 w:v poison ivy/oak mix and the clinical response assessed followed by sequenfial punch biopsies prior to and including fhe 1st 
sign of erythema. Cryostat sections were immunohisfochemically stained. KCs grown in either Lab-Tek slides or dishes were 
incubated with highly purified urushiol or pentadecyl-catechol (PDC). the inactive constituent of poison ivy. and slained for ICAM and 
HLA-DR using immunoperoxidase and immunofluorescence/FACS analysis. In vivo. a consistent early change. before any erythema 
was focal basal KC ICAM without HLA-DR. occurring in the absence of a dermal T cell infiltrate. On day 3. with the onset 01 edema. 
there was widespread KC ICAM & HLA-DR coincident with a prominent infiltrate of LFA-I+.LFA-3+ .UCHL-I+.2H4- ("memory") T 
cells with a 4:1 CD4:CD8 ratio. In Lab-Tek slides. urushiol. bul not PDC. induced KC ICAM expression. This was confirmed by FACS 
analysis since 72 hrs incubation with urushiol induced KC mean channel fluorescence of 12 +/- 3 (n:3) over background and there 
was only minimal expression of HLA-DR. Thus. urushiol can directly induce epidermal KC ICAM expression and Ihis suggests that 
the initiation of altered epidermal T cell trafficking occurs in a non-Iymphokine-medialed. PK-C dependent fashion. The subsequent 
memory T cell infiltrate. and consequent induction of HLA-DR by tymphokines such as gamma interferon. may act in concert as an 
amplification process to produce the characteristic eruption of rIlus dermatitis. 
ADJUVANT THERAPY WITH INTERFERON ALFA 2B ON MALIGNANT MELANOMA PATIENTS AFTER SURGICAL EXCISION 
OF SKIN OR LYMPH NODE RECURRENCE. B. Guillotl. D. Cupissol2• M. Caubel2• G. GUille@. C. Viraben:L C. Drobachef@,Ji 
Bonnefoi:L A. Thyss;). J. Labeille5• J.M. Bonnet-Blanc. J. CameneM; (t . Service de Dermato-Phlebologie. Hopital Saint-Charles. 
Montpellier. France. 2. Centre Val d'Aurelle . Montpellier. France. 3. CHR de Brest. Toulouse. Besan~n. Annecy. Nice. Amiens. 
Limoges. Tours. France). 
The prognosis of metastatic malignant melanoma is very poor and classical adjuvant therapies remain disappointing. The 
mean time of response has been described of 2 - 5 months. The disease progression is in relationship with the tumor size. Surgical 
excision is not able to cure the patients definitely. and it is necessary to test the efficacy of new adjuvant therapy. In order to treat 
residual disease. we have performed the feasibilty of treatment with interferon alfa-2b 10 million U 3 times a week for I year in 
pafients with skin and/or lymph node recurrence after surgical excision and without any metastatic disease. 48 patients are included 
in this study. 28 patients are evaluated after I year. 5 cases were stopped before the end of the treatmenf for toxic events. Among 
the 23 evaluable patients 9 are in complete remission (39%) and still show 14 relapses. Results seem better than with surgery alone 
but it is too early for definite conclusions. 
INCREASE OF DNA SYNTHESIS AND EXPRESSION OF BULLOUS PEMPHIGOID ANTIGEN ON NORMAL HUMAN 
KERATINOCYTES BY ADDITION OF INTERFERONS. H. Hachisuka. K. Okubo. T. Karashima. Y. Sasai; Dept. of Dermatology. 
Kurume Univ. School of Medicine. Kurume. Japan 
Although interferon is a suppressive factor on keratinocyte proliferation and has the ability to induce HLA-DR antigen on 
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human keratinocytes, its role on keratlnocytes is still unknown in detail. In this study, we examined the eflect of interteron on DNA 
synthesis and expression of HLA-DR and BP antigen on normal human keratinocytes. Normal human keratinocytes were cultured in 
keratinocyte growth medium containing EGF. After 24 hrs initial cultivation, interferon ALPHA, Band y were added to each well and 
subsequently incubated for 48 hrs, 96 hrs and 144 hrs. DNA synthesis was indicated by 3H-thymidine incorporation. Expression of 
HLA-DR and BP antigen on keratinocytes was measured by laser flow cytometry. Interleron ALPHA, B and y showed remarkable 
enhancement of DNA synthesis after 96 hrs cullivation. Interferons enhanced the expression of HLA-DR and BP antigens on normal 
human keratinocytes. Although it has been reported that high concentration of interferon inhibits keratinocyte growth in long·term 
culture, we demonstrated that interferons induce the expression of HLA-DR and BP antigens, and iow amounts of interferons 
enhance DNA synthesis aller 96 hrs. This resull indicales that interferons induce keratinocyte activation at initiat stage in this assay. 
We suggest that interferon plays an important role on the interaction between inHammatory cells and keratinocytes by inducing 
keratinocyte activation. 
EFFECTS OF INTRADERMAL APPLICATION OF rlFN·y IN CUTANEOUS LEISHMANIASIS CAUSED BY L. TROPICA. G. Harmsl, 
K. Zwingenberger1, A.K. Chehade2, P. Rac~, M. Douba£ M. Roepke I , U. Bienzle I ; I Landesinstitut fOr Tropenmedizin, Bertin, FR 
Germany; 2Dept. of Dermatology, University of Aleppo, Syria ; 3Bemhard-Nocht-lnstitut fOr Tropenmedizin, Hamburg, FR Germany 
In a controlled study human recombinant interferon gamma (rIFN-y) was tested in cutaneous leishmaniasis in Syria. rlFN-y 
(25 microg) or saline were applied perilesionally"on 4 allemating days. An acute inflammatory reaction was observed around treated 
but not control lesions. rlFN·y treated lesions healed completely in 69 % and partially in 15 % of the cases within 4 to 8 weeks after 
treatment. No local or systemic side-effects were noted. Histological examination of skin biopsies obtained from treated lesions but 
not controls before, 3 and 9 weeks after treatment revealed increased numbers of mononuclear cells and plasma cells as well as 
granuloma formation. Immunohislochemical staining showed increase of CD4t, COBt and CDI4t cells as well as augmentation of 
COlt, CD25t, and HNKlt cells, expression of HLA-DR antigen and of prolileration antigen. We conclude, that local application 01 
rlFN·y enhances cell-mediated immune responses and thus promotes Ihe healing of cutaneous leishmaniasis. Results of a more 
recent comparative study, enrolling 44 patients with 60 lesions, treated with either rlFN-y or Glucantime (N-methyl-glucamine 
antimoniate) will be reported. 
EXACERBATION OF PSORIASIS WITH ALPHA INTERFERON. P. Harrison, Dept. of Dermatology, Beaumont Hospital. Lancaster, 
U.K. 
Gamma interferon has been shown to possibly improve psoriasis, but reports have conflictingly indicated both a beneficial 
and adverse effect from alpha interferon. We have studied 10 patients (4 males and 6 females, age range 35 - 77. mean 51) with 
widespread chronic plaque-type pSOriasis who, after hospital admission to achieve clearance of their skin condition, received a 
course of alpha interleron. Each patient was given recombinant alpha inlerferon 3 million units subcutanecusly 3 times weekJy for 3 
months and there was no other concomitant systemic medication. Patients were reviewed monthly to monitor clinical progress and 
adverse effects. One patient had transienl neutropenia and another moderate Hu-like symptoms which did not necessitate the 
stopping of treatment. At the end of the 3 month study period only one patient's psoriasis remained in complete remission, another 
patient's skin was slightly active and a further patient's skin moderately active. However, 2 patients' pSOriasis had undergone 
significant exacertoation at the end of 1 month. 4 at the end 01 2 months and 1 at the end 013 months. In conclusion, alpha interferon 
did not demonstrate any beneficial effect upon psoriasis and, furthermore. may precipitate exacertoation of the condition. 
THE MEDIATION OF LYMPHOCYTE EXTRAVASATION. J.B. Hay and A.N. Kalaaji, Depts. of Immunology and Pathology, 
UniverSity ofToronto, Ontario, Canada. 
Lymphocytes leave the blood in large numbers at sites of delayed hypersensitivity lesions and allografted tissues. Although 
Iymphokines have been considered as mediators of this process for several years. direct, quantitative evidence for this conclusion 
has only recently been described. We have used an assay involving the labeling of lymphocytes from efferent lymph of sheep with 
ll1-indium to test various potential molecular mediators. This assay involves a three-hour pulse of intravenously injected labeled 
lymphocytes. In strongly positive dermal sites more than 100 times the radio-activity is detected over that seen in negative sldn sites. 
Approximately 100 test sites can be compared per animal, thereby permitting a complete analysis of dose responses and the kinetics 
of accumulation. Experiments to date have led to the conclusion that IL-I. IL-2, prostaglandin E2, trnlp. rabbit and sheep zymosan 
activated plasma and casein are ineffective. In contrast, the most potent inducers of lymphocyte localization observed to date are 
TNFALPHA and IFNy. Significant but modest effects have been seen with IFNALPHA. The maximum extravasation with TNFALPHA 
occurred 12 - 15 hours aller injection. It is now feasible to use this quantitative assay to pharmacologically modulate TNFALPHA, 
IFNy tymphocyte traffic in situ {supported by MRC Canada). 
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LYMPHOKINE EFFECTS ON CELLULAR CYTOTOXICITY. R.B. Herberman, Pittsburgh Cancer Institute, Pittsburgh, PA, USA 
Lymphokines playa major role in regulating the generation and levels of reactivity of cytotoxic effector cells. Interferons 
(IFN) ALPHA and B substantially increase the cytotoxic activity of natural killer (NK) cells, whereas IFNALPHA has a less consistent 
effect. IFNs can also appreciably affect the susceptibility of target cells to cell·mediated lysis, increasing susceptibility to lysis by 
cytotoxic T lymphocytes (CTL) and inducing resistance to lysis by NK cells. Interleukin 2 (IL2) has a very potent variety of effects on 
cytotoxic effector cells. IL2 facilitates the generation of CTL and promotes their proliferation. via interactions with IL2 receptors on 
activated T cells. IL2 also strongly augments NK activity. promotes the differentiation of NK cells from precursors, and stimules 
proliferation of these effector cells. IL2 as well as IFNALPHA or B also stimulates the antibody·dependent cellular cytotoxic activity of 
NK cells. IL2·activated killer cells, termed Iymphokine·activated killer (LAK) cells, when administered in vivo together with IL2, have 
appreciable anti·tumor effects in some patients with melanoma or renal cell carcinoma, and currently a clinical trial is being 
performed with adherence·purified LAK cells and IL2, which also have considerable cytotoxic activity and are being investigated for 
their therapeutic activity. TILs from various types of cancer have been shown to include a mixture of NK cells and major 
histocompatibility complex·unrestricted T cells, as well as specific anti·tumor CTL. Recent studies have indicated that addition of 
tumor necrosis factor (TNF) to TIUIL2 cultures helps to, at least transiently, 'Increase the proportion of CTL active against autologous 
tumor cells. 
INTERFERONS AND HERPES VIRUS INFECTION. M. Ho, Infectious Diseases and Microbiology, University of Pittsburgh, 
Pittsburgh, PA, USA 
The well controlled studies of the prophylactic and therapeutic efficacy of interferon against various members of the herpes 
virus group have been among the earliest and most prolific. They have adequately pointed out the potential as well as limitations of 
the use of interferons in acute virus disease. Interferon has been shown to be effective against herpes keratitis and herpes zoster. 
We studied the prevention of herpes labialis after surgical decompression for trigeminal neuralgia. When patients received 7 x 104 
units for 5 days beginning one day before operation. reactivation of herpes simplex virus, evidenced by shedding of virus in throat 
washes, was markedly reduced and lesions were also reduced. However, treatment prior to surgery or after surgery alone was 
ineffective in preventing reactivation. We also completed a study of interferon on initial (first episode) genital herpes. Beginning with 
72 hours of onset of lesions, women received 5 x 104 u/kg for 12 doses over 14 days (about 3.6 x 107 U) in placebo. Interferon 
produced quicker healing and significant reduction in the duration of virus shedding. Virus titers were also decreased but the 
frequency of subsequent recurrences was not affected. These studies show that interferon is a potent anti·herpes agent which, 
however, cannot compete with the effect of nucleoside antivirals. Like the nucleosides it has no demonstrable effect on latent 
infection. Whether in combination with other agents it might still be a factor in this area remains to be seen. 
GROWTH OF HEMATOPOIETIC CELLS (NORMAL OR NEOPLASTIC) TREATED WITH INTERFERON·GAMMA (IFN·y) IN 
LETHALLY IRRADIATED SYNGENEIC MICE. A.A. 10riot, M. Neril, T. Zeit, G.B. Rossi!:, and E. Bonmassar3; t Dept. of Virology, 
University, Perugia; 2Dept. of Virology, Istituto Superiore Sanita, Rome; 3Dept. Exp. Med. and Biochem. Sc., II. University, Rome, 
Italy 
Previous observations have reported a decreased susceptibility of IFN·y treated cells to NK cytolysis in vitro. In this study, 
we examined the impact of in vitro IFN·y treatment of normal or tumor cells of hematopoietic origin on their susceptibility to natural 
resistance (NR) in vivo. In vivo NR was evaluated by injecting cells treated in vitro ovemight with IFN·y (200 U/5 x 105 cells) 
intravenously into lethally irradiated (850 R) syngeneic mice, incapable of mounting elicitable graft responses (Cudkowicz G. and 
Lotzova E., Transplant. Proc. 4; 1399, 1973). Cell growth was evaluated 4 ·5 days later in terms of 1251UdR uptake. Bone marrow 
cells of DBN2 (H·2d), C57B1 /6 (H·2b), C3H (H·2k) and BALB/c (H·2d) Origin and Friend leukemia cells (FLC) of DBAl2 origin and 
the benzopyrene·induced ascitic leukemia EL·4 of C57B1I6 origin were used. A significantly higher prOliferation of normal or tumor 
cells treated with IFN·y was observed in normal or Poly I:C stimulated syngeneic mice, as compared with untreated cells. No 
diHerences were observed in mice with reduced NR as a consequence of pretreatment with cyclophosphamide or anti·Asialo·GMI 
serum. Taken together, these data suggest that the direct interaction of IFN·y with cells of hematopoietic origin can protect them 
from in vivo NR. Although this observation can be of therapeutic value in bone marrow transplantation, it calls attention to the 
potential detrimental effect of IFN treatment in antitumor regimens. 
CLINICAL STUDY OF SUN4800 (RECOMBINANT INTERFERON GAMMA) ON SKIN CANCER. The SUN4800 Skin Cancer Study 
Group (K. Ishihara, S. Ikeda', S. Mori", H. Urabe'" and T. Arao .... ); National Cancer Center Hospital, Tokyo; 'Saitama Medical 
School; "Gifu Univ. School of Medicine; '''Faculty of Medicine, Kyushu Univ.; .... Kumamoto Univ. School of Medicine, Japan. 
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Clinical sludy of SUN4800 on various skin cancers (82 piS) was performed by 47 cooperaling institulions using "The crileria 
of direci effect of chemotherapy on skin cancer". Among 26 eligible cases (drip infusion) of mycosis fungoides, 2 cases of complete 
response (CR) and 13 cases of partial response (PR) were observed with a response rate of 57.5 % (15126) . 2 CR and 1 PR were 
also obtained out of 4 cases (intratumoral administration). SUN4800 was also effective for adult T cell leukemiMymphoma, 
squamous cell carcinoma, Bowen's disease and Paget's disease etc. Major side-effects were flu-like symptoms, anorexia and 
nausea/vomWng. Mild leukopenia, neutropenia and increase of transaminase were also observed. Most side-effects were transient 
and not critical. Above results indicate that SUN4800 is a new useful agent for mycosis fungoides in all stages, especially in 
erythematous and infiltrative/plaque stages. 
ANTIVIRAL ACTIVITY OF INTERFERONS_ H. Jacobsen, S. MiHnacht, A. Klolzbucher; German Cancer Research Center, Institute of 
Vinus ResearchiATV, Heidelberg, FR Germany 
Intelierons (IFNs) induce in susceptible cells an antiviral state, which blocks viral replication and protects cells against 
vinus·mediated lysis. The antiviral activity combines several independent mechanisms, which may have varying effects on different 
vinuses. Extensively characterized antiviral mechanisms are the 2',5'-oligoadenylate system which seems to affect predominantly 
picoma - and reoviruses and the Mx-protein, which interferes specifically with the replication of myxovinus. We have analyzed the 
effects of IFNALPHNB on the growth of HSV-l as a possible model for the antiviral activity on DNA vinus. Analysis of viral gene 
expression reveated a major point of inhibition earty in replication, i.e., at the level of "immediate earty" (ie) gene expression. In 
Northem blot analysiS of the "ie" ICP-4 transcript a stable reduction in steady state levels and a delayed kinetic of RNA accumulation 
was observed. In nuclear nun-on experiments a reduced rate of transcription for "immediate early" and "early" genes was 
determined. Since neither the stability of "ie" RNAs was decreased by IFNy nor did IFN-treatrnent reduce vinus uptake or stability of 
the infecting viral DNA in the nucleus, we conclude that the inhibition of "ie" transcription leads eventually to reduced vinus growth. 
Combination of IFNALPHNB with IFNy leads to a synergistic effect suggesting dilferent antiviral mechanisms. When we analyzed 
the inhibition of HSV·l replication in IFNy treated cells, we failed to observe any stable reduction in "ie" tranSCription or in ICP-4 
mRNA steady state levels. However, there was a marked inhibition in ICP-4 protein compared to control·infected cells suggesting a 
translational inhibition of ICP-4 expression. Possibly, these different effects of IFNALPHNB and IFNy cause inhibition of viral 
replication at different points of the growth cycle and may account for the synergistic reduction in virus yield. 
RESPONSE OF MICE TESTIS TO HUMAN GAMMA INTERFERON: A CELL KINETIC STUDY. N_R. Kalla, A. Mann, W. Aulitzky, J. 
Frick; Dept. of Biophysics, Panjab University, Chandigarh, India; Dept. of Urology, Comell Medical Centre, New York, USA; Dept, of 
Urology, General Hospital, Salzburg, Austria 
Interferons are a lamily of proteins produced by cells in response to certain viral or non-viral agents. It is known that 
interferons exhibit antitumor and anticellular effects besides their more widely known antiviral effects. Interferons have been reported 
to inhibit cell differentiation. In our study three groups of male mice were adm inistered 2, 10 and 20 ugm gamma interferon 
intratesticularly. Quanlitative study of spermatogenic events was done by the method of Clermont and Leblond. In another 
experiment, interferon (2 ugm) was administered subcutaneously for 30 days. Sperm motility was estimated by the routine method. 
At 10 ugm dose, the changes in the individual cell types were accompanied by overall disorganization of cells, stage 7 spermatids 
and stage 16 spermatozoa decreased significantly. Also stage 7: pachytene spermatocyte ratio was reduced markedly. At 20 ugm 
dose the effect of the dnug was more deleterious. Subcutaneous administration of interferon did not have any effect on the 
histoarchitecture of the testis. Intelieron (2 - 20 ugm) did not have any effect on sperm motility in vitro. Our studies suggest that 
interferon has a direct cytotoxic effect on the dividing and differentiating cells. The fully differentiated cells, however, do not respond 
to the cytotoxic effect 01 interferon. 
EFFECTS OF IMMUNOMODULATING CYTOKINES ON PMN. A. Kapp and G. Zeck-Kapp, Depts. of Dermatology and Pathology, 
Univ. of Freiburg, Freiburg, FR Germany 
Activated polymorphonuclear neutrophilic granulocytes (PMN) play an important role in propagation of inflammatory 
reactions and are capable of mediating tissue damage, particularly by release of reactive oxygen species and lysosomal contents. 
Cytokines produced by immune as well as non· immune cells were recently suggested to influence PMN functions. Therelore, the 
effect of relevant immuno-modulating cytokines on the oxidative metabolism of isolated human PMN was tested using lunctional as 
well as ultrastnuctural criteria. For detection of granulocyte activation different assay systems were used: 1. lucigenin.oopendent 
chemiluminescence (Cl), 2. superoxide-{iismutase (SOD) inhibitable cytochrome C reduction (superoxide), 3. horseradish 
peroxidase-mediated oxidation of plhenol red (hydrogen peroxide), 4. release of myeloperoxidase, 5. ultrastnuctural detection of 
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hydrogen peroxide-production, 6. scanning and transmission electron microscopy (SEM and TEM resp.). The following recombinant 
human cytokines were tested: tumor necrosis factor (TNF), Iymphotoxin (LT), GM-CSF, M-CSF, G-CSF, PDGF, TGF-B, interteukin-l 
(IL-l) ALPHA and B, IL-2, IL-3, IL-4, IL-6, MONAP/MOC/NAF (lUI), interferon-ALPHA and -yo Only TNF, LT and GM-CSF were 
significant direct stimuli of the oxidative burst in human PMN, whereas IL-3 and MONAP were active only at extremely high 
concentrations. None of the other cytokines tested induced any significant effect on isolated human PMN at physiological 
concentrations. The results clearly demonstrate that only selected cytokines are capable of influencing granulocytes. Release of 
these mediators represents a specific signal for PMN activation in inflammatory disease states. 
EFFECT OF INTERLEUKIN 1, 2, 3, and 4 ON DNA SYNTHESIS AND EXPRESSION OF HLA-DR AND BULLOUS PEMPHIGOID 
ANTIGEN ON NORMAL HUMAN KERATINOCYTES. T. Karashima, K. OkUbo, H. Hachisuka, Y. Sasai; Dept. of Dermatology, 
Kurume Univ. School of Medicine, Kurum~. Japan. 
Keratinocytes are capable of releasing some kind of immunomodulating cytokines such as epidermal cell derived 
thymocyte activating factor (ETAF). Although this fact suggests Itlat keratinocytes may participate in immunological reactions of the 
skin, the role of interteukins on keratinocytes is still unclear. In this study, we examined the effects of interleukins on DNA synthesis 
and expression of HLA-DR and bullous pemphigoid (BP) antigen on normal human keratinocytes. Normal human keratinocytes were 
cultured in KGM medium. Interteukins 1, 2,3 and 4 were added 10 each well and subsequently incubated for 48 hrs, 96 hrs and 144 
hrs. After pulsing with 3H-thymidine, radioactivities were counted. Expression of HLA-DR and BP antigen was measured by laser 
flow cytometry. Interleukin 1, 2, 3, and 4 showed remarkable enhancement of DNA synthesis. Interteukin 4 enhanced the expression 
of HLA-DR antigen, and interJeukin 3 enhanced BP antigens on keratinocytes. Although each interleukin can enhance DNA 
synthesis, the expression of HLA-DR antigen and BP antigen was induced by different interJeukins. 
TREATMENT OF AIDS-RELATED KAPOSI'S SARCOMA WITH ZIDOVUDINE (AZT) AND MODERATE DOSES OF ALPHA-2B 
RECOMBINANT INTERFERON. A. Katsambas, N. Stavrianeas, E. Koumantaki, P. Stavropoulos. M. Papa and J. Stratigos; Dept. of 
Dermatology, 'A. Syngros Hospital', University of Athens, Athens, Greece. 
The combination of zidovudine (AZT) and moderate doses of alpha-2b recombinant interferon (Infa-2b) was studied in 13 
patients with AIDS-associated Kaposi's sarcoma (KS). The diagnosis of KS was confirmed by skin biopsies. The patients were given 
AZT in a dose of 600-1200 mg daily p.o. and Infa-2b in a dose of 5-10 x 106 Ulm subcutaneously three times weekly: The mean 
duration of therapy was 8 +1- 4.6 months, The results of our study tumor response are as follows: 
(table 1) 
Tumor Partial Stable 
burden No RegreSSion response disease Progression 
Minimal 6 3 2 0 
Medium 5 0 1 2 2 
Large 2 0 0 0 2 
According to table 1 a major response of regression or stabilization of the disease is obtained in 69 % (9/14) of the patients treated 
with the above therapeutic schedule. The drugs were tolerated with an acceptable toxicity. This study indicates thatlnfa-2b can be 
used in combination with AZT to control the progression 01 AtDS-related KS. 
INTERFERONS AND CYTOKINES FOR TREATMENT OF MELANOMA. J.M. Kirkwood, M.S. Emstoff; Pittsburgh Cancer Institute 
and University of Pittsburgh, Pittsburgh, PA, USA. 
A wide array ot potent immunoregulatory molecules, including interferons (tFNs), monokines, and Iymphokines has 
become available for the therapy of human melanoma. Interferon gamma (IFNg) has been studied in greatest depth among the 
interferons, as a monocyte activator; ~ also regulates T cell function and distribution, and the expression ot tumor cell surface 
antigens. IFNg biological response modifier (BRM) functions occur at dose ranges significantly below the maximal tolerable dosages. 
Optimal BRM dosages of IFNg are now being confirmed and tested in trials against metastatic melanoma and as adjuvant therapy in 
setting of high-risk melanoma after resection. The T cell growth factor interJeukin-2 (tL-2) has shown antitumor activity when 
administered systemically to patients with metastatic melanoma at high dosages, alone or with the adoptive transfer of Il-2 activated 
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(LAK) lymphocytes oblained iTom peripheral blood, or lumor-inliltraling (TIL) lymphocytes. We have recenlly developed methods 10 
purii)' LAK cells to homogeneity and are testing anti-tumor activity of adherence-purified (A-LAK) cells in combination with IL-2 for 
therapy of melanoma. IL-2 and LAK programs have exhibited a wide range of activity to dafe, and have spurred eHorts to generate 
more effective and durable autologous cytolytic T cell responses at our institution. Vaccination in vivo, followed by secondary in vitro 
restimulation of vaccine-primed regional lymph node lymphocytes may achieve this goal, in a protocol of adoptive T cell transfer with 
systemic IL-2 administration. Regional delivery of IL-2 and other cytokines may be the most physiologic avenue for these mediators, 
given their short half-life_ RegionallL-2 has been active against bfadder carcinoma, ovarian carcinoma, and head and neck cancers. 
A phase Ib trial is now in progress to determine the optimal dose of regionally administered intralymphaticlintradermal IL-2 in transit 
and regionally melanoma. Ultimately, the most effective role for BRMs will likely be in combinations with one other, and conventional 
surgical , radiation, chemotherapeutic approaches. An understanding of the in vivo biological effects of these agents will be essential 
to the end combination applications, however. 
POSSIBLE SYNERGISTIC EFFECT OF INTERFERON ALFA 2B AND RETINOIDS IN THE TREATMENT OF CUTANEOUS T-
CELL LYMPHOMA. R. Knobler, F. Trautinger. E.M. Kokoschka, Th. Radaszkiewicz. M. Micksche; II. Dept. of Dermatology, 
University of Vienna, Vienna, Austria 
In the present pilot study we have investigated the possible synergistic therapeutic effect and side-effect profile of low dose 
IFN in combination with retinoids lor the trealment 01 cutaneous T -cell lymphoma (CTCL) and premalignant cutaneous T-helper cell 
proliierations. 9 patients (pts; 5 women and 4 men; mean age 57.1) 'Mlre included in this pilot study . 7 patients had histologically 
confirmed cutaneous T-cell lymphoma and 2 were classified as cutaneous lymphocytic infiltrates. 4 pts with CTCL had received 
previous therapy including chemotherapy and electron beam irradiation, 3 pts had not received any specific previous trealment. The 
treatment schedule consisted of 2 MililU IFN-ALPHA2b (Schering AG) s.c. 3 limes weekly anc daily administration of 13-cis retinoic 
acid (RoaccutanR) 1 mg/kg p_o._ The 2 pts with lymphocytic infiltrales received IFN monotherapy according to the above-mentioned 
dose regimen. Lesions were histoiogically examined for lymphocytic infiltrales in lhe dermis andior characterislic Pautrier 
microabscesses within the epidermis. The combined lherapy resulted in considerable response rates in patienls with CTCL, i.e. 2 CR 
and 3 PR. These documenled remissions were mainlained by conlinuous therapy within an observalion time of up 10 15 months 
even alter dose reduction of both agents by 50 'to. Side-effecls of IFN therapy were negligible and did not result in a need to 
disconfinue treatment. These results clearty demonstrate that the combination of low dose IFN with a standard dose 01 refinoids 
results in considerable long-term responses together with minimal dose limiting side-effects_ These observations appear auspicious 
for further extended dinical investigations of this new combination therapy_ 
IMMUNOLOGICAL EFFECTS OF INTERFERON_ J. Knop, Dept. of Dermatology, University of Mainz , Mainz, FR Germany 
There is a substantial body of information that interferons have a profounc effect on both cellular and humoral immune 
responses. Interferons, in particular interferon gamma, can be regarded as immune regulatory agents which modulate the immune 
response at three levels. 1. Interferon gamma enhances the antigen presenting properties of celts by increasing the expression of 
dass II antigens and adhesion molecules. 2. Interferon gamma and also interferon alpha anc beta modulate immune regulatory T-
suppressor lymphocytes. Inhibition of these cells will enhance delayed hypersensitivity reactions. However, depending on time anc 
dosing interferons may also inhibit contact hypersensitivity or other delayed hypersensitivity reactions. 3. Interferons induce or 
enhance certain markers and !uncfions in macrophages such as Fc gamma receptor of MAC-f , LFA-f involved in adhesive 
interactions which are !undamental for many macrophage !unctions. In addition interferons regulate the secretion of various factors 
and monokines such as plasminogen activator, complement, inlerleukin 1 and possibfy TNF alpha. The cytotoxic capability of 
macrophages is increased by interferon trealmenl as welt as the intraceltular kilting of microorganisms. Interferons in association with 
other cytokines may affect many celts directly or indirectly involved in the immune response, such as endothelial celts. Many 
contradictory results have been published, but I believe that interferons, in particular interferon gamma, are of prime importance for 
the induction and enhancement of immune anc inflammatory reponses. 
DISTINCT CYTOKINE mRNA EXPRESSION BY DIFFERENT HUMAN MELANOMA CELL LINES. A. K5ckl. M. Mickschefj! 
Vetterteinf, T. Schwacl, F. Trautinger1. P. Neunerl, J.C. Anse~, D. Damm4, TA Lugerl ; 1 Dept. of Dermatology II and LBf-DVS, 
Lab. Celtbiol., Univ. of Vienna; 3Dept. of Dermatology Lainz, Vienna; 2lnst. Appf. Exp. Oncel., Univ. of Vienna, Austria; 4VA Med. 
Centre, Portland, OR, USA 
Melanoma cell lines have recently been shown to release cytokines such as interteukin 1 and suppressor factors. 
Therefore in the present study different human melanoma celt lines (KRFM, WMS, WI64, Shelton) were investigated for their 
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capacity to express mRNA specific for cytokines such as IL-IALPHA, IL-l B, IL-6, platelet-derived growth factor (PDGF), tumor 
necrosis factor (TNFALPHA) and granulocyte macrophage colony stimulating faclor (GM-CSF). Upon Northern blot analysis all 
melanoma cell lines tested constitutively expressed IL-1 ALPHAwhich was upregulated upon stimulation with PMA, LPS and rhlL-
1 ALPHA. In contrast, none of the cell lines expressed IL -1 B. Moreover, only the Shelton cell line was found to express constitutively 
both IL-6 and TNFALPHA which were upregulated upon stimulation with PMA. Conslitutive GM-CSF mRNA expression was not 
detected in any of the cell lines. However, upon stimulation with PMA all melanoma cell lines expressed signifICant levels of GM-CSF 
mRNA. In addition, using the PDGFB probe homologous to the v-sis oncogene, all melanoma cell lines tested constitutively 
expressed PDGFB mRNA which was stimulated upon exposure to PMA. These findings indicate that melanoma cell lines 
spontaneously or upon appropriate stimulation vary in their capacity of cytokine mRNA expression. Although the pathophysio-Iogical 
role of these growth and differentiation factors during the development of melanoma is not yet fully understood, they may regulate 
metanoma cell growth as well as modulate the host immune response to this neoplasm. 
LONG-TERM ADJUVANT THERAPY OF HIGH RISK MALIGNANT MELANOMA WITH RECOMBINANT INTERFERON ALFA 2B. 
E.M. Kokoschka. F. Trautinger. M. Miscksche. R. Kokoschka; II. Dept. of DermatOlogy, University 01 Vienna, Vienna, Austria 
In this study we evaluated the adjuvant therapeutic effects of recombinant interteron alia 2b (IFN) in operated stage I high 
risk melanoma patients (tumor thickness> 1.5 mm, level> 3) and tumor-free stage II patients. IFN-treated patients are compared to 
untreated controls. Dose schedule consisted of 3 x 106 IU 3 times a week for 1 month, 3 x 106IU twice a week in the 2nd month, 3 x 
106 IU once a week from month 3 - 6, followed by 2 x 106 IU once a week. Therapy was continued for at least 2 years or until 
progression. Mean observation time in stage I patients was 612 days and 1215 days in stage II patients. NK cell activity was tested 
during follow-up and showed good correlation to the clinical outcomes. Side-effects consisted of influenza-like symptoms (WHO 
grade I) and usually were seen 4 - 8 hrs after s.c. application of IFN. After 600 days 91 % of the IFN treated stage I high risk 
melanoma patients (n=53) and only 75 % of the control patients (n=55) were still tumor-free. This benefit is only observed in the first 
2 years of follow-up and disappears during further observation. Mean time of therapy was 520 days in these patients, corresponding 
well to the time of therapy response. 7.5 % 01 the IFN-treated patients (controls: 19.5 %) suffered from progreSSion to the regional 
lymph nodes and in 11 .3 % metastases at distant sides were found (controls 12.2 %). In operated stage II melanoma patients we 
found no significant difference between both groups: after 1200 days 64 % of the IFN-treated patients (n= 16) and 60 % of the 
controls (n=33) were still tumor-free. These findings suggest that adjuvant IFN therapy in stage I high risk patients is of good clinical 
relevance. ft can be indicated thai IFN is able to have an immunstimulating and an antiprol iferative effect on malignanl melanoma. In 
a small number of stage II patients IFN therapy alone could not influence lhe progression of the disease. This may be due to an 
immundeficiency which cannot be regulated by an IFN monotherapy. 
ROLE OF INTERLEUKIN-I IN CENTRAL AND PERIPHERAL MECHANISMS OF HOST DEFENSE REACTIONS. E.A. Korneva, 
VA Lesnikov and E.G. Rybakina; Instilute of Experimental Medicine, Leningrad, USSR 
Inlerleukin-l (IL-l), immunoregulatory leukopeptide with potyfunctional properties, is involved in the mechanisms of host 
defenses. Preoptic area of the anterior hypothalamus has been shown 10 be the primary site of action of IL-l as endogenous 
pyrogen in the CNS. Injections of highly purified IL -I derived from human monocytes in a dose of 40 - 400 pg into this brain area 
results in a fever reaclion in animals. Different models have shown peripheral effects of IL-l : stimulating action on colony forming 
activity of the bone marrow cells, normalizing effect on fibrinolysis, development of resistance to bacterial endotoxin. An important 
role for IL-l in functional relationships between the nervous and immune systems of the organisms is thus postulated. IL-l can be 
Clinically applicable for modulating the impaired mechanisms of the organism's defenses. 
TREATMENT OF CONDYLOMATA ACUMINATA WITH RECOMB INANT INTERFERON GAMMA. L. Kowalzick and H. Mensing; 
Dept. of Dermatology, University of Hamburg-Eppendort, Hamburg, FR Germany 
12 patients suffering from recurrent genitoanal condyfomata acuminata were treated with recombinant IFN gamma 
(Bioferon) in an open controlled phase II study. 7 male and 5 female patients entered the study, mean age was 27.8 +/- 7.5 years, 
mean duration of their disease 24.5 months. Half of the patients received either 50 or 100 microg of IFN gamma respectively given 
dally by subcutaneous injection for seven days. This regimen was repeated every five weeks, for at least 3 times. Mild ftu-like 
symptoms occurred in 8 patients, mostly after the initial injections. The mean leukocyte count was decreased by 1.600 cellslmicrol 
from day 0 10 7 of each therapy cycle. The overall response rate reached 50% with 5 complete remissions and I incomplete 
remiSSion. 1 patient showed a partial remission, 4 a stable disease and one a progressive disease. Since 4 of the patients healing 
with complete remission were in the 100 microg group, we would favour this dosage for further ciinicaltrials. 
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INFLUENCE OF MELANOMA CELL CONDITIONED MEDIUM (MCCM) AND OF BASIC FIBROBLAST GROWTH FACTOR (bFGF) 
ON HUMAN MELANOCYTES AND MELANOMA CELLS. K. Krasagakis. C. Garbe. Ch.C. Zouboulis. S. Kruger. K. Schroder. C.E. 
Ortanos; Dept. of Dermatology. Univ. Medical Center Steglitz, The Free University of Berlin, Berlin (Wesl), FR Germany 
The purpose of this study was to investigate the influence of melanoma cell conditioned medium (MCCM) and of basic 
fibroblast growth factor (bFGF) on cultures of normal human melanocytes and 01 melanoma cell lines in vitro and to compare their 
effects. Monolayer cultures of normal human melanocytes, obtained by using the technique of Eisinger and Marco, and human 
melanoma cell lines (StML-ll , StML-12 and SKMel-2Bj were bolh cultured in serum·free DMEMIF12 1:1 medium, supplemented 
with 1 mglml bovine serum albumin. The medium of all dishes was changed every 1 -2 days in order to minimize autocrine growth 
stimulation. 40 . BO % MCCM and bFGF (0.2- 20 nglml) were added 10 quadruplicate dishes and cell proliferation was assessed by 
cell counting and by a fluorometric microassay in comparison to untreated controls. MCCM had no effect on the proliferation of 
human melanocytes. On the contrary, low densities of human melanoma cells, being in the prelogarithmic phase of growth, were 
significantly stimulated by MCCM (52 . 99 % over the conlrols); at higher densities the stimulatory effect was not observed. The 
addition of 0.2 • 2 ng/ml bFGF stimulated the proliferation 01 human melanocytes in a dose dependent manner (50 . 122 % over the 
controls). Concentrations above that level did not reveal any further stimulation. Human melanoma cells at low densities also 
underwent dose dependent growth stimulation (up to 22 -54 % over the conlrols under 20 nglml bFGF). Melanoma cell lines being in 
the logarithmic phase of growth were not affected by bFGF. In conclusion, both MCCM and bFGF stimulate the proliferation of 
human melanoma cell lines growing in vitro, however, only bFGF was found stimulalory for human melanocytes. Both substances 
failed to enhance the prolileration of melanoma cells being in the logarithmic phase of growth, a result possibly due to sufficient 
production of autocrine growth factors during the phase of exponential cell proliferation. 
NK·CELL ACTIVITY AND IFN RESPONSE OF LEUKOCYTES FROM "ANTI·IFN" POSITIVE PATIENTS WITH PSORIASIS. V. 
Lackovic, L. Borecky. F. Vlcek. L. Sinka. J. Rovensky; Institute of Virology, Slovak Academy of Sciences, Bratislava Dermatological 
Departments, Bratislava and Piest'any, Czechoslovakia 
Mean values of NK·cell activily in psoriatic patients (n=40) were significantly lower (39.6 +1- t7.7) than in the group of 
healthy controls (59.3 +1- 17.4, n=30). This decrease was mosl pronounced in patients with "anti·IFN" activity in the blood and 
activity form of the disease (23.6 +1- B.2, n=9). However, the NK-cell activity of IFN·positive patients corresponded to the lower range 
of normal controls (54.6 +1- 7.2, n=6). IFN·alpha did not augment the NK·cell activity. In the group of IFN·positive patients (t .44) it 
was higher than in healthy controls (1 .14). Upon stimulation with Con A (20 uglml) of unseparated leukocytes in whole blood from 
psoriatic patients showed an impaired IFN-gamma production. The IFN-gamma production was in correlation with "anti·IFN" activity 
in circulation. 
LOCALIZATION OF INTERFERONS IN PSORIATIC LESIONS. J.K. Uvden. R. Matre and R. Nilsen; Broegelmann Research 
Laboratory for Microbiology and Institute of International Health, University of Bergen, Bergen, Norway 
Murine MoAbs against IFN·ALPHA and IFN·y were used to study IFNs in cryostat sections from psoriatiC skin lesions. The 
IFNs were more pronounced in section from highly active psoriaSiS than in sections from stationary psoriasis. In highly active 
psoriatic lesions IFN·ALPHA was localized to keratinocytes in stratum basale, to some dendritic cells, probably Langerhans cells, 
and to some mononuclear cells in derm is. IFN·ALPHA was usually not delected in sections from stationary psoriasis. IFN·y was 
localized to stratum corneum, to keratinocytes around microabscesses and to mononuclear cells in the dermal cell infiHrates, 
predominantly in highly active psoriatic lesions. Both IFN·ALPHA and IFN·y were localized to some endothelial cells in the papillary 
dermis. The MoAbs did not stain sections from unaffected skin from patients with psoriasis or sections from healthy individuals. The 
findings indicate that the IFN·syslem in the skin may be of significance in the pathophysiology of psoriasis. 
PAPILLOMAVIRUSES: INFLUENCE OF EXTRACELLULAR AND INTRACELLULAR FACTORS ON THEIR BIOLOGY. D.R. Lowy, 
P. Martin. W.C. Vass. J.T. Schiller, and T.J. Velu; Laboratory of Cellular Oncology, National Cancer Institute, Bethesda, Maryland, 
USA 
Papillomaviruses (PV) have three major transforming genes, E5, E6, and E7, whose relative importance varies with the PV 
type. E5 is a major transforming gene for bovine papillomaviruses (BPV), which induces fibmpapillomas in its natural host. The 44 
amino acid BPV E5 protein product localizes to cytoplasmic membranes, including the plasma membrane, and can stimulate DNA 
synthesiS in the absence of serum. In our studies of the mechanism by which this small peripheral protein might induce cellular 
transformation, we have found BPV E5 can stimulate the activity of EGF receptors and CSF-l receptors. When introduced into NIH 
3T3 cells, normal human EGF receptors and CSF-l receptors can confer ligand (growth factor) dependent cell transformation, but 
562 ABSTRACTS THE JOURNAL OF INVESTIGATIVE DERMATOLOGY 
there is no detectable biological activity witout ligand. However, these receptors can cooperate with E5 to induce cell transformation 
in the absence of ligand, and the response of the receptors to ligand is potentiated by E5. The cooperation between E5 and the 
growth factor receptors has seme specifity in that two other cellular tyrosine kinases which are not growth factor receptors, c-src and 
c-fes, do not cooperate with E5. Analysis of EGF receptors in cells that contain E5 indicates that E5 induces a significant 
prolongation of receptors half-life in the presence or absence of ligand. This longer receptor half-life appears to be mediated via an 
E5 dependent inhibition of the normal pathway by which receptors are internalized and probably contributes significantly to the 
greater activity of the receptors in the presence of E5. We conclude BPV E5 protein can influence both the basal activity of growth 
factor receptors and the response of receptors to ligand. These eflects are mediated, at least ',n part, by E5 inhibiting normal receptor 
internalization and degradation. 
EVIDENCE OF AN EPIDERMAL CYTOKINE NETWORK. T.A. Lucer, Dept. of Dermatology II and LBI-DVS, Lab. Cellbiol., Univ. of 
Vienna, Vienna, Austria 
The concept of the epidermis as a site for the initiation of immune responses has only evoked over the past decade. There 
is strong evidence that 3 types of epidermal cells have immune functions. Accordingly the epidermis harbors dendritic cells having 
antigen presenting capacity and cells belonging to the T-cell family. Moreover, keratinocytes are capable of secreting various 
immunomodulating cytokines. Thus the epidermis appears to contain all constituents necessary for initiation of an immune response. 
Cytokines are glycoproteins which are synthesized and secreted by various cells and which bind to specific receptors on target cells 
and regulate activation, proliferation and differentiation of immune as well as non-immune cells. Keratinocytes upon injury I.e. 
mechanical irritation, UV-irradiation, tumor promoters (PMA) synthesize and release interleukin (IL) -I ALPHA, IL-IO, IL-6, colony 
stimulating factors (CSF), tumor necrosis factors-ALPHA (TNF·ALPHA) as well as growth (transforming growth factor 0) and 
suppresser (contra-IL-l ) factors. There is strong evidence for a networ\( of interacting cytokines maintaining a proper balance which 
only partially has been discovered se far. However, excessive or insufficient production of these mediators may contribute to certain 
disease states, particularly those with infectious and autoimmune origins. Thus may cytokines appear to be promizing candidates for 
treatment of infectious, autoimmune, immunodeficiency and malignant diseases. Future studies will clarity the therapeutic efficacy of 
the combined application of different cytokines and further investigations are alse needed to elucidate the Iymphokine cascade in 
vivc. 
GAMMA-INTERFERON IN DERMATOLOGY. G. MaMe, Dept. of Dermatology, University of Cologne, Cologne, FR Germany 
Gamma-interteron (gIFN) is the cytokine interteron among interterons which might have a special impact on skin lesions. 
We will present the results of 49 patients treated with gIFN. The patients suffered from pseriasis (n.ll ), genital warts (n.19), 
bowenoid papulosis (n.3), epidermodysplasia verruciformis (n=2), Behcet disease (n.3), malignant melanoma (n.6), basal cell 
carcinoma (n.4), and mycosis fungoides (n=I) . Pseriatic patients received SO microgld sublesionally during the first week and SO-
100 microgld for another two weeks. HLA-DR expression of keratinocytes was found in lesional and uninvolved skin above the 
injection site but not in distant locations. In spite of that, there was neither an increased epidermotropism of lymphocytes nor an 
influence on lymphocyte subsets al the injection site. Epidermal growth as shown by the labeling index and the S-phase duration 
was not affected. Correspondingly, we failed to observe a cfinical effect of glFN on skin lesions and joint complaints in 8 patients with 
arthropathy. Genital warts were treated 5 days per weeks wit SO-lOa microgld glFN followed by an intermission of 3-4 weeks. 
Treatment was repeated for up to 6 times. Injections were pertormed subcutaneously in the abdominal skin. There was a response in 
8 patients (37%) including the majority of 5 patients experiencing complete remission. The response did not occur before the third 
therapeutic cycle had been completed. 63% at patients with genital warts did net improve even aner 6 cycles. Apparently, there were 
responders and nen-responders who could not be discriminated by age, extent, duralion, tocation of the leSions, and pretreatment. 
Among the other diseases treated, a favorable response was demonstrated in Behcel disease. The side-effects headed by "common 
cold" symptoms at the beginning 01 the therapy were tolerable. Exclusively, in pseriatic patients we observed an increase of the 
blood triglyceride levels not found in patients with other diagnoses. Our experiences reveal that glFN is effective in a group of 
patients with genital warts, in patients with Behcet disease and partially in those with bowenoid papulosis but less favorable in 
pseriatic patients. 
IN VITRO EFFECT OF IMMUNOMODULATORY CYTOKINES ON NK CELL ACTIVITY OF PERIPHERAL BLOOD 
MONONUCLEAR CELLS (PBMC) FROM PATIENTS WITH HPVI6-INDUCED ANOGENITAL TUMORS. S. Majewski, M. Malejczvk, 
J. MalejCzyk', L. Rudnicka, M. Skopinska, M. Misiewicz, S. Obalek, S. Jablonska; Dept. Dermato!. and 'Dept. Histo!. & Embryo!., 
Warsaw Med. School, Warsaw, Poland 
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Recently. we found that in patients with HPVl6·induced tumors there is a significant decrease of NK cell activity against 
SK·v cells (human keratinocyte line harboring integrated HPVI6 DNA) while activity against KS62 erythroleukemic cells was 
preserved (Int J Cancer 43:409. t 989). The present study was untertaken to find out whether NK cell activity against both targets in 
these patients could be stimulated by cytokines. PBMC from healthy volunteers and patients with PHVt6~ndcued premalignant and 
malignant lesions were preincubated in vitro for 24 hrs with IL·2 (10 Ulml). IL-£ (I Ulml). and IFN·ALPHA (1000 Ulml) and then 
tested for NK cell activity against KS62 and SK·v cells by StCr·release assay. We found nermal NK cell activity against K562 cells of 
patients' PBMC. which could be significantly stimulated by all three cytokines. The most petent cytokine was found to be IL·2. In 
contrast. in patients with HPVl6·induced anogenital lesions the activity against the specific SK·v target cells was dramatically 
lowered and was not stimulated by any cytokine. However. NK cell activity against SK·v cells could be significantly stimulated by 
these cytokines in healthy individuals. These results suggest that in patients with HPVt6-induced anogenital tumors there is a 
specific block of NK cell activity against disease·specilic largel cells which cannet be reversed by stimulation with immuneregulatory 
cytokines. 
SPONTANEOUS TNFALPHA PRODUCTION BY A KERATINOCYTE CELL LINE HARBOURING THE HPVI6 GENOME: AN 
AUTOCRINE MECHANISM LIMITING INFECTED CELL GROWTH. J. MalejczytU. M. Malejczkf. A. Kiic~ G. Orlhi T.A. Luger~; 
t Dept. Histol. & Embryol. and 2Dept. Derm .• Warsaw Med School. Warsaw. Poland; 41nstitut Pasteur. Paris. France; 3Dept. Derm. 
II. University 01 Vienna and LBI·DVS. Lab. Cellbiol.. Vienna. Austria 
Recently a keratinecyte cell line (SK·v) has been established from a lesion 01 a patient with bowenoid papulosis. which 
harbours multiple integrated copies 01 HPVI6 DNA. TNF·ALPHA in addition of being cytotoxic lor certain tumors has been shown to 
be a multifunctional regulator of immunity and inllammation. Therelore in the present study it was investigated whether SK·v cells 
produce TNF·ALPHA. Using a cytotoxic assay with L929 cells and TNF·ALPHA specilic ELISA SK·v cells were lound to 
constitutively produce TNF·ALPHA. This observation was further confirmed by Western blot experiments. Moreover. upen Northern 
blot analysis using a TNF·ALPHA cDNA probe. SK·v cells expressed TNF·ALPHA specifIC mRNA. On the other hand. when 
exogenous rhTNF·ALPHA was added to SK·v cells a marked dose·dependent decrease 01 their proliteration activity was observed 
as measured by 3H·TdR incorporation and cell counting. This growth inhibitory capacity of TNF·ALPHA could be abrogated by the 
addition of anti·TNF·ALPHA antibodies. Furthermore. anti·TNF·ALPHA antibodies alone caused a Significant increase 01 SK·v cell 
proliferation. pessibly by blocking SK·v derived TNF·ALPHA which may represent an impertant autocrine pathway pessibly limiting 
the development and growth 01 HPV·associated neoplasia. It also might explain the very siow growth and frequent spentaneous 
regression of boweneid papulosis lesions. 
INTERLEUKIN·2 THERAPY FOR MALIGNANT HEMANGIOENDOTHELIOMA. M. Masuzawa·. T. Asai· ... K. Nishioka". S. 
Nishiyama"; Dept. of Dermatology. 'The Kitasato Institute Medical Center Hospital and UKitasato University School of Medicine. 
'Saitama and "Kanagawa. Japan 
Malignant hemangioendothelioma (MHE) involving the scalp is a highly invasive and metastatic neoplasma. Its prognosis is 
extremely peor. though therapeutic trials have been conducted. In the present study. we treated two cases of MHE on the scalp. 
diagnosed histologically. with intralesional injections of recombinant interleukin·2 (rIL·2). Case I : a 80·year-old lady had four·month 
history of an edematous purpuric macule. 9 cm in diameter. evident on the frontal region of the scalp. Case 2: a 79·year-old man had 
three·month history of a solitary hemorrhagic edematous macule. 6 cm in diameter. situated over the vertex. A couple of small 
bleeding nedules was seen in the center of the macule. The total dose of 350.000 • 700.000 IU of r1L·2 (350.000 IUlml. TGP·3. 
Takeda·chemical Industries. Ltd .• Osaka) was injected daily into the lesions. The hemorrhagic lesions disappeared by the r1L·2 
injection within one month. accompanied by infiltrating lymphocytes. In case I . any signs of recurrence have not been observed 
witout any treatment over 2 and a half years. In case 2. however. the central ulcerated nodule persisted in spite of the additional 
injection over the next three months. Minimal surgical excision and skin transplantation was performed to remove the ulcerated 
lesion and an additional r1L·2 was iniected at the surgical margin. During one year. disease has been free without treatment. 
Electronmicroscopically lymphocytes aHached tightly to the degenerated tumor cells in the injected lesions. These observations 
suggest that the intralesional injection of r1L·2 is elfective for the treatment of MHE. especially its macular lesion. Nodular or 
ulcerative lesions were resistant to this treatment, but combination therapy with minimal surgical excision was helpful for the 
treatment of MHE. 
CLINICAL EVALUATION OF INTERFERON THERAPY IN MALIGNANT MELANOMA. G.A. McLeod. Queensland Melanema 
Project. Princess Alexandra Hospital. Brisbane. Australia 
The activity of interterons (IFNs) in the management of malignant melanema (MM) has been evaluated in trials using a 
range of dosages. methods and frequencies of administration and types of IFN. Toxic effects of IFN have been found to be largely 
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dose and frequency related, and are controlable. Completed trials have been for efficacy in advanced disease. Phase II trials of 
recombinant (r) alpha IFNs have shown response rates up to 23 %. A collation of results of a number of trials suggest that response 
rates of about 16% can be expected using IFN as a sale agent. This is about the same response rate as can be achieved with the 
most commonly used chemotherapeutic agent, DTIC. Other IFNs have been evaluated (including rIFN·gamma, lymphoblastic IFN 
and rIFN·beta) but they have shown lower response rates and similar toxic effects. Most responses are temporary and long·term 
survival rates have not been shown to be altered. As response rates with alpha·rlFN are marginally low, combination therapy using 
IFN with chemotherapeutic agents has been studied. Initial results using human IFN and cimetidine were encouraging but other 
interferons combined with cimetidine have not been shown to be more effective than rlFN alone. In a two centre Australian phase 1·11 
study, rlFN alpha-2a in combination with DTiC produced a response rate of 27%, a higher rate than that accepted as achievable with 
either agent alone. A European study using the same combination also showed an improved response rate. Other agenls have been 
evaluated in combination with IFNs and indications are that they also may produce improved response rates. To funher evaluate 
combination therapy an Australian multi-<:entre randomized trial comparing rlFN alpha-2a1DTIC with DTIC alone is now progressing. 
EFFECTS OF LOCAL CONTINUOUS HIGH DOSE IL-2 APPLICATION ON BLADDER UROTHELIUM OF CANCER PATIENTS. l 
Meier, E. Huland, H. Huland; Dept. of Urology, Klinikum Steglitz, The Free University of Berlin, Berl in (West), FR Germany 
Efficient IL-2 induced tumor toxicity correlates with dose and time of incubation. Efficient i.v. doses lead to severe 
cardiopulmonary side-effects. We recently reponed (Cancer Res. 1989) on the development of a new therapeutic model for 
advanced bladder carcinoma which allows activation of IL·2 responsive immune cells direclly at the tumor site by repeated 5 day 
bladder perfusion cycles with very high and constant IL·2 concentration without inducing serious side-effects. Urine cytology permits 
permanent monitoring of immune and tumor cells at the tumor site. Beside local and general immunoactivation . shown by an 
increase of IL-2 receptor expression· a distinct local and systemic eosinophilia was induced by treatment. Eos. leukocytes increased 
up to 65 % locally after therapy. Blood eosinophilia occurred with poor correlation to local eosinophilia. Only after therapy the mab 
EG 1 (specific for all eosin. granula) and the mab EG2 (specific only for activated granula) stained bladder tumor cells, indicating that 
granula 01 80S. leukocytes have actively been secreted on biadder carcinoma cells. Blood eos. leukocytes did stain with the mab 
EGI but not with the mab EG2 indicating that activation of eos. leukocytes occurred only locally. Activation of eosinophil leukocytes 
at the tumor site is part 01 the IL·2 induced antitumor response. 
EXPERIENCE WITH INTERFERON THERAPY OF HIV-RELATED KAPOSI'S SARCOMA IN HAMBURG. W. Meigel', P. Kem", A. 
Plenenberg', M. Dietrich" ; Dept. of Dermatology, St. George's General Hospital ' , Clinical Dept., Hospital for Tropical Diseases, 
Hamburg", FR Germany 
Objective: To determine the value of IFN·alfa 2a therapy of HIV·related Kaposi's sarcoma (KS) with reference to rates of 
remission and recurrence, and survival times. 43 male patients (average age: 43 yrs) suffering from HIV·related KS were treated with 
recombinant interferon alia 2a (Roferon, Hoffmann·La Roche). 41 patients received 18 million IU daily s.c. in the first 3 months, 
followed by 18 million IU s.c. 3 times weekly. 2 patients received an initial dose of 36 million IU daily. The patients were divided into 4 
groups, depending on their response to therapy: complete remiSSion (CR), partial remission (PR), stable disease (SD), and 
progressive disease (PD). On evaluation after 3 months, 5 patients (12 '!o) were assigned to the CR group, 7 (1 6 '!o) to the PR group, 
7 (1 6 %) to the SD group, and 24 (56 '!o) to the PD group. Further observation (minimum : 12 months) showed that 36 of 43 patients 
(84 '!o) had died. The mean survival time (including the 7 patients still alive) was 16 months. The time to recurrence in groups CR, 
PR and SD differed; freedom from recurrence was longest in the CR group. Mean values for CD4 lymphocytes were 344/mm3 in the 
CR, PR and SD groups, compared with 2471mm3 in the PD group. The cause of death was KS in 15 patients (lung involvement, 
bieeding, cancerous cachexia), and opportunistiC infections in 15. 1 patient died of Burkitt's lymphoma, 1 committed suicide and the 
cause of death in 1 patient was unclear. Treatment of HIV-related KS with interferon leads to complete or partial remission of KS in a 
proportion of the patients. Since little is known about the natural course of the disease, objectification of the success of therapy in 
terms of prolongation at surv'lval time 'IS difficult. 
GAMMA· INTERFERON INHIBITS HUMAN CYTOCHROME P450 DEPENDENT ENZYME ACTIVITY. H. Merk, S. Sefkow; Dept. of 
Dermatology, University at Cologne, Cologne, FR Germany 
fnterferons are able to influence the expression at genes of the cytochrome P450 (P450) supergene·famify. P450 isozymes 
playa major role in the metabolism of an innumerable number of drugs, other xenobiotica, steroids, fatty acids, arachidonic acid, 
prostaglandines or leukotrienes and therefore their inhibition by interferons may result in many effects, such as interactions with the 
metabolism of drugs. Known examples are warfarin and theophylline. P450 isozymes are present in the liver, but also in most other 
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organs such as the lung, skin and immunocompelent cells, e.g. lymphocytes or monocytes. However, little is known about the 
mechanism how interferons influence P450 gene expression and there is no easy obtainable screening system to investigale this 
effect of several interterons on P450 dependent metabolism in human lymphocytes. Polymorphonuclear cells of healthy volunteers 
were prepared from venous blood, incubated with benzanthracene, dexamethasone and recombinant alpha-, beta- and gamma-
interteron (10, tOO, 1000, and 10000 IE/ml). P450 dependent aryl-hydrocarbonhydroxylase (AHH)-activity was determined using 
benzo(a)pyrene as substrate. Furtheron, P450 dependent metabolism ot benzo(a)pyrene to phenol, quinone and diol metabolites 
was assessed after separating the metabolites by HPLC. Benzanthracene induced AHH-activity 10 to 30 fold in the presence of 
dexamethasone. There was a markedly differenl effect of alpha-, beta-, and gamma-interteron on the basal as well as on the induced 
AHH-activity. There was no effect of alpha- and beta-interteron, but a strong, dose-dependent inhibition by gamma-inlerteron up to 
61%. In accordance with these results especially the 7,8-diol-lormation of benzo(a)pyrene was inhibiled by gamma-interferon. Our 
results demonstrate that the P450 inhibition by interteron is present in the easily obtainable human leukocytes which may be helpful 
to sludy this effect of interferons on the protein and mRNF level in human cells and to screen new interferons for this important 
effect, especially by using interferons for therapeulic reasons_ 
ANTIVIRAL ACTIVITY AND LOW INCIDENCE OF OPPORTUNISTIC INFECTIONS IN PATIENTS WITH POOR PROGNOSIS 
AIDS-RELATED KAPOSI'S SARCOMA TREATED WITH BETASERINTERFERON. S. Miles, S. Marcus, R. Mitsuyasu; Dept. of 
Medicine, School of Medicine, Los Angeles, CA, USA 
A phase II safety and efficacy Irial was initiated to treat 39 patients with two dose levels (90 and 180 MU, SO) of 
BetaseronR (recombinant human interferon beta). Most palients had advanced stage HIV-infection and nearty all had one or more 
risk tactors which predict poor clinical response to interferon therapy (high HIV p24 antigenemia, low CD4 count, elevated beta2 
microglobulin, prior opportunislic infections, prior systemic chemotherapy)_ All patients had near normal hepatic, renal and 
hematologic values. Four patients received zidovudine (AZ1) during the study and were thereafter excluded from analysis, as was 
one patient who manifested a pre-existing opportunislic infeclion (01). Two patients had clinical complele responses to Irealrnent and 
four had partial responses (overall major tumor response of 16%); 16 (42%) had stable disease_ Betaseron significanctly decreased 
HIV p24 anligen levels and increased beta2 microglobulin in patients with> 50 pg p24 antigen and < 3_0 beta2 microglobulin at 
baseline. No efficacy differences were noted between the two dose levels. High doses caused more toxicity, which was primarily 
injection sHe necrosis_ Statistically but not clinically significant decreases were seen in hemoglobin and CD4 levels_ No palient 
developed < 1500 granulocytes and no patient became Iransfusion dependent. Only one patient had an on-study 01. This deveioped 
one week after enlry and probably existed pre-study. As Betaseron has a wide range of in vitro anti-viral activity, the remarkably low 
incidence of 01 may be due to both the agent's enhancement of immune function and its direct action against opportunistic 
organisms. Because of their demonstrated in vitro synergism, further evalualion of Betaseron is warranted in the trealrnent of HIV-
infection, afone and in combination with AlT. 
STRAtN DIFFERENCES tN THE INDUCTION OF CUTANEOUS GRAFT-VS-HOST DISEASE (GYHD) IN THE RATS_ M_ Mostarica-
Stojkovic, S_ Stosic-Grujicic, Z. Ramic and M.L. Lukic; Inst. Microbiol. Immunol. Sch_ Med_ and Inst. BioI. Res., Belgrade, Yugoslavia 
Systemic GYHD arising in Fl hybrids injected with parental T lymphocytes appears either as lethal, acute, 
immunosuppressive GYHD, or as a chronic disease aSSOCiated with different autoimmune phenomena. In order to analyse the 
immunoregulatory mechanisms determining the form of GYHD, we have compared the GYHD-inducing capacity of the lymphocytes 
from two rat strains differing in the susceptibility to T-cell dependent autoimmunity and the frequency of COB+ cells. Sublethally 
irradiated (AD x DA) Fl rats developed clinical signs of GYHD two weeks after i.v. injection with 5 x 107 spleen cells from either 
parental strain. All AO-injected Fl rats succumbed by day 25, while the majority of DA-injected Fl rats (70 'I.) remained alive more 
than two months. Since it is known that during GYHD epidermal cells (EC) undergo functional alterations, we examined the 
production of cytokines by EC, and correlated their change to the severity of the disease. The presence of IL-l in culture 
supernatants and trypsinized EC has been investigated by both co-mitogenic thymocyte proliferation and direct mitogenic effect on 
the IL-l-responsive T-cell subclone Dl0S. Although all EC spontaneously released IL-l into the culture supernatant, EC from GYHD 
skin exhibited increased IL-l production, in comparison to control Fl rats_ Excess produclion of IL-l correlated with severity of 
GYHD and was more pronounced in AO-cell recipients. In addition, the supernatant media from cutaneous GYHD cells contained 
cytokines that specifically suppressed T-cell bioassays for IL-l, but not IL-2_ During the course of disease, we were not able to 
observe IL -2 production by any of EC tested_ Our results show that in comparison to DA, AD lymphocytes having higher numbers of 
CD8+ cells induce acute, lethal form of GYHD, which is associated with more vigorous locat production of immunoregulatory 
molecules from the Fl host epidermis_ The increased amounts of both IL-l and IL-l antagonists might be either a primary GYHD-
related change, or might be a consequence of GYHD-induced change in the skin_ 
566 ABSTRACTS THE JOURNAL OF INVESTIGATIVE DERMATOLOGY 
THERAPY OF CLASSIC KAPOSI'S SARCOMA WITH RECOMBINANT INTERFERON-ALPHA 2B. P. Morel, M, Rybcjad, L. 
Borradori; Clinique Dermatologique, Hopital Saint Louis, University of Paris VII, Paris, France 
In classic, non-AIDS associated Kaposi's sarcoma (KS) radiotherapy and chemotherapy have been widely used with 
varying success and morbidity. We here report our preliminary experiences with the management of classic KS with low doses of 
interferon (IFN)-alpha. Ten patients with a median age of 62 (range 20 to 76) years were treated long-term with 5.106 units of 
recombinant IFN-alpha 2b given subcutaneously three times a week. Of the 10 patients, 6 presented with cutaneous disease only, 
while 4 had additional visceral involvement. After 6 months of therapy with low doses of IFN-alpha, 7 of 10 patients had major 
responses (defined as a decrease 01 at least 50% of the number and biperpendicular size of lesions) of the cutaneous lesions, while 
in three patients stabilization of skin disease was observed, Of the four patients with visceral lesions, one patient showed a complete 
response (defined as the disappearance of the lesions) of a cardiac tumor (as assessed by computerized tomography scan), white in 
the other three pafients (incuding two with life-threatening gastrointestinal tract lesions and pleuro-pericardial disease respectively) 
stabilization of the visceral lesions occurred. On the whole, the long-term results over a median duration 01 t2 months are also 
satisfactory: IFN-alpha continued to control KS in all patients, recurrences in new sites were not observed, IFN treatment was 
generally well tolerated, including old patients. Administration 01 low doses 01 IFN-alpha was feasible on an outpatient basis. In 
conclUSion, our results suggest that in patients with classic KS treatment with low doses of IFN-alpha is effective and well tolerated. 
However, further studies are needed to establish the exact role of IFN-alpha as alternative to radiotherapy and chemotherapy. 
BETA- AND GAMMA-INTERFERON THERAPY OF MALIGNANT MELANOMA. W. MOiler, W. Lechner, R. Dummer, J. Dues; Dept. 
of Dermatology, University of WOrzburg, WOrzburg, FR Germany 
Because of the poor prognoSis of high risk malignant melanoma in spite of generous surgical removal it is advisable to look 
for an additional therapy. Interferons might provide a possible therapeutic approach because of their antiprotiferative, antitumoral and 
immunomodulatory qualities. In vitro y-IFN seems to enhance the inhibitory effect on tumor growth of 8-IFN. A clinical combination of 
both tFNs might improve the prognosis 01 high risk melanoma. After surgery we treated patients with melanoma clinical stadium II-IV 
by giving S-IFN in a dosage of 2-3 MiIIlU three limes a week s.c. or i.v., depending on the primary tumor localization, y-IFN was 
applied s.c, every four weeks for three days 50 microg. Therapy lasted for six months. Half of the patients received 8-IFN i.v .. the 
other half s.c, Only the first group included sladium IV melanoma, in the second group there were stadium II and III palients. So far 
the overall results appear to be the same in both groups. Antibody formation against 8-IFN was found in almost half of the patients, 
80% of them receiving 8-IFN s.c. The follow-up lasted up to 18 months, so far most of the patients are still without recurrences. Our 
impression is that patients with muttiple inoperable metastases do not profit by the additional therapy. The efficacy of the combined 
interferon therapy will need further investigation by treating more patients and a longer follow-up period, 
EFFECT OF BRM ON CELL GROWTH OF CULTURED CELL LINES AND CULTURED T-CELLS. T. Nagatani, M. Okatsu, T, 
Matsuzaki. S. Ichivama and H. Nakajima; Dept. of Dermatology, Yokohama City University School of Medicine, Yokohama, Japan 
Cutaneous T-cell lymphoma (CTCL) has been defined as a helper T-cell lymphoma with marked affinity for the skin, 
Several biological response modifiers (BRMs) have recently been applied for treatment of CTCL, but the effects of these are still 
unknown. In this report, the effects of natural interferon-ALPHA (IFN-ALPHA, FPI-31), recombinant interferon-y (rIFN-y, SUN4800). 
recombinant interleukin-2 (rIL-2, S-6820) and tumor necrosis factor (TNF) on cultured cell lines (Daudi, HUT78, HUTf02 and K562) 
and long-term cultured T-ealls (AWA and NAKA) were studied, HUT78 and HUTt02 cell lines were established from a patient with 
ATL and showed T-cell phenotype. AWA cells (CD3+, CD4+, CD8-) were obtained from biopsied skin of patients with mycosis 
fungoides (CD3+, CD4t, CDB-). NAKA cells (CD3+, CD4t, Cd8-) were obtained from blopsied skin of patients wi1l11ymphomatoid 
papulosis (CD3t, CD4-t, CD8.). Each cell line was cultured in flat-bottom dishes with a suitable number of cells in RPMI 1640 
medium supplemented with 10 % cord blood serum and 10 microglml gentamicine. Each BRM was added to the culture system at 
the beginning of the culture_ The cell number was counted and adjusted every three or four days. A growth inhibitory effect of IFN-
ALPHA was detected on AWA, NAKAo Daudi and HUT78 cell lines, but not on HUn02 and K562, A growth inhibitory effect of rlFN-y 
was detected only on AWA cultured T -cells. In IL-2 it was observed only on HUTt02 cell lines. In TNF it was observed on long-term 
cultured cells, AWA and NAKA. These results showed that the effect of BRMs has some specifity for tumor cells, and that some 
BRMs have direct toxic effects against tumor cells .. 
THE MOLECULAR BASIS FOR CELLULAR PATIERN RECOGNfTlON-A DERMATOPHATOLOGY VIEWPOINT. B,J. NickolOff, 
C_E.M. Griffiths, Univ, of Michigan, Ann Arbor, USA 
Since we first reported in 1987 that gamma interferon (IFN-y) treated keratinocytes (KCs) irereased the binding of LFA·l 
expressing T-ealls via intercellular adhesion molecule-t (tCAM), much progress has been made in our understanding of the 
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functional consequences of these interactions. To decipher the pathophysiological significance of these results, we asked whether 
different cellular patterns of inflammation, which the dermatopathologist uses for diagnosis, could be understood in molecular terms. 
20 different dermatoses involving 100 patients were examined immunohistochemically, and whereever T -cells were in close 
apposition to the epidermis, the KCs expressed ICAM, and where there was no epidermal infiltration by T-cells, the CDs were ICAM 
negative. The intensity of the dermal inflammation correlated to the extent of endothelial cell (EC) ICAM expression. Thus, despite 
the diversity of antigenic stimuli which cause these diseases, the production of IFN-y, which can induce ICAM, represents a final 
common pathway. It is now possible, therefore, to look beyond cellular patterns of inflammation as seen by light microscopy, to 
assign specific molecules and cell types to these patterns. Since ICAM can be induced on a variety of cell types such as KCs, ECs, 
fibroblasts (Fbs), dermal dendrocytes (DDs), we propose the follOwing scenario: For those diseases with 1 Hy a dermal perivascular 
T-cell infiltrate, the ICAM expressing EC is centrally important; for those diseases with both a perivascular and interstitial 
Iymphohistiocytic infiltrate the ICAM expressing DO and Fb is paramount; for lichenoid tissue reactions, the ICAM expressing KC is 
the important cell type. Of course, the importance of these non-lymphoid cells probably reflects not so much the intrinsic property of 
the cell , but rather the type and quantity of antigens, cytokines and Iymphokines to which it is responding in its immediate 
microenvironment. Despite our ignorance regarding the initiating etiological antigen(s) responsible for most dermatological diseases, 
we can at least begin to comprehend the pathophysiological basis involving final common cellular and molecular pathways, from this 
dermatopathology viewpoint. 
ALPHA INTERFERON THERAPY IN DISCOID AND SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS. J.F. Nicolas, J. 
Thivolet. J. Kanitakis, B. Chouvet; Clinique Dermatoligique, Hopital Ed. Herriot, Lyon, France 
Ten patients presenting with discoid lupus erythematosus (OLE) or subacute cutaneous lupus erythematosus (SCLE) were 
treated with interteron alpha 2a. Eight of them received low or intermediate doses (10 to 45 x 106 units (U)lweek) for a short period 
of time (4 to 8 weeks), with a complete clearing or a marked improvement of skin lesions in 4 and 2 patients respectively; one patient 
experienced a worsening of cutaneous lesions whereas the clinical condition of the last one was not affected by interteron. Two out 
of the 10 patients presenting with SCLE received high doses (100 to 120 million unitslweek) for 12 weeks with a complete clearing of 
lesions in one case and a marked improvement in the second one. Thus, taken together these results comprise a marked 
improvement or clearing of cutaneous lupus lesions in 8 out of the patients receiving interteron alpha 2a therapy. However, respcnse 
to interteron was only of short duration and within a few weeks after interteron withdrawal, al l patients who were improved or cleared 
relapsed to a clinical condition similar to the one before therapy. Circulating antinuclear antibodies (ANA) were detected before 
treatment in 4 patients and ANA titer was not modified by interteron in 3 of them. The fourth patient showed a marked albeit transient 
increase in ANA titer with no clinical translation. Side-effects included fever and a flu-like syndrome in all patients leading to dose 
reduction in one case. Biological toxicity was limited to an increase of liver enzyme levels in 2 cases: no hematological toxicity was 
noted. This study suggests that interferon alpha 2a represents a new interesting approach in the treatment of OLE and SCLE. 
Ongoing trials will define the optimal treatment schedule for the maintenance of interteron-induced improvement of cutaneous lupus 
erythematosus. 
IMMUNOMODULATORS AND CYTOKINES IN MENTAL DISEASES. T.I. Nevidimova, Tomsk Mental Healthy Research Institute of 
the USSR AMS, Sosnovy Sor, USSR 
Psychiatric patients often show pathologic skin reactions, which can be interpreted as side-effects of 
psychopharmacotherapy and reflect immunological imbalance. Clinico-immunological studies of 130 schizophrenic patients using 
lymphocyte blasttransforrnation test induced by phytohemogglutinin, HSV antigen, thymus preparation thymlain and recombinant 
interleukin-2, revealed a wide range of reactions correlating with clinical state of the patients. Thymalin treatment of several patients 
gave promiSing results: mental state improved with normalization of immunologicaf parameters and disappearance of skin reactions 
as side-eHects. The similar dynamic of clinical and infectious-allergic statuses is explained by the unity of nervous and immune 
systems having common mediators (inlcuding hormones and Iymphokines). antigens and receptors. Many psychopharmacological 
drugs with antihistamine eHect are used in dermatology, while seme immunomodulators produce psychotropic effect. Optimization of 
treatment of psychiatric patients is possible on the basis of testing and correcting immunity chains, including Iymplnokine production. 
It is perspective to use immunomodulators in the treatment of therapeutically resistant cases characterized by the stability of 
psychopathologic symptomatology, immunological diserders and side-effects - skin and other reactions. 
APPLICATION OF B-INTERFERON IN VIRUS INDUCED PAPILLOMAS. M. Niimura, Dept. of Dermatology, The Jikei University 
School of Medicine, Tokyo, Japan 
Eighty patients with bilateral common warts of the extremities were treated at weekly intervals with intralesional injections 
of either fibroblast interteron (IFN-B) or placebo (human serum albumin 9 mg and lactose 3 mg per vial). Lyophilized IFN 3 x 106 
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units was diluted with 3 ml of saline matched with identical viats of placebo. Eighty sets of three viats of IFN-S or placebo were 
labeled either A or B by a controller whe maintained the code until the experiment was completed. Each patient received 0.1 x 106 
units ot tFN into the warts on one side and placebo injections into these on the matching extremity. Warts were measured each week 
and the progress or lack thereof was scored on a scale 01 -I (worse) to 3 (cured). Therapy continued until either atleasl one 
extremity had cleared or the patient had received ten weekly injections. Sixty-four patients were treated to completion. Fineen 
patients failed to complete the course 01 study and one patient exhibited complete spontaneous regression. More than 81 % of the 
IFN-treated extremities were either cured or responded eHectively to therapy. Onty !7% of the placebo-treated lesions responded in 
this fashion. A statistical analysis of these data confirms the effecliveness of intralesional IFN therapy. Forty-two IFN-treated 
extremitieS were cured of warts, While only seven placebo-Ireated exlremities were cured. The average number of IFN injections until 
cure was 5.9 +1- 1.7. A1thcugh IFN proved to be effective, the method of application and the need for repeated injections suggest that 
this therapy may not be helpful in routine cases but only in selected patients with whom other therapy has failed. 
EPIDERMAL CYTOTOXICITY - THE ROLE OF INDUCTION OF ADHESION MOLECULES BY CYTOKINES. D.A. Norris, University 
of Colorado and DVAMC, Denver CO, USA 
Immunologic cytotoxicity is an important endpoint 01 the immune response, resulting in discrete membrane damage to 
cellular targets. Immunologic cytotoxicity can be induced through specific antigen recognition in classical cellular or humoral immune 
responses, or by 'natural' immune responses in which Tor B lymphocyte activation is not required. The number of distinct cytotoxic 
mechanisms is large and involves lymphocytes, monocyte/macrophage and granulocyte effectors. Cytotoxicity involves three 
important phases: nonspecific attachment, specific recognition, and target lysis. Epidermal cytotoxic reactions have been studied in a 
number of important skin diseases: contact dermatitis, lupus erythematosus, lichen planus, vitiligo and malignant melanoma. 
Numerous types 01 immunologic cytotoxicity are implicated in these diseases: MHC-restricted lysis by cytotoxic T lymphocytes, lysis 
by activated macrophages, antibody dependent cellular cytOloxicity (ADDC), natural killing (NK), Iymphokine activated killing (LAK), 
and natural cytotoxicity (NC). II appears that leukocyte attachment by the inlegrin LFA-! through the ligand ICAM-! is a cruCial first 
step in these interactions. The expression of ICAM-I by melanocytes and keratinocytes is greatly enhanced by gamma interferon 
(IFN-y). ICAM-! induction on keratinocytes is dependent on the state 01 cell differentiation, and is influenced by retinoids and 
corticosteroids. Ultraviolet radiation initially suppresses interferon-induced ICAM-I expression in both cell types, but ICAM-! 
expression by keratinocytes is greatly enhanced 48 - 96 heurs after UVR. ICAM-I induction may be important in photosensitive skin 
disease, dermatitis, depigmenting disorders, and malignancies of melanocytes and keratinocytes. 
MODULATION OF INTERCELLULAR ADHESION MOLECULE-! (ICAM-I ) EXPRESSION IN THE EPIDERMIS BY CYTOKINES 
AND ULTRAVIOLET RADIATION: AN IMPORTANT ASPECT OF IMMUNOLOGIC REACTIONS OF THE EPIDERMtS. DA Norris, 
M.B. Lyons, M. Kashihara-Sawami, J.J. Yohn; University of Colorado and DVAMC, Denver CO, USA 
Intercellular adhesion molecule·1 (ICAM-I) is the ligand for the integrin cellular adhesion molecule LFA·I . Interaction 01 
ICAM·I on parenchymal cells and LFA·I on leukocytes mediate leukocyte attachment to a variety 01 cells, iniliating numerous 
contact-dependent immunologic processes. Our purpose was to study the expression of ICAM·I on cultured human keratinocytes 
and melanocytes and to delermine the effects of immunologic cytokines and ultraviolet radiation (UVR) on antigen expression. For 
this purpose we developed a cell sorter (FACs) technique which demonstrated binding of an ICAM+speciflC monoclonal antibody 
(RR·I) to the surface of human keratinocytes and melanocytes grown in cell culture. Keratinocyte ICAM·! expression was greatly 
augmented by gamma interferon (IFN'g), but not by IL·! , GMCSF, TGF-B or TNF·a (IL-! and TNF·a produced mild synergistic effect 
with IFN-g). Melanocyte ICAM·I expression was augmented by IFN-g, IL-I and TNF·a. High dose UVA (100 mJ/cm ) Significantly 
inhibited induction 01 ICAM·! by IFN-g in both cell types, but keratinocyte ICAM·' expression was greatly enhanced by UVR after 48 
hcurs, with or without IFN-g. Thus, UVR demonstrates a biphasic effect on keratinocyte ICAM·', with initial suppression being 
lollowed by strong enhancement. Only UVR and IFN-g were found to be strong inducers of keratinocyte ICAM·! . On the other hand, 
melanocyte ICAM·' was enhanced strongly by IFN-g, IL·' , and TNF·a, but was only inhibited by UVA. Thus, different potential 
immunoiogic targets in the epidermis shew quite different pattems of regulation 01 ICAM·! expression .. 
EXPRESSION OF INTEALEUKIN·8 (IL·8) AND GRO PROTEINS IN HUMAN FIBROBLASTS. P. Nyirkos, P. Mason and E.E. Golds; 
Joint Diseases Laboratory, Shriners Hospital tor Crippled Children and McGill University, Montreat, Quebec, Canada 
In our previous work using 35S-melhionine and 35S-cysteine labeling, autoradiography and N·terminal protein sequence 
analysis, we have identified two Iow-motecular weight proteins secreted from fibroblasts that may playa role in mediating 
inflammatory responses: (I) inlerleukin-8; (2) a protein predicted from the gro eDNA, which is reported to have melanoma growth 
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stimulatory activity and is related to Il-8. In skin and lung fibroblasts (AG4148 and HFl-l) both Il-l and TNF induce Il-S and gro 
secretion. While Il-l induces both proteins equally well , with TNF, Il-S production is predominant over gro as detected by SDS-
PAGE followed by autoradiography. Induction of the gro and Il-S is inhibited by actinomycin-D and dexamethasone, but not by 
indomethacin. No induction of these two proteins is detected by treatment with PDGF, EGF, basic FGF, Il-l, Il-6, gamma-IFN, 
bombesin, substance P or lPS, although, in each instance, these factors either induce other proteins, increase overall protein 
synthesis or stimulate proliferation. In melanoma cells (Hs294T), Il-l induces little Il-S in contrast to fibroblasts. Gro, which is 
constitutively secreted at a low level in melanoma cells, is not significantly induced by Il-l . 
EFFECT OF CYTOKINES, TGF-B AND CYClOSPORIN A ON DNA SYNTHESIS AND EXPRESSION OF EGF RECEPTOR OF 
NORMAL AND MALIGNANT KERATINOCYTES. K. Okubo, T. Karashima, H. Hachisuka, Y. Sasai; Dept. of Dermatology, Kurume 
Univ. School of Medicine, Kurume, Japan 
mRNA of interleukin-l (Il-l) and other cytokines have been detected in keratinocytes (KC), and TGF-B and cyclosporin A 
(Cy-A) inhibit KC growth. The roles of these cytokines on KC are still unsolved. Clinically, high amounts of Il-l were found in 
keratinocytes of psonatic skin and Cy-A was used as therapeutic reagent for psonasis. We demonstrated reciprocal regulation of 
DNA synthesis and EGF receptor expression by interleukin (Ils) and TGF-B, Cy-A on A431 cells and normal human KC. A431 
epidermoid carcinoma cell line and EGF dependent normal human KC were used. After 96 hrs incubation with Il-l, 2, 3, 4, (5-10 
units) and TGF-B (10 ng) or Cy-A (10 microg), cells were stained with anti-EGF receptor monoclonal antibody. DNA synthesis of cells 
was measured by 3H-tymidine incorporation after 48 hrs, 96 hrs and 144 hrs starting cultivation with Ils, TGF-B or Cy-A. TGF-B and 
Cy·a completely inhibited DNA synthesis of KC and A431 cells, and Ils enhanced DNA synthesis of normal human KC but not A431 
cells. TGF-B and Cy-A induced suppression of DNA synthesis was not recovered with Ils. TGF-B or Cy-A induced decrease of EGF 
receptors on normal human KC and A431 cells was inhibited by Ils. We found that Ils and TGF-B were important factors which 
regulate DNA synthesis and expression of EGF receptor of normal human KC. Since EGF binding was increased in psonatic 
epidermis, Cy·A might suppress the expression of EGF receptor and DNA synthesis. 
TREATMENT OF PSORIASIS BY NATIVE INTERFERON BETA CREAM. J. Ophir, S. Brenner; Dept. of Dermatology, Ichilov 
Hospital , Tel-Aviv Medical Center, Tel-Aviv, Israel 
Interferons are proteins which interfere with viral replication, inhibit cell growth and affect cell differentiation both in benign 
and malignant diseases. Interferons have an antiproliferative activity on human keratinocytes. Since psonasis is a disease 
characterized by increased epidermal proliferation of keratinocytes, we used interferon beta, 100,000 ulgr x 3/day over a period of 4-
5 weeks, which we found particularly effective for topical treatment in 12 psonatic patients. In eight patients, the lesions disappeared 
completely or improved significantly, in one patient there was a slight improvement, and in three patients no improvement was 
noticed. We are now conducting a double blind trial on a major series of patients. 
IFN-y AND ENHANCEMENT OF LAK CEllS ACTIVITY IN NPC PATIENTS. R. Oueslati, M. lakhdhar, M. Chouikha; lab. 
d'immunoi. cell., Hopital Militaire de Tunis, Tunis, Tunisie 
It has been reported that interferons (IFN) are immunomodulatory agents. In our study we detected a high titer of IFN-y in 
the sera of nasopharyngeal carcinoma patients (NPC), the geometnc mean (32 +1- 10 U/ml) was determined by the plaque reduction 
assay with vesicular stomatitis virus (VSV). To determine whether this cytokine modulates lymphoid cell activity (LAK) we incubated 
the PBl patients with different doses of IFN-y; this showed that 1000 U/ml of rlFN-y could only slightly enhance the LAK cytotoxictty 
(26 +/- 5 vs. 20 +/- 4 %). In contrast, we found that 200 U/ml of rll-2 increased the cytotoxicity to 60 % but this cytotoxicity was dose 
and time dependent. Although IFN-y is produced by PBl cells dunng incubation with rll-2, the inability of anti-IFN-y antibodies to 
inhibit Il -2-induced cytotoxic activity suggested that the potential effect of rll-2 on killer cells is not mediated by IFN-y; however, anti· 
IFN-y partially inhibited the PBl proliferation mediated with rll-2 and abolished the cell proliferation induced with rIFN. 
INTERFERON-GAMMA - A POTENT INDUCER OF lOCAL INFLAMMATION. J. Pinocy, U.T. Hopt; Dept. of Surgery, University of 
TObingen, TObingen, FR Germany 
Inflammation is characterized by a local increase in vascular permeability (VP), regional blood How (RBF) and in 
accumulation of leukocytes such as neutrophils, monocytes and lymphocytes. There is circumstantial evidence that these reactions 
are mediated by cytokines. Whether interferon-gamma (IFN-g), however, participates in the initiation of such inflammatory reactions, 
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is still controversial. Thus, the effect of IFN-g on VP, RBF and lymphocyte recruitrrent (lR) was studied in healed sponge grafts, 
implanted subcutaneousty into Balblc mice. VP, RBF and lR were measured with 1-125·albumin, RbCl·a6 and Cr-51 labeled 
unsensitized lymphocytes, respectively. IFN-g significantly increased VP as well as RBF by 33 and 12 % within 1 hour after injection. 
Thereafter, however, the stimulatory effect disappeared quickly. RBF even got suppressed resignificantly compared to untreated 
controls. local lR was stimulated by IFN-g also very early. Contrary to VP and RBF, maximum stimulation of local lymphocyte 
accumulation was found only after 10 hrs reaching an increase of more than 40%. This local stimulation of lR could still be detected 
even as 24 hrs after local injection. This time course at the effect or IFN·g on LR dillers markedly from those of interleukin-, and 2. 
The effect of IFN-g on lR is clearly dose-dependent, reaching a plateau phase with as lillie as , ,000 U. Increase of the local injected 
dose up to 100,000 U did not show any further effect. Thus, IFN·g might playa crucial part in the regulation of local inflammation. In 
addition, it could clearly be shown that the effect of IFN-g on VP and RBF on the one side and lR on the other side is mediated by 
different mechanisms. The strong effect of IFN-g on local lR suggests that this mediator might be most important for the regulation 
of immunologic inflammatory reactions. 
EFFECT OF ERYTHROCYTE MEMBRANES ON THE PRODUCTION OF ERYTHRO-POIESIS·MODUlATING FACTOR BY 
SPLEEN CEllS. Y. Pukhova, E.I. Elsukova, Institute of Biophysics, USSR, Academy of Sciences, Siberian BranCh, Krasnoyarsk, 
USSR 
The aim of the present paper is to study the effect of eryhtrocytes or their membranes on the erythropoietic factor 
production by mice spleen cells. Spleen cells were incubated in the absence of erythrocytes or their membranes or in their presence 
at a temperature of 371C during 4 hours and then' hour with crystalline silica. The erythrocyte membranes were obtained by talline 
silicia. The erythrocyte membranes were obtained by iwatshenko method. Erythropoietic activity of supematants of the spleen cell 
suspensions was determined by 59Fe uptake into red blood cells of polycytemic mice. It was shown that spleen cells produce the 
tactor with erythropoiesis·modulating activity. The production of this factor is caused by the presence of autologous erythrocytes or 
either allogenic or syngenic erythrocyte membranes in spleen cell culture. The rate of 59Fe uptake into erythrocytes of polycytemic 
mice is dose dependent, it decreases both in the absence of erythrocyte membranes and in the presence of their high 
concentrations. The factor is specific in respect to erythropoiesis activation. The cell targets for it are the cell targets for 
erythropoietin. The factor does not possess pirogenic properties. Erythropoiesis-modulating factor is supposed to be a product of 
erythrocyte antigens processing by macrophages. The most speCific torm ot the tactor is reached when it is processed by T· 
tymphocytes at their cooperation with macrophages. 
Il·' AND tl-6 tN PSORtAStS. E.P. Prens, J. van Damme', M. Bakkus, K. Brakel. R. Benner and Th. van Joost; Depts. of 
Dermatology and Immunology, Erasmus University Ronerdam and 'Rega tnstitute, University of leuven, The Netherlands 
locally produced cytokines may play an important role in the initiation and maintenance of psoriaSiS lesions. We studied 
whether Il·l and Il·6 occur in suction blister fluid from lesional and univolved psoriatic skin. The expression of Il-l and IL-6 mRNA 
in serum·free cultured keratinocytes (KC) and in fibroblasts from psoriaSiS lesions, uninovtved skin and skin from healthy individuals 
was also studied. Il-l was measured in an IL-IS specific ELISA. Il·6 was measured in a functional assay using Il-6 dependent 
hybridoma cells. Il-1AlPHA, IL·tB and IL-6 mRNA were detected by Northern blot analysis. Suction blister tluid from lesional and 
uninvolved psoriasis skin and from skin of healthy individuals did not contain Il· t B. In contrast, freshly prepared epidermal cells from 
lesional skin showed a high expression of membrane bround Il-l B. Blister fluid trom lesional psoriatic skin did contain low but 
signiticant levels at IL -6 (range 20 - 200 U/ml). Blister lIuid tram uninvolved psoriatic skin and from healthy individuals, however, did 
not contain IL-6. Supernatants of KC cultures did not contain Il-6. Cultured KCs did express elevated levels of Il·l B as well as Il· 
1 ALPHA rRNA when compared with normal KCs and the HEP-2 cell line. Fibroblasts from psoriasis lesions expressed low levels of 
IL-,e mRNA, no IL-,ALPHA mRNA and slightly elevated levels of tL-6 mRNA. We conclude that the Il-6 that occurs in psoriasis 
lesions is locally produced, and that a major part is derived tram dermal fibroblasts. 
TREATMENT OF PSORIASIS AND PSORIATIC ARTHR ITIS WITH INTERFERON GAMMA. G. Rassner, G. Fierlbeck; Dept. of 
Dermatology, University of Tubingen, Tubingen, FR Germany 
In a clinical long·term study 51 patients with psoriatiC arthritis and stable plaque or guttate psoriasiS were treated with 
subcutaneous adminstration of recombinant interferon gamma. Patients were treated with doses of 50 to 100 ug daily for the firsl two 
weeks and then three times per week for several months. Some patients showed improvement of the joint symptoms coincident with 
the treatrrent. The cutaneous manifestations did not show any significant response, especially not after intralesional injection. In a 
series of patients punctiform psoriatic foci were observed at the s~e of injection. As an indication for a connection between IFN 
VOL 93. NO. 4 OCTOBER 1989 ABSTRAcrs 571 
gamma and local induction 01 psoriasis a patient was seen in whom psoriatic foci could be elicited at the site of injection by IFN 
gamma, but not at Altinsulin or placebo inlections. This resull is in contrast 10 interteron alpha, which has been reported to cause an 
exacerbation of the disease also far away from the injection site. Also HLA-DR expression by keratinocyte was only seen at the 
injection site of IFN gamma when the biopsy specimen was taken of uninvolved skin on the fifth day of treatment. In a placebo-
controlled double blind study, 24 patients with psoriatic arthritis were given a 28 days' treatment with 100 ug IFN gamma. The 
principal cirterion for the statistical evaluation of the therapeutic success was improvement of the Ritchie Index by at least 25%. The 
chi-square test showed superiority of the interferon arm over the placebo arm an error probability of ALPHA < 1 %. Influenza-like 
symptoms (nausea, fatigue, headache and sweating) were recorded more frequently in the interferon group than in the placebo 
group. 
MODULATION OF THE ANTI-TUMOUR ACTIVITY OF TUMOUR NECROSIS FACTOR BY MONOCLONAL ANTIBODIES. D. 
Rathjen and R. Aston; Peptide Technology Ltd_, Dee Why, Australia 
Tumour necrosis factor alpha (TNF) is a protein produced by activated macrophages in response to a number of stimuli 
including lipopoly-saccharide. It is a potent mediator not only of haemorrhagic necrosis of tumours but also inflammation. Recently, 
TNF has been shown to have angiogenic properties. Thus, in tumours TNF may concomitantly stimulate tumour development 
through its angiogenic acti~ty and promote tumour destruction by direct cytotoxicity. We are investigating the structure/function 
relationships of TNF using a panel of mouse monoclonal anlibodies (MAbs) produced against human recombinant TNF. To date 11 
MAbs have been evaluated for their effects on TNF-mediated cytotoxicity in ~tro and on WEHI- I64 and Meth A sarcoma (solid and 
ascites) tumour development in vivo. Competitive binding studies showed thai the anlibodies recognize three domains on TNF with a 
least five non-overtapping epitopes. While in general antibodies which inhibited TNF cytotoxicity in vitro also inhibited TNF-mediated 
regression, one antibody was identified (MAb 53) which did not inhibit killing of WEHI-I64 cells in vitro but did inhibit tumour 
regression. A second MAb (MAb 25). in the presence of a little as 0.3 pg of TNF caused mart<ed proliferation of WEHI-I64 cell in 
vitro. This effect was not observed in cultures containing MAbs but no TNF. In vivo MAb 25 inhibited completely the TNF-induced 
regression of Meth A tumours but not regression of WEHI-I64 tumours. The reason for these disparate results, particularty of the 
MAb mediated uncoupling of the proliferative effects of TNF from cytoloxicity is unclear, however, we are investigating the effects of 
these MAbs on endothelial cells cultured in the presence of tumour supernatants and TNF in order to mimic in vivo conditions. Our 
observations suggest that various TNF functions may be separated by MAbs of appropriate specificity. 
IMMUNOLOGICAL INVESTIGATION OF THE EXPRESSION OF THE GAMMA INTERFERON INDUCED 53 kD PROTEIN BY 
HUMAN KERATINOCYTES. A. Reano, J. Viac, S. Hesse, D. Schmitt, J. Thivolet; INSERM U. 209, CNRS URA 189, Hopital Ed.-
Herriot, lyon, France 
Incubation of human keratinocytes with recombinant gamma interferon (g-IFN) has been shown to induce the synthesis of 
non-ionic detergent soluble proteins with striking production of a 53kD protein complex. We investigated the expression of this 53kD 
component (S53) with the aid of a specific antiserum by IIF technique and immunoblotting assay. In g-IFN treated cultures, P53 Ag 
was expressed by 100% of keratinocytes; but immunoelectron microscopy, P53 Ag appeared located in the granular component of 
the cytoplasm unrelated to keratin filaments. II was not expressed in control cultures and sound skin. When blotted on two 
dimensional gel separated extracts, the antiserum reacted with four species of PI 5.3 - 5.8 and MW 53kD, in agreement with 
previous data. The threshold concentration of g-IFN required to induce P52 expression was 2 IU/ml; no further increase was 
observed using doses of more than 100 IU/ml. Maximum expression was achieved after 36 hrs of incubation. Although P53 
synthesis can be induced by g-INF in short-term organ culture of normal skin, IIF study of patient skin biopsies, showing intense 
inflammatory reaction with HLA-DR expression by keratinocytes, failed to detect P53 Ag_ The study is in progress to investigate P53 
expression in skin diseases using more sensitive techniques. 
DEFECTIVE IFN-GAMMA PRODUCTION IN HYPER-lgE ATOPIC DERMATITIS PATIENTS: EVIDENCE FOR AN INTRINSIC 
ABNORMALITY. U. Reinhold, W. Wehrmann, S. Kukel. HW. Kreysel; Dept. of Dermatology, University of Bonn, Bonn, FR Germany 
We performed a series of studies to examine mechanisms for the decreased in vitro production of interferon-gamma (IFN-
gamma) in nineteen hyper-gE atopiC dermatitis (AD) patients. The present wort< shows that IFN-gamma production of peripheral 
blood mononuclear cells (PBMC) induced by phytohemagglutinin (PHA) is profoundly diminished in AD patients wihereas proliferative 
response, as indicated by 3H-thymidine incorporation, was similar to that by control PBMC. The addition of 40 Ulml interteukin-2 (Il-
2) to cultures stimulated with PHA failed to restore IFN-gamma production in defective cases. We show that the defect can also be 
observed after stimulation with monoclonal antibody OKT3, specific for the CD3 complex on T -cells, or after stimulation with high 
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levels 01 IL-2 (200 U/ml). Removal 01 adherent cells in PBMC did not correct defective IFN-gamma production. Activation by the 
phorbolester tetradecanoyl-phorbol-13-acetate (TPA) in conjunction with the calcium ionophore ionomycin (10) induced IFN-gamma 
production in both AD patients and controls but still significanlly less amounts of IFN-gamma in AD patients. Phenotypic analysis 01 
PBMC revealed increased proportions of CD4, T helpernnducer cells and decreased proportions of CD8, T cytotoxicJsuppresser 
cells and CD1S, natural killer (NK) cells in AD patients, resulting in an increased CD4/CD8 ratio as compared to controls. No 
correlation was observed between numbers 01 T-cell subpopulations and IFN-gamma generation in AD patients and controls. A 
significant correlation was found between IFN-gamma generation in vitro and IgE serum concentration in AD patients. Our data 
suggest that the decreased production ollFN-gamma by hyper-lgE AD patients is due to intrinsic dillerences in capacity to produce 
IFN-gamma. Moreover, the findings indicate that decreased production ot IFN-gamma may be an important factor in the 
pathogenesis of this disease. 
TREATMENT OF BASAL CELL CARCINOMAS WITH INTRALESIONAL INTERFERON ALPHA-2B. S. Reitamo, M. Komulainen. P. 
Lilius, P. Gr6hn; Dept. of Dermatology, Helsinki University Central Hospital, HelSinki, Finland 
Recent studies suggest that intralesional interleron alpha is effective in the treatment 01 basal cell carcinomas. However, 
these results could not be confirmed in another study. We studied the effect 01 intralesionai interferon alpha-2b in six patients (two 
males, four females, age 60 - 75 years, mean age 66) with one to three (total t 1) basal cell carcinomas (size 0.25 to 1.5 cm) . 
Interleron alpha-2b at 3 x 106 IU was administered intralesionally into one basal cell carcinoma three times weekly for three weeks 
with a total dose of 27 x t 06 IU. During the follow-up of five to seven months complete healing was achieved in only two out of the 
six treated basal cell carcinomas. Additionally, in one of the patients with multiple basal cell carcinomas healing was observed in one 
non-treated leSion, whereas the treated lesion remained unaffected. In addition to usual side-€ffects associated with inlerferon 
therapy, e.g. flu-like symploms, one patient with an earlier history of (seronegative) arthralgias developed a seropositive rheumatoid 
arthritis. The present results suggest that interleron alpha-2b shows some effect in the treatment of basal cell carcinomas. However, 
its usefulness is limited by side-effects, which can be relatively disabling for elderly patients. 
ROLE OF TNF tN CELL MEDIATED CYTOTOXICITY. G. Riethmiiller, HWL. Z"legler-Heitbrock; Institute for Immunology, Munich, 
FR Germany 
TFN was initially defined by its ability to destroy subcutaneous tumors in the mouse and we know today that this effect can 
be explained by TNF action on Ihe vascular syslem, on the tumor cells and on the cells of Ihe immune system. Both monocytes and 
lymphocytes are able to produce TNF. The cell medialed cytOloxilCity 01 monocytes can be studied in vitro by using target cells, like 
Wehil64 pretreated with actinomycin D. In this syslem antibody neulralization demonstrates that TNF secreled by the monocytes is 
the major effector molecule. In addition, a transmembrane form of TNF may induce lysis of target cells after direct ceil-cell·contaci 
with resultant binding of TNF to its receplor. The cascade of molecular events leading 10 cell death after TNF-receplor binding are 
still elusive, but reactive oxygen and DNA fragmentation appear to be involved. Among the lymphocytes TNF production has been 
demonstrated for both cytotoxic T -<:ells and for natural killer cells. Firm evidence to demonstrate an involvement of TNF in the 
cytotoxicity mediated by these cells is lacking. In addition to being directly involved in cell mediated cytotoxicity of monocytes TNF 
can also enhance cytotoxic activity of these cells. Furthermore, the in vitro generation of cytotoxic T -cells is substantially enhanced 
by TNF possible due to a proliferative effect. Hence, TNF may be involved in cell mediated cytolysis as an effector molecule and as 
enhancing element. 
INTERFERON ALPHA-2A IN THE TREATMENT OF SIX PATIENTS OF CUTANEOUS T-CELL LYMPHOMA. E. Rinne, L. Forstrom, 
A. Lassus; Dept. of Dermatology, Helsiniki University Central Hospital, Helsinki, Finland 
Six patients (4 males, 2 females) with stages lA-III mycosis fungoides (5 pat.) or Sezary syndrome (f pat.) were entered 
into a controlled trial of interleron alpha-2a. The dosage was escalated to 18-36 million IU subcutaneously daily for 3 months and 
thereafter the highest tolerated dose was administered 3 times weekly. The totat treatment time varied from 9.2 months to 25.8 
months. All patients showed an antitumor response during the first 3 months. One patient had a complete response, which was 
histologically confirmed and lasted 33 months including 6 months maintenance therapy. In other patients some minor response was 
achieved, but not 50% response rate. Strict adherence to the protocol was not possible, 2 patients of tumour stage also received 
electton beam therapy to selected tumours during the interteron therapy. During the maintenance therapy the response was minor 
and at the end of treatment one complete response, 4 stable diseases and 1 progressing disease (the 5ezary pat.) were achieved. 
All patients suffered from flu-like side-effects, fatigue, weight loss and anorexia. Four patients had grade 3 leukopenia and 
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neutropenia, and four patients grade 2 liver toxicity. All side-eHects were transient and reversed after dose reducting or 
spontaneously during therapy. The patient with a complete response developed neutralizing interferon antibodies during the therapy, 
in other patients these were not detected. Due to the small patient sample size no statistical methods could be used. According to 
our experiences the best efficacy was achieved with a high-dose regimen. 
THE INTERFERON STATUS IN PATIENTS WITH MALIGNANT TUMORS AND ITS CHANGES IN TOTAL HPYERTHERMIA AND 
ARTIFICIAL HYPERGLYCEMIA. D.Y. Risina, LV. Korobko, I.G. Zhakov, S.Z. Fradkin, E.A. Zhavrid; Scientific Research Insti tute of 
Oncology and Medical Radiology of the BSSR Health Ministry, Minsk, USSR 
The interferon (INF) status was examined in 72 patients with malignant melanoma of the skin, malignant tumors of soft 
tissue and bone before and in the course of special treatment. Substantial differences in interteron values in the patients examined 
and practically normal people were discovered. The serum IFN titers were significantly higher (10-100 fold) in patients than in normal 
people. Leukocytes of tumor patients produced no ALPHA-IFN in response to Newcastle disease virus in 81 % of cases, in normal 
people the ALPHA-IFN tilers being 16-128 units. Production of y-IFN in response to stimulation of leukocytes by a staphytococcal 
enterotoxin A was significanlly lower in patients than in normal people (37 and 632 units, respectively). In 18 patients IFN was 
examined before and after treatment with total hyperthermia and artificial hyperglycemia with chemotherapy (TH and AHG). In 12 
patients the IFN levels was 2-64 times as less as the initial level, in 3 patients it remained unchanged, and only in 3 patients some 
increase was observed. Thus, the results obtained show that there were marked changes in the IFN system in patienls with 
malignant tumors. The TG and AHG procedures caused favourable changes in serum IFN blood levels in most patients examined. 
INTERFERON ALPHA-2A COMBINED WITH PHOTOCHEMOTHERAPY FOR CUTANEOUS T-CELL LYMPHOMA. H. Roenigk ir., 
S. Rozen, E, Springer, T, Kuzel; Northwestern University Medical Center, Chicago IL, USA 
The anti-tumor ellect of PUVA plus recombinant human inlerferon alpha-2a was evaluated in fifteen patients with 
cutaneous T-cell lymphoma (CTCL). Median age was 54 (range 41 - 75). Eight were stage IB, four were stage liB, one was stage III, 
one stage IVA, and one IVB. Twetve patients had received previous therapies including topical or systemic steroids (10), topical 
chemotherapy (4), and electron beam radiation therapy (3). Interferon was given intramuscularly three times per week. Three 
patients received 6 x 106 units, thre patients received 12 x 106 units, three patients received 18 x 106 units, and six patients 
received 30 x 106 units. PUVA therapy was also given three times per week during disease clearing. Initial exposure times to UVA 
ranged from 0.5 - 3,0 joules/em . Exposure times are increased by 0.5 joules/cm more depending on erythema, With remission, 
maintenance PUVA is given once per week for four weeks and then every two to four weeks Twelve patients achieved a complete 
remission and two patients a partial remission. The median time to partial remission was approximately one month (range 1 - 2) and 
to complete remission three monlhs (range t - 12). The median duration of response is greater than 13 months. Only one patient 
who achieved a complete response has progressed. Constitutional symptoms were noted with interferon therapy. Evidence of 
interferon associated photosensitivity was seen requiring delays in PUVA therapy. No significant laboratory abnormalities were 
noted. 
EFFECTS OF EPIDERMAL GROWTH FACTOR AND HUMAN BETA INTERFERON ON EPtTHELIAL HEALING OF DENDRITIC 
HERPETIC KERATITIS (HSV-l) IN RABBIT CORNEAS. A. Romano and D. Wassermann; Maurice and Gabriela Goldschleger Eye 
Insti tute, Sheba Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel 
A study was conducted to evaluate the effect 01 HulFN-beta and EGF each one separately and in combination, on 
epithelial wound healing and stromal cloudiness in herpetic dendritic keratitis (HSV-l) in rabbit corneas. The HulFN-beta was 
administered at a concentration of 200,000 IU/d and EGF at a concentration of 0.001 mglday; each divided into 4 doses for 7 days. 
After seven days post inoculation there was no difference in epithelial would healing between the differently treated groups and the 
placebo group, but increasing cloudiness in corneal stroma was observed in the EGF treated groups and in the HulFN-beta and EGF 
combined treated groups. Histopathologic examination discovered hyperplastic epithelium over the damaged stroma with heavy 
PMN and lymphocyte infiltrales and new vessels in the stroma of the IFN and EGF combined treated group. Similar findings, though 
less severe, were observed in the IFN treated group. Very mild PMN infiltrates were observed in the IFN treated group and normal 
histological structure was observed in the placebo group. EGF in the active herpetic dendritic keratitis seems to facilitate replication 
and propagation of the virus with increased inflammatory response. The inhibitory action of IFN can be overcome by combination 
with EGF. These findings may have their practical application in avoiding the use of growth factors in viral active herpetic keratitis 
and also to use these growth factors carefully in the treatment of non-healing sterile epithelial ulcers when the cause of the ulcer is 
suspected to be a post-herpetic infection. 
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INTERFERON IN AIDS-ASSOCIATED KAPOSI'S SARCOMA. W. Rozenbaum, S. Gharakhanian, B. Cardon, M.s. Navarette, R. De 
Sahb; Rothschild Hospilal, Paris, France 
Recombinant alpha 2a interferon (IFN) was used to treat biopsy-proven AIDS-related Kaposi'S sarcoma (KS), The links between the 
clinical aspect and biological parameters, HIV-antigen (Ag) level and clinical response were assessed, as was length of survival. 
Between March 83 and Dec 87 we treated 102 male KS patients by IFN (18 MU/day; mean duration t68 +/- n days). Clinical 
response was assessed according to standard oncologic criteria. Ag was assessed before and during treatment, measured blind by 
the Abott technique. Mortality data are presented as estimates of the survival distribution by the actual life table method. CHI and t-
test comparisons were performed when needed. Mean duration between diagnosis and treatment was 60 +/- 98 days. Patients were 
classified as 61 KS alone of whom 29 (36 %) had a complete response (CR), and 19 KS with opportunistic infections, of whom 3 (10 
%) with minimal oesophagal candidiasis had a CR. Patients with isolated cutaneous KS had a higher frequency of CR (23155, 45 %) 
than those who had mucosal lesions (8/35, 23 '!o) and those who had visceral lesions (1112 , 8%). Patients who had a higher 
pretreatment value of total lymphocyte count, T 4 count and T 4rr8 ratio, a lower value of B2 microglobuline and absence of CMV 
viremia, had a signifICantly higher chance of clinical response_ CR was observed in 14/27 (52 %) of the Ag-negative (Ag-N) group but 
in only 14149 (29 %) of the Ag-positive (Ag-P). Ofthe 5 Ag-P patients who had evolutive lesions, 4 became Ag-P. Ag levels were 
lower during IFN (185 pglml) than before (345 pgIml) (p < 0.001). In the Ag-P group, the drop was significantly greater in patients 
with CR and 7 of the 9 who became Ag-N had a CR. The cumulative probability of survival (CPS) was 68 % at 1 year and 49 % at 2 
years, and the median survival time was 691 days. For KS alone the CPS was 75 % and 56 %, with half the pts still alive at 1000 
days. AIDS-related Ks is more likely to respond to IFN if it is not associated with 0.1., if there are no visceral lesions, if the immune 
system is not altered, and if the HIV Ag level is low or if it drops to a lower level, before or during treatment. 
INFLUENCE OF INTERFERONS ON HUMAN DERMAL MICROVASCULAR ENODTHELIAL CELLS IN VITRO. Zb. Ruszczak, E. 
Imcke. M. Detmar. C.E. Orfanos; Dept. of Dermatology, University Medical Center Steglitz, The Free University of Berlin, Berlin 
(West), FR Germany 
Contradictory results have been reported on the effect of interferons (IFNs) on human endotheliaf cells of various origin. 
We investigated the in vitro effect of IFN-alpha, IFN-beta, and IFN-gamma on human dermal microvascular endothelial cells 
(HDMECs) isolated from the newborn/children foreskin by enzyme treatment followed by continuous Percoll gradient centrifugation. 
The endothelial origin of the cells was confirmed by labeling for factor VIII-rAg" UEA-I and by electron microscopy. Second passage 
HDMECs were treated with IFN-alpha, IFN-beta, and IFN-gamma (0.1 - 10,000 Vml) for 2, 4, and 6 days, Growth was evaluated by 
determination of cell numbers, thymidine incorporation and by a fluorogenic growth assay. Reactivity of MAbs was visualized by 
APAAP immunocytochemistry. Under IFNs treatment marked alterations of the typical cobbiestone morphology of HDMECs were 
found. Dose- and time-deperdent inhibition of HDMEC growth was observed under alllFNs tested. Moreover, IFN-alpha showed a 
dose-dependent cytopathic effect. Expression of HLA-DR, HLA·DQ, and ICAM-l was stimulated by IFN-gamma, but not by IFN-
alpha and IFN-beta. Our results demonstrate growth inhibition of HDMECs by all IFNs tested, while only IFN-gamma showed 
immunomodulatory activity. 
BIOLOGY AND THERAPY OF EPIDEMIC KAPOSI'S SARCOMA: THE AMERICAN EXPERIENCE. B. Safai, P. Myskowski, S. 
Krown; Memorial Sloan-Kettering Cancer Center, New York, USA 
Kaposi's sarcoma (KS), once considered a rare human tumor with cluster distribution, has become one 01 fhe clinical 
manifestations of Acquired Immune Deficiency Syndrome (AIDS). Laboratory data indicated the development of KS may nol be 
associated with the host immune deficiency, as it was previously believed. In fact, it appears that a subtle perturbation in the immune 
regulatory mechanism could be the initial cause of KS. In other words, KS appears to be a growth factor derived proliferative process 
involving lymphatic and possibly blood vessels. Prior to the discovery of AIDS virus, a series of clinical trials with highly purified 
interferon alpha preparations demonstrated efficacy of this agent in the treatment of KS-AIDS. A subset of KS-AIDS patients 
characterized by the fack of systemic 'B' symptoms (fever, weight loss, night sweat), absence of prior opportunistic infection, lack of 
circulating interferon, and relative preservation of immune function appear to be the most likely cases to benefit from interferon alpha 
treatment. It has been shown that high doses of alpha interferon are superior to the low dose treatment. In addition to ~s antitumor 
effect, recent experiementat triats indicate that interferon alpha may in fact be an effective inhibitor of the Hlv-replication. 
IN SITU AND IN VITRO PRODUCTION OF INTERLEUKIN-6 IN LEPROSY PATIENTS. J,F, Salazar-Gonzales, L. Baranda. R. 
Gonzales-Amaro, C. Ahumada. O. Martinez-Maza, T. Hirano, R.L. Modlin. T.H. Rea. C. Abud-Mendoza, R. Garcia-Aguayo, B. 
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Moncada. T. Kishimoto; Fac. Med, UASLP, San Luis Potosi, Mexico; and Depts. ObstlGynecol. and Micro.llmmunol., UCLA Sch. 
Med., Los Angeles, CA, USA; Sch. Med., USC, Los Angeles, CA, USA, and Inst. Mol. Cell. BioI., Osaka Univ., Osaka, Japan 
IL-6 is a multifunctional cytokine produced by diverse cell types and iits role in the pathogenesis of diverse immune 
disorders is unclear. IL.£ promotes the proliferationldiffe-rentiation of CD4+ and CD8+ T-cell (cytotoxic T-cells) and differentiation of 
B-cells to Ig-secreting cells. The role of IL.£ in the immunopathology of leprosy has not been examined. IL.£ producing cells in skin 
lesions were demonstrated by immunoperoxidase using a monoclonal antibody anti-IL.£. IL-6 activity was quantitated in plasma and 
supernatants (sn) from antigen- and LPS-stimulated PBMC (24 hrs sn) by a bioassay using an IL-6-dependent cell line (MH60.BSF2 
hybridoma celiS). We found substantial production of IL.£ in the skin lesions along the clinical spectrum of leprosy, including 
lepromatous (LL) and tuberculoid (IT) leprosy patients. Staining of cells positively for IL.£ in skin sections was completely abolished 
by exogenous rIL'£. The number of IL.£-producing cells seems to be lower in some LL granulomas as compared to IT. Erythema 
nodosum leprosum (ENL) superimposed to LL showed a high number of IL .£-producing cells. In vitro studies indicated that sonicated 
M. leprae and NT -O-BSA (terminal sugar of PGL-1 coupled to BSA) induces IL.£ production in bo1h LL and IT patients. M. leprae-
induced IL-6 production was lower in LL (1.06 U/ml) than IT (1 .69 U/ml) PBMC, whereas NT -O·BSA·induced IL-6 production was 
siightly higher in LL (1.40 U/ml) than IT (1.18 U/ml) PBMC. No difference was found in LPS-induced IL.£ production in leprosy 
patients and controls. IL.£ activity was low in plasma with no differences between groups of patients and controls. Our data indicate 
Ihat M. leprae infection induces local production of IL.£ and suggest that the high IL.£ production observed in IT patients might 
provide an activation signal for phenotypically helper (CD4+, 4B4+) and cytotoxic (CD8+, 9.3+) T -cells, numerically predominating in 
IT skin lesions. In contrasl, substantial IL.£ production in skin lesions from LL patients might provide an activation signal for 
phenotypically suppressor (CD8+,9.3-) T -cells, 'a subset numerically predominating in LL skin lesions. On the other hand, IL.£ may 
act as a B-cell differentiation factor 2 (BSF-2) in ENL reactions, an immune complex·mediated complication in leprosy. Our results 
support the hypothesis that IL.£ may play different roles in the immunopathology of leprosy and its effects depend on the particular 
cell types localized in the target issue. 
ACTIONS OF TNFAND IFN ON CULTURED VASCULAR ENDOTHELIUM. N. Sato, T. Goto, N. Tsuruoka, T. Nishihara. J.G. Beitz, 
P. Calabresi and A.A. Frackelton, jr.; Dept. of Biochem., National Defense Medical College, Saitama, Suntory Institute for Biomedical 
Research, Osaka, Japan, and Dept. of Medicine, Roger Williams Cancer Center and Brown University, Providence, RI, USA 
We examined the effects of TNF-ALPHA, B, and IFN-yon human or ral capillary ECs in vitro, used an angiogenesis model 
which consists of microvessel fragments and myofibroblasts (Mfs), and found that TNFs (5 - 1,000 U/ml) and IFN-y (1 - 1,000 U/ml) 
inhibit the in vitro capillary formation. The mode of inhibitory action 01 TNFs and IFN-y was also examined by using bovine capillary 
and human vein ECs. Exposure to TNFs and IFN-y resulted in morphologic changes and inhibited growth of cultured ECs. TNF-
ALPHA was also shown to inhibit migration of human and bovine ECs. Cytotoxic activity of TNFs was observed in rat, human and 
bovine capillary ECs. Although TNFs and IFN-y stimulated Mf growth, these inhibited collagen production of Mfs. Thus, TNFs and 
IFN-y may inhibit in vitro capillary growth both directly by their effects on ECs and indirectly through their effects on Mfs. Recently, 
we have found that microvascular ECs possess receptors for platelet-derived growth factor (PDGF). PDGF treatment (3 - 10 nglml) 
increased capillary development in vitro, suggesting that these receptors function in EC biology. We are currently exploring whether 
TNFs and IFN-y inhibit PDGF-induced capillary growth in vitro. 
THE ROLE OF EPIDERMAL CYTOKINES IN INFLAMMATION AND IMMUNITY. D.N. Sauder, McMasler University Medical Cenlre, 
Hamilton, Ontario, Canada 
Over the past two decades it has become increasingly clear that the skin plays a significant role in epidermal immunity and 
thus functions as the peripheral arm of the immune system. The immune function of the epidermis involves at least two distinct cell 
types: the epidermal Langerhans cells, which represent the major antigen presenting cell of the epidermis and the keratinocytes 
which are a source of polypeptide factors known as cytokines. Previous studies have shown that keratinocytes synthesize and 
secrete inteneukin-1ALPHA and B. Recent studies have shown that keratinocytes are also a source for interteukin-3, interleukin.£ 
and the hemopoietic colony stimulating factors; granulocyte colony stimulating factor G-CSF, granulocyte-monocyte colony 
stimulating factor GM-CSF and macrophage colony stimulating factor M-CSF. Thus, keratinocytes serve as a potent source for 
immunoregulaforyand pro-inflammatory cytokines. In addition to synthesizing and expressiong these cytokines, keratinocytes have 
been sown to possess high affinity receptors for certain cytokines such as interleukin-, . Keratinocytes also respond to inteneukin-' 
by directed migration. These studies suggested that inteneukin· 1 may be beneficial in would healing. Studies using split thickness 
wounds in animals have confirmed this. In spite of the beneficial effects of inteneukin-1 in wound healing, excess amounts of 
interleukin· 1 may be detrimental and may contribute to disease activity in certain inflammatory and neoptastic diseases. 
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HIV-ASSOCIATED KAPOSI'S SARCOMA RESPOND TO LONG-TERM ALPHA INTERFERON (rlFN ALPHA 2A) MONOTHERAPY. 
F.M. Schaart. B. Bralzke, R. Stadler, C.E. Orfanos; Department of Dermatology, University Medical Center Steglilz, The Free 
University of Bertin, Bertin (West), FR Germany 
Long-term follow up of 5 male HIV-positive pts is reported, who received continuous (>2 years) rlFN alpha 2a monotherapy 
for disseminated, mucocutaneous KS, 5 pts with histologically proven KS, all homo- or bisexuals, received 18 Mill IU rlFN alpha 2a 
s.c. daily for 3 months and, thereafter, every other day. I pt showed complete (100%) remission of the KS lesions within 12 months 
of therapy, lasting until today (40 months). In another pt complete remission was observed within 7 months, proven histologically_ 
However, arnitrary therapy withdrawal after 18 months resulted in new tumor progression. Reintroduction of rlFN alpha 2a therapy 
again suppressed the disease. In I pt, stabilization was achieved by IFN therapy over a period of 6 months but, thereafter, stow 
tumor progression reoccured_ The pt still participates in active liIe (48 months after diagnosis of KS!). Meanwhile, 2 pts died of the 
tumorous disease; the survival time was 25 resp. 28 months after diagnosis of KS. Laboratory changes under IFN therapy were: an 
initial transient leucopenia (5 pIs), an inilial decrease (2 pts) or continuous increase (2 pts) in platelet counts. Subjective side-effects 
were mainly (4 pIs) Hu-like symptoms. In no case withdrawal of IFN therapy was necessary because of side-effects, Ol's did not 
occur in any pI under IFN therapy. long-term rlFN alpha 2a therapy (>24 months) may have the potential to induce complete 
remiSsion of HIV-associated KS, significantly increases survival time of KS pts, possibly inhibits Ol's and is usually well tolerated_ 
INFLUENCE OF CYTOKINES ON IN VITRO PRODUCTION OF NATURAL AUTOANTIBODIES IN BULLOUS PEMPHIGOID. J. 
Schaller I , U_-F. HaustelnL S.T. KiessiCJ£, and T_ Giese3; Dept. of Dermatologyl and Dept. of Medical Immunoloay3, Kart-Ma,x: 
University Leipzig and Dept. of Medical Immunology2, Humboldt-University Bertin, GDR 
In 10 patients with bullous pemphigoid we investigated the in vitro antibody production (lgG and 19M) without and after 
PWM and SAC mitogenic stimulation. Compared to controls, we found the IgG and IgM production in vitro within normal ranges by 
ELlSA-technique_ In addition, when studying the inHuence of natural and recominbed IL-2, IL-I , cyclosporin A, BCGF and 
myelopeptide on the in vitro antibody production we found no difference between bullous pemphigoid and controls. On the other 
hand, investigations of in vitro production of natural autoantibodies (anti-DNA and anti-keratin) showed a significantly higher anti-
DNA and anti-"eratin autoantibody production in bullous pemphigoid compared to controls. The regulation of natural autoantibody 
production in vitro in bullous pemphigoid was different, because there was no influence of cytokines on the anti-keratin autoantibody 
production whereas the effects on anti-DNA autoantibodies was well established. In the relationship between anti-DNA-IgG and anti-
keratin-lgG we have found a decreased index under the influence of BCGF and between anti-DNA-IgM and anti-keratin-lgM a 
decreased index under the influence of all investigated cytokines. It is well established that a natural self-reactivity may be essential 
for the normal functioning of the immune system. From our results we conclude a separate regulatory mechanism 10 be responsible 
for the in vitro production of anti-keratin autoantibodies resulting in the disturbance of self-tolerance against epidermal structures in 
bullous pemphigoid. 
INDUCTION OF rRNA FOR HLA-DRB IN HUMAN KERATINOCYTES COCULTURED WITH INTERFERON-GAMMA. A. 
Scheynius!, H_ Nilssoni, C. Johanssoni, K. Sandberg2, K. Fu~, and G.V. Alm2; lDept. of Clinical Immunology, Karolinska 
Hospital, Stockholm; 2Dept. of Veterinary Immunology, Swedish UniverSity of Agricultural Sciences and Interferon Laboratory, 
Uppsala University, and 3Ludwig Institute for Cancer Research, University Hospital, Uppsala, Sweden 
It is well established that interferon-gamma (IFN-y) can induce expression of class I human leukocyte antigens (HLA) on 
keratinocytes both in vitro and in vivo_ The mechansisms are, however, unknown. The aim of the present study was to investigate 
the appearance of rRNA for HLA-DR in explanted human keratinocytes exposed in vitro to recombinant IFN-y and to follow the 
subsequent expression at HLA-DR, -DO and -DP antigens. Using in situ hybridization with a (35S) UTP-tabeled HLA-DRB cRNA 
probe, mRNA positive cells were detected already within 6 hours with maximal numbers of positive cells as well as the amount of 
mRNA per cell after 48 hours. The corresponding protein HLA-DR, as analysed by immunoperoxidase staining, was detected on 20-
40 % at the cells after 24 hours and on almost all cells within 48 hours_ The expression of HLA-oa and -DP antigens were always 
exceeded by that of HLA-DR_ Whereas an increase in the concentration of IFN-y above 50 Ulml did not affect the maximal level of 
HLA-DR reactive cells, there was a fourfold increase in the trequency at cells reactive with HLA-DQ and a \Wotold increase (or HLA-
DP when the IFN-y concentration was raised from 50 to 500 U/mL When IFN-y was withdrawn from the cultures, HLA-DR mRNA and 
protein synthesis ceased - indicating the conlinuous need for IFN-y to maintain the HLA-DR synthesis in keratinocytes. 
IMMUNOPHENOTYPING IN CUTANEOUS T-CELL LYMPHOMA TREATED WITH ALPHA-A-INTERFERON. J_ Scheel, A. Stiefel; 
Dept. of Dermatology, UniverSity of Heidelberg, Heidelberg, FR Germany 
We analysed the pattern of infiltrating cells in cutaneous T-cell lymphoma (CTCL) of low grade malignancy (mycosis 
fungoides) prior to the systemical administration of alpha-a-interferon and under treatment. Skin biopsy specimens of 3 patients 
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suffering from CTCL (stage lIa) as proven by histopathology and clinical examination were evaluated. All patients received 
recombinant alpha-a-interleron 18 Mill IEld.i.m. and showed partial remission. Biopsies of each patient were taken (i) from a skin 
tumor immediately prior to treatment with interferon and (ii) from a tumor after a 3 month period of interleron therapy. 5 microg 
cryostat sections were stained with a panel of 24 monoclonal antibodies to various leukocyte antigens and the peroxidase/anti-
peroxidase (PAP) immunoenzyme technique. All specimens taken prior to treatment showed dense, cellular infiltrates predominantly 
composed of CD4+ and COB- T-Iymphocytes. Most of the cells showed no or weak reaction with cell surlace markers CDS, Leu-8 
and CD7. 2/3 biopsies showed few admixed cells poSitive for Ki-l (CD30) and Ki·67. Biopsies of tumors taken after a 3 month period 
of treatment with alpha-interleron showed similar densijy and composition of inifttrating cells. However, some minor differences could 
be observed in treated lesions: a) increase in CD8+ positive cells (2/3), b) increase in Leu-8+ cells (313), c) neither Ki-l + nor Ki-87 + 
cells could be detected in any biopsy taken during the treatment. In conclusion, T-Iymphocytes in tumors of CTCL systemically 
treated with alpha-interleron display a more mature pattem of antigenicity than in untreated lesions (i.e. lacking signs of an increased 
proliferation or a loss of surface markers). We do not know whether the observed changes indicate a reduced proliferation at tumor 
cells or an increasing number of admixed tumor reactive T-Iymphocytes. A significant increase of infiltrating NK-cells or 
macrophages, which were shown to acl in tumor defense, could not be observed. 
TNF-PREINCUBATION REGULATES THE RESP IRATORY BURST IN POLYMORPHONUCLEAR LEUKOCYTES TO DIFFERENT 
STIMULI SIMILARLY AS BACTERIAL LIPOPOLYSACCHARIDE. R.E. Schopf, R. Keller, M. Rehder, F. KaJlinowski', P. Vaupel' ; 
Depts. Dermatology and Physiology', University of Mainz, Mainz, FR Genmany 
TNF has been shown to directly stimulate polymophonuclear leukocytes (PMN). We were interested whether TNF also 
influences subsequent stimulation similar to bacterial lipopolysaccharide (LPS), a known primer of PMN. 5 x tOS PMN from 3 
differenl donors were incubated with rTNF-ALPHA (O.OOt to t microglml, 2.0 x t07 U/mg protein, LPS-free, BASF, FRG) and LPS 
(0.01 to to microglml, E. coli) for 60 min. Next, PMN were stimulated with zymosan, opsonized zymosan (0.3 mg/ml), zymosan-
activated serum (ZAS, t :6), PMA (833 nglml), aggregated immunoglobulin (agglg, 0.5 mg/ml), and formyl-Met-LeU-Phe (FMLP, 104 
M71). The respiratory burst was measured by luminoHmhanced chemiluminescence (CL), release of 02 and H202 for 60 min. Anti-
TNF antibody (1 :60) was used to block CL responses. Scatchard plot analysis was employed to detenmine FMLP receptors. Both 
TNF and LPS directly stimulated PMN. Preincubation with TNF led to a dose-dependent, increased respiratory burst upon 
stimulation with buffer (mean 272 %), zymosan (31 %), agglg (81 %), and FMLP (1 3t %) whereas stimulation by opsonized 
zymosan and PMA were unaffected as measured by CL. 02 release exhibited no change upon stimulation by PMA, 02 release was 
higher by the other stimuli, as was H202 release with all stimuli. LPS led to priming by buffer (1 055 %), zymosan (101 %), ZAS (167 
%), agglg (338 %), and FMLP (377 %) as determined by CL, 02 release was enhanced by all stimui but PMA and agglg, H202 
release by aJl stimuli except agglg. Anti -TNF blocked priming by TNF of the FMLP response. Scatchard plots revealed 18,200 (Ka = 
1.3 x 10-10 M) FMLP receptors for control PMN, 20,700 (Ka = 1.25 x 10-10 M)for TNF- and 19,300 (Ka = 1.32 x 10-10 M) for LPS-
treated PMN. We conclude that TNF is able to prime PMN for an enhanced respiratory burs~ similar to LPS. The primed response is 
not, however, accompanied by increased ceJl membrane receptors for FMLP but rather seems to be associated with improved signal 
transduction from the cell membrane to the cytoplasm. 
INTERFERON-GAMMA INCREASED TRIGLYCERIDE LEVELS. H.J. Schulze, G. Mahrle. G.K. Steigleder; Dept. of Denmatology, 
University of Cologne, Cologne, FR Germany 
Recent observations provided evidence that factors produced by the immune system, namely IFN-gamma - a potent 
macrophage activator - can regulate lipid metabolism in man (Kurzrock et aI., J Exp Med 164:1093; Schulze et aI., Lancet 11:926, 
1986).52 patients with chronic plaque psoriasis and psoriatic arthritis (n=10 patienls), Behcet disease (n=3), human papilloma virus 
intection (n=24), malignant melanoma (n=6), basal ceJl carcinoma (n=4), and various other diseases (n=5) were entered on phase II 
studies of recombinant IFN-gamma. The patients received rlFN-gamma s.c. at a dose of 50 microg (0.7 x 106 U) per day. On day 0 
and then in weekly intervals blood samples were drawn after the patients had fasted for 12 hrs. 9 out of 10 patients showed a 
marked> 38 % increase in triglyceride but not in cholesterol levels, which was already evident at day 7 of therapy, peaked between 
the second and third week, returned to baseline levels after discontinuation of the therapy, and was reproducible after a therapy-tree 
interval of several months. The mean +/- SO of Jhe pretreatment triglyceride levels in psoriatic patients with nonmal triglyceride 
values was 116 +/- 44 mg/kl vs. a levels of 192 +/- 39 mg/dl after the onset of therapy (n=9, p < 0.001 by the paired T-test). This 
hypertrigly-ceridemia was cJharacterized by an increase in very Iow-density lipoproteins, indicative for a type 4 hyperlipoproteinemia 
pattern (increased pre-beta traction) as shown by lipoprotein electro·phoresis perlormed on 2 patients. In the psoriatic patient no.l0 
who showed a pathologic pretreatment triglyceride profile (310 mg/dl) Jhe level increased to 1,108 mg/d after 27 days of treatment. 
In contrast to Jhe psoriatic patients, none of Jhe 42 non-psoriatic patients displayed rlFN-gamma induced hypertrigly-ceridemia 
except 2 patients who already had had increased triglyceride levels before therapy (226 +/- 17 vs. 463 +/- 28 mg/dl). 
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INTERLEUKIN 6 IS A POTENT STIMULATOR OF HUMAN NATURAL KILLER CELL ACTIVITY. T. Schwarzl, J. KrUlmannf.J1 
Kimbauer2, A. Urbanski2, G. Klappacher3, M. Micksche;t J. Maleieczyk£, E. Schauer2 , T.A. Luger2; 1 Dept. Derm. Lainz, 2Dept. 
Derm. II, Univ. Vienna and LBI-DVS, Lab. Cellbiol., 31nsl. Appl. Exp. Oncol., Vienna, Austria 
Major hislocompatibility complex non'restricted Cytoloxic cells play an importanl role in Ihe killing of lumor cells in vilro and 
polentially in vivo. The aclivity 01 these natural killer (NK) cells is regulaled by several cytokines such as interleukin (IL) 2 and 
inlerferons. Therefore, in the present study using 1<562 targel cells and a 4 hr 51Cr release assay il was investigaled whether 
recombinant human IL-6 augments the cytotoxic activity of human natural killer (NK) cells. IL -6 is produced by many different cells 
and is also known as interferon B2, B-rell stimulatory factor 2, hybridoma growth factor, hepatocyte stimulating factor and 26 kD 
protein. IL-6 stimulated the activity of human CD3- NK cells but not that of CD3< non MHC-restricted cytotoxic T-Iymphocytes. As is 
the case with IL·2, the IL-6·mediated augmented cytotoxicity was a result of a more efficient lysis, but not due to an increased 
effector target cell binding. Moreove, the effect of IL-6 on NK cell activity was blocked by a monoclonal antibody directed against Il-2 
and IL·6 itself was found to be a potent inducer of IL-2 production in cultured human peripheral blood mononuclear cells. Thus it may 
be concluded that IL-6 enhances the cytotoxic activity of NK cells via IL·2. This newly recognized property of IL-6 which is produced 
by almost any cell may be 01 importance in host defense microbes and malignanCies and therelore could contribute to improve the 
adoptive immunotherapy using Iymphokine activated killer cells. 
ACTION OF INTERFERONS ON THE TUMOR-INDUCED ANGIOGENESIS MODEL IN VIVO. YA Sidky and E.C. Borden, Depts. 
of Human Oncology and Medicine, University of Wisconsin Clinical Cancer Center, Madison, WI, USA 
Interferons (IFNs) have established antitumor action; the mechanism underlying this is, however, not yet clear. To probe 
the possible contributiOn of inhibition of angiogenesis by IFNs, we assessed vascularization in the mouse skin initiated by either 
human or murine tumor cell tines. Tumor cells initiate the appearance of blood vessels at the site of cell inoculation. This could be 
evaluated to the number of hrs afterwards. The number of vessels is related to the number of tumor cells inoculated and their 
potency to initiate angiogenesis. Angiogenesis can also be initiated by explant unto the mouse cornea. Tumor·induced angiogenesis 
(TIA) in the skin or cornea was inhibited by IFNs or the potent IFN inducer polyriboinosinic·polyribocytidylic aCid. The effects of IFNs 
were species specific; human IFNs inhibited vascular responses initiated by human tumor cell lines only and mouse IFNs affected 
those by murine tumors. This suggested that in contrast to other known angiogenesis inhibitors IFNs modulated the signal for 
angiogenesis produced by the tumor cells. Thus, mouse or human tumor cells treated in vitro with homologous IFN were significantly 
(p < 0.005) less competent to initiate angiogenesis than were untreated cells. The observation that inhibition of angiogenesis was 
distinguishable 24 hrs ailer celt inoculation suggested that the antiangiogenesis potency was independent of the anti proliferative 
effects of IFN. In additon, IFN impaired the vascular response caused by IFN·resistant L1210 leukemia cells withOut affecting their 
proliferation. Homologous IFNs also inhibited angiogenesis initiated by allogeneic or xenogeneic lymphocytes. Inhibition of 
Iymphocyte·induced angiogenesis required a lower dose and/or shorter incubation period than that needed to modulate TIA. Thus, 
inhibition of TlA by IFNs was species specific, occurred at least partly by modulation of the signal inducing angiogenesis, and was 
expressed in the absence of antiproliferative effects. Angiogenesis may thus be another facet of neoplastic growth subject to 
inhibition by IFNs and their inducers .. 
BASIC AND INTERLEUKIN·2-AUGMENTED NATURAL KILLER CELL ACTIVITY IN LICHEN PLANUS. M. Simon ir, J. Hunyadi; 
Dept. of Dermatology, University of Erfangen-NOmberg, Erlangen, FR Germany 
Natural killer cell (NK) activity of peripheral blood lymphocytes against K 562 cells was investigated in lichen planus (LP). 
38 LP patients with cutaneous or oral mucosal involvement and 20 healthy controls participated in the study. A statistically significant 
decrease in the NK response in LP patients with extensive erosive oral mucosal involvement (p < 0.02) and in generalized acute 
eruptive LP (p < 0.01) was noted compared to those with nonerosive LP of the oral mucosa or healthy controls. Interleukin·2 failed to 
restore completely the reduced NK activities in our patients with LP. 
PIG LEUKOCYTIC ALPHA tNTERFERON IN DERMATOLOGY. LT. Shetsiruli, Research Insotute of Dermatology, Tbllisi, USSR 
The present paper provides results of studies carried out in Georgian Institute of Dermatology and aimed at investigation of 
the therapeutical efficacy and tolerancy of pig leukocytic alpha interferon (PlI), experimental batches which were prepared in Tbilisi 
Institute of Vaccines and Sera, where its antiviral activity and non· toxicity was proven. Clinical trials in ophtalmologic, stomatologic 
and pediatric practice confirmed therapeutical efficacy of PLI. Patients with viral and non-viral dermatoses, viz., herpes progenitalis, 
aphtous stomatitiS, herpes zoster, molluscus contagiosum, cond;iomata acuminatum, lichen ruber planus and psoriasis vulg. were 
treated with PLI in the Institute of Dermatology. Interleron was applied in a form of oinlmen~ solution and powder. Excellent results 
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were obtained in treating patients with molluscus contagiosum, herpes zoster and condylomata acuminalum. Two or three cycles 01 
complex therapy involving PLI were prescribed to the patients with herpes progenitalis, aphlOus stomatitis, lichen ruber planus and 
psoriasis. 75 - 80 % of these patients had an earlier onset of clinical recovery and significant improvement with longer remiSsion and 
mild course of recurrences as compared with routine methods of treatment. Simultaneously, normalization of autoimmune state 
indices was observed. Tolerance to the treatment was satisfactory. Thus, antiviral activity, non-toxicity and significant role of HB 
antigen and AIDS virus free PLI in the complex therapy of the patients with the above denrratoses was shown both experimentally 
and clinically. 
INTERLEUKIN-l-L1KE ACTIVITY IN NORMAL RAT SKIN IS DOWNREGULATED BY INTERFERON-y. C. Skoalund, A. SchevniuS 
and O. SOder; Depts. ot Ctinicallmmunology and Paediatric Endocrinology, Karolinska Hospital, Stockholm, Sweden 
It is generally considered that inteneukin-l (IL -1) has an important role in stimulating the proliferation of T -<:ells in 
cutaneous immune responses and that IL-l is regulated by other cytokines. IL-1-iike activity is also present in nonrral epidenrris (elL-
1). We have now investigated how local treatment with one cytokine, interferon-y (IFN-y), may inHuence the constitutive IL-l activity 
in normal rat skin. Lewis rats were injected with 5 x 104 U of rat recombinanl lFN-y into both ears and controls were given PBS. The 
animals were sacrificed at 6, 24, 72 hrs or after 7 days and the ears cut off at the bases. Aquous extracts from homogenized ears 
were tested in a murine thymocyte IL-l bioassay with responder cells from a highly IL -I sensitive strain after adjustment of protein 
concentration. All samples were tested in differentn concentrations and IL -I activity was calculated from the obtained dose response 
curves. Twenty-four hrs after injection of IFN-y, elL-I was reduced to 66 % of the PBS injected controls (p < 0.05). At 72 hrs no 
difference was seen. As expected, the IFN-y injection induced expression of class II antigens on the keratinocytes as judged by 
immunohistochemistry. The expression was maximal at 24 hrs and completely vanisihed at 7 days. Thus, the increased dass II 
expression was parallelled with reduced elL-I . This interesting relation may support our previous observations that IFN-y can 
mediale changes in epidermal cells which can contribute 10 the downregulalion of immune responses (Skoglund el aI., Immunology 
66:190, 1989). 
CORRELATION OF CLINICAL RESPONSE WITH MORPHOLOGIC AND IMMUNOLOGIC CHARACTERISTICS IN CUTANEOUS 
T-CELL LYMPHOMA PATIENTS TREATED WITH INTERFERON ALPHA-2A. E. Springer, S. Rosen, T. Kuzel, H. Roeniok Jr.; 
Northwestem U. Med. School, Chicago, II., USA 
Eighteen patients (pts) with cutaneous T -<:ell lymphoma (CTCLl were trealed with either interferon (IFN) alpha-2a afone (5 
pts), or in combination wilh PUVA (13 pts). Hislopathologic examination and immunophenotyping of skin biopsies were correlated 
with clinical response to treatment. ()j the five pIS with IFN alone, three pIs were stage Ib and two pts were stage III. IFN dosages 
ranged from 3 x 106 unils 10 36 x 106 units per day. One pt had a complete response (CRl , three pis had a partial response (PR) 
and one pi had no response (NR). Of the thirteen pis treated with IFN plus PUVA, seven pts were stage Ib, Ihree pis were stage lib, 
one pt was stage III, and one each stage IVa and IVb. IFN dosages ranged from 6 x 106 units 10 30 x 106 units, 3 x weekly. Ten pts 
had a CR, two pts had a PR, and one pt had NR. For each pt a biopsy of involved skin was evaluated for cellular atypia. 
Immunophenotyping was perfonrred on a frozen skin biopsy specimen using the immunoperoxidase technique wilh monoclonal 
anlibodies to T- and B-<:ell antigens. In the majority of pts with PR or NR (517), the infiltrate showed moderale to marked atypia, 
whereas in the majority of pts with CR (1011 1) the infillrate showed minimal 10 moderate atypia. On immunophenotyping, all of the 
piS with PR or NR had a denrral infiltrate that was CD4+CD8- (helper cell). The majority of pts with CR also had an infiltrate that was 
CD4+CD8-, however, in three pis there was a mixed infiltrate. ()j the seven pts with PR or NR five had deletion of the pan-T-cell 
antigen CD7, whereas only two of eleven PTS with CR were CD7 antigen negative. CD2 antigen was deleted in one pt with PR, and 
CD5 antigen was deleted in one PT with NR. These results suggest, immunologic study combined with morphotogic evaluation may 
have prognostic signifICance on PT response to treatment with IFN or IFN plus PUVA. 
LONG-TERM COMBINED rlFN ALPHA-2A AND All THERAPY. CLINICAL CONSEQUENCES AND SIDE-EFFECTS. R. Stadler, B. 
Bratzke, F. Schaart. C.E. Orlanos; Dept. of Denrratology, University Medical Center Steglitz, The Free University of Benin, Benin 
(West), FR Genrrany 
Interferon alpha has been shown to be effective in treating HIV-associted KS in at least 30 % of patients. Zldovudine has 
proven to be of benefit for AIDS patients. Both drugs have also been shown to have an inhibitory effect of HIV replication. Based on 
these data we combined both drugs for therapy of HIY-associated KS 10 evaluate tolerance and dinical efficacy. 17 homosexual men 
with histologically proven HIY-associated KS were treated in an open trial with rlFN alpha-2a 18 x lOS IU every other day and 
zidovudine 800 -1200 mg/day. Therapy was slOpped within the first months for 5 patients, 2 of them for subjective side-effecJs and 3 
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of them due to severe opportunistic infections or HIV-cachexia. 12 evaluable patients received combination therapy for 3 to 20 
months (average 9 months). Dosage was reduced as needed based on cytotoxicity. 3 patients developed a complete remission 
lasting 4 to 14 months after initiation of therapy, 3 patients had stable disease and 6 patients were progressive. 2 patients with 
remission had T4 counts less than 20 cells/mm3 (T41T8 ratio 0.1). In this group HIV cultures were positive under therapy. Drug-
related toxicities included neutropenia, anemia, thrombocytopenia, neurological dysfunction (I pat.), fatigue weakness and were 
clinically controllable without longer interruption of therapy. In contrast to IFN montherapy patients with low T 4 counts responded. 
The overall response rate seems to be slightly better than for interferon alone. 
TREATMENT OF MYCOSIS FUNGOIDES WITH RECOMBINANT ALPHA 2B INTERFERON IN COMBINATION WITH 
ETRETINATE. N. Stavrianeas, A. Katsambas, A. Vareltzides, P. Stavropoulos, D. Polydorou, P. Zika and J. Stratigos; Depl. of 
Dermatology, I\. Sygros Hospital, University of Athens, Athens, Greece 
The efficacy and safety of recombinanl alpha 2b interferon in combination with etretinate was studied in six patients with 
mycosis lungoides. Four palients were in stage tV (tumours and nodules-erythroderma of the skin and dermopathic 
lymphadenopathy) and two in stage II (plaque stage). None of the patients had visceral involvemenl. rlFN was given subcutaneously 
once daily during the first month and then three times weekly lor up to 12 months. The initial dose was 3 x 106 units per day and 
then increased to 9.18 and 36 x 106 according to the response and the side-effects. Etretinate was given daily in a dose of 0.7 
mgikg. Clinical examinations and laboratory investigations were performed every week for 2 months and then monthly. The results of 
our study are as follows: Two patients in stage II have gone into complete remission, which has now lasted for 8 months witl10ut any 
additonal therapy. In three other patients a significant partial remission was noted and finally one patient went to progressive 
disease. The combination ot both drugs is not accompanied by additional toxicity. In cutaneous T -cell lymphomas the therapeutic 
effect seems to be synergistic in redUCing the number and size of skin lesions and the needed abselute dose of interferon to control 
the disease. 
IN VITRO EVALUATION OF THE IMMUNOSUPPRESSION BY RETINOIDS. S. Stosic-Grujicicl , L. Ejdusl , S, Konstantinovic, and 
M.M. Simic3: Iinsi. BioI. Res., 2Dermatology Clinic, 31nsl. Microbiol. Immunol. Sch. Med., Belgrade, Yugoslavia 
Retinoids have potentially important use in dermatology_ Since the therapies with retinoids suppress immune funclions and 
inflammations, we have analysed Ihe mechanisms of aclion of Ihree synthetic retinoids: etretinate, roaccutane and tretinoin. Based 
on reports suggesting that T -cells playa central role in the pathogenesis of pseriasis and related diseases, we have used a model of 
in vitro activation of T-Iymphocytes by mitogenic lectins. 1\11 retinoids that we have studied, inhibited in a dose-dependent way PHA-
and ConA-stimulated proliferation of T-Iymphocytes from various seurces. A detailed analysis of early, inducible events of T-cell 
proliferation revealed that retinoids did not interfere with IL-I production, IL -2-R expression, induction of la-anligens, or generation of 
suppresser T -cells. The production of IL -I by macrophages was alse unaffected. On the other hand, all the compounds inhibited in a 
dose-dependent way IL-2-driven prolileration of already activated T -cells, i.e. T-cell blasts. Our results thus suggest that part of the 
therapeutic effects of retinoids in diseases with significant disbalance of T-helpers and T-suppressers could be mediated by 
antiproliferative action of the drugs on activated T-cells, without affection of generation of suppresser T-cells. 
IMMUNOREGULATfON IN EPIDERMIS: SELECTIVE IMMUNOSUPPRESSIVE EFFECTS OF GLUCOCORTICOIDS, 
CYCLOSPORINE AND RETINOIDS. S. Stosic-Grujicic, L. Ejdus, M.L. Lukic and M.M. Simic; Insl. BioI. Res. and Insl. Microbiol. 
Immuno!. Sch. Med., Belgrade, Yugoslavia 
Immunological mechanisms play an important role in lhe pathogenesis of psoriaSiS and related diseases. Most of the 
therapies, including corticosteroids, cyclosporin and retinoids, suppress cellular immune functions and inflammation. In order to 
elucidale mechanisms of immunosuppression, we have studied the effects of glucocorticoids (dexamethasene, hydrocortisone and 
triamcinolone acetonide), cyclosporin A, and retinoids (etretinate, roaccutane and tretinoin), on tI1e distinct events involved in the 
activation and proliferation of T-Iymphocytes. All the compounds examined inhibited in a dose-clependent way lectin-stimulated 
proliferation of T-Iymphocytes from various seurces. Measurement of IL-I activity in culture supematant of accessery cells showed 
that only cyclosporin and glucocorlicoids interfered wrth the Il-I production. Moreover, in accessery cells glucocorti-coids induced 
specific IL-I inhibitor, which competed for Il-l receptors on Il-l-dependent target cells and inhibited early events of T-cell activation: 
the induction of Il-2-R and IL-2 production. Preincubation of purified T-cells witl1 cyclosporin A revealed direct inhibitory action of the 
drug on the same inducible Il-l-dependent events. Thus, it seems tI1at glucocorti-COids and cyclosporin A inhibited the sensitivity of 
T-cells to the dual action of Il-l of promoting Il-2 production and expression of reactivity to Il -1 induced by antigel1J1ectin, erther by 
direct action on T -cells, or indirectly, through the induction of Il-l inhibitor. However, retinoids did not interfere with the induction of 
both inducibfe events. The generation of nonspecific suppresser T -cells was not affected by the presence of any im munosuppressive 
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agent tested. Anatysis 01 the late events of T-cell proliferation showed that retinoids inhibited IL·2-driven proliferation of T-cell blasts, 
while glucocorticoid-induced inhibitory factor was inactive. Taken together, our results describe selective antiprolileratve effects 01 
glucocorticoids, cyclosporin A and retinoids on T-Iymphocytes, combined with unaffected generation of suppressor T-cells and 
consequent down·regulation of the immune reactions. 
ROLE OF INTERFERON-GAMMA IN KERATINOCYTE SUSCEPTIBILITY TO IN VITRO LYSIS BY CYTOTOXIC T·CELLS AND 
L YMPHOKINE-ACTIVATED KILLER CEllS. F.W. Symington and E.B. Santos; Fred Hutchinson Cancer Research Center, Seattle, 
WA,USA 
It has been suggested that human keratinocytes (KCs) must be exposed to interferon-gamma (IFN-y) before they can be 
lysed in vitro by cytotoxic T -cells (CTL) or Iymphokine-activated killer cells (LAK). We studied this issue further because of ijs 
importance for understanding normal and pathological Iymphocyte/KC interactions. CTl effectors were cloned from alloantigen' 
primed cultures by limiting dilution in the presence of IL·2 and antigenic B Iymphoblastoid cells (BCLL). The CD3+/CD8+/CD4-
clones lysed appropriate BCll and PHA blasts but not third partly BCLl or 0562 in 51Cr·release assays. LAK effectors that readily 
lysed Daudi and K562 targets were generated by culturing peripheral blood mononuclear cells in 1,000 U/ml of recombinant tl-2 for 
8 days. Human basal KCs were cultured in complete MCDB153 medium, exposed to recombinant IFN·y (0 - 500 U/ml) for 72 . 96 
hours, trypsinized, and used as targets in 51Cr·release assays. lytic susceptibilities of different target populations were analyzed by 
comparing lytic units calculated from triplicate .assays at six effector:target ratios. Results with CTl effectors were as follows: 1) 
untreated KCs were specifically lysed by all four tested clones and bulk culture effectors, 2) clones were 2 to 5 times more active (2.3 
f l· 1) against IFN-y-treated KCs than against untreated KCs, J) the rank susceptibilities of syngeneic targets to specific lysis were 
BCll>IFN-y·KC>KC>PHA-blasts. Regarding lAK lysis: IFN-y·treated KCs were either less sensitive (n=4) or as sensitive to lysis as 
untreated KCs in five experiments with both autologous and allogeneic LAK and KC populations. We conclude that KCs need not to 
be exposed to IFN-y to be lysed by either CTL or LAK effectors, that IFN-y treatment can increase KC sensitivity to CTL lysis, and 
that such treatment decreases rather than increases KC sensitivity to lysis by LAK effectors .. 
INTERFERON ALFA·2B IN THE TREATMENT OF CUTANEOUS NEOPLASMS AND PAPilLOMA VIRUS INFECTION. D.J. 
Tanner, E.A. Peets, E.L. Taylor, L. Eron, R.C. Cornell , H.T. Greenway, J.C. Vance, L. Edwards, S. Tucker, E. Vonderheid, J. 
Douglas; Schering·Plough Research, Kenilworth, NJ; Div. Inlect. Dis., Fairtax Hospital, Falls Church, VA; Scripps Clinic & Research 
Foundation, la Jolla, CA; Univ. Minn., Hennepin Hosp., Minn. MN; Univ. Arizona, Tucson, AZ. , Texas, Houston, TX; Dis. Control 
Serv., Denver, CO; Skin & Cancer Hospital, Phila, PA, USA 
Interteron (IFN) (interteron alfa·2b) has demonstrated activify in several dermatoiogic conditions. Usage has already been 
approved by regulatory agencies of many countries in the treatment of condylomata acuminatum intralesionally (U.). Additionally, 
several studies have demonstrated enhanced efficacy and/or prolonged recurrence-free intervals when IFN has been combined wijh 
other modalities such as electrocautery, cryosurgery and topical podophyllin. IFN has atso demonstrated mar1\ed efficacy against 
basal cell carcinomas in controlled, double blind, parallel group studies. One and one-half million units IFN (LI.), ti.w. x 3 weeks led 
to an 86 % biopsy proven cure rate at 3 months post therapy vs. 29 % for placebo; moreover, 95 % of these patients remained free 
of tumor for 1 year following therapy as documented byexcisional biopsy and multiple sectioning of the lesional site. Eighty·three per 
cent of the patients felt the cosmetic results at one year to be excellent. A similar regimen for the treatment of cutaneous squamous 
cell carcinomas of varying degrees of severity has demonstrated mar1\ed efficacy in this disease. This is in accord with the high 
percentage of cures demonstrated for actinic keratoses. Additionally, IFN has proved to be of value in clinically normalizing areas of 
skin in plaques 01 mycosis lungoides, with some concomitant histologic ·Improvement. 
NEW DEVELOPMENTS IN THE TREATMENT OF NON-HODGKIN'S LYMPHOMA WITH INTERFERONS. E. Thiel, Dept. of 
Hematology and Oncology, Univ. Medical Center Steglitz, The Free University of Berlin, Berlin (West), FR Germany 
First experiences with IFN treatment in mal~nant lymphomas in relapse after or resistant to chemotherapy have been 
rather discouraging, especially in non-Hodgkin's lymphomas (NHL) of high grade malignancy. Meanwhile, new IFN treatment 
approaches in NHl of iowor intermediate grade have proven to be us utmost benefit if applied in a low tumor burden stage. In this 
way 'maintenance' therapy with IFN after remission induction may be of advantage in improving the quality of response and, 
hopefully, in prolonging survival. A surprisingly high response rate (up to 70 %) was noted in a small group of patients who had 
received IFN as initial therapy. Based on the success of IFN-y in hair cell leukemia (Cll) in in vitro differentiation induction 
experiments, we conducted a study on early stage Cll patients with low leukemic load. All patients responded with a decrease of 
WBC and of cell marker identified lymphoma cells, but no complete eradication of the leukemia was possible. Enhancement of class 
II antigen expression on monocytes and improvment of serum immunoglobulin levels were noted in some patients. Whether IFN-y 
treatment will result in long-term beneficial effect in early stage CLL is now evaluated in larger study. 
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SUCCESSFUL THERAPY OF HISTIOCYTOSIS X WITH ETRETINATE AND ALPHA 2B INTERFERON. K.-H. Tiedemann, J. 
Bandmann and G, StOttgen; Dept. of Dermatology, University Medical Center Rudolf Virchow, The Free University of Berlin, Berl in 
(West), FR Germany 
The name histiocytoSiS x summarizes a group of several diseases with unknown etiology. The primary lesions are 
granulomas with histiocytic cells showing typical Langerhans cell granules. The appearance of histiocytoSis x shows a pattern of 
diseases varying from distinct granulomas like the eoSinophilic granuloma of the bones up to generalized diseases like Hand 
SchOller Christian's disease. Therapy includes X·ray therapy of loCalized lesions or cytostatic treatment of generalized diseases. We 
report about an 38 year old male patient suffering from Hand SchOller Christian's disease with diabetes insipidus, hepato- and 
splenomegaly and exuberant lesions of the intertrigineous skin regions. The diabetes inSipidus is treated by giving 
desmopressinacetate-spray. Different therapeutic regimens such as corticosteroids, azathioprine and etretinate alone failed in order 
to treat the systemic and the skin lesions. Combination of alpha 2b interferon 1 million IU given subculaneously 5 times a week 
combined with etretinate 0.6 mQl1<g led to normalization of the size of liver and spleen. The skin lesions improved. Up to now no 
serious Side-effects were seen. 
INTERRELATIONS OF BLOOD SERUM INTERFERON, COMPLEMENT SYSTEM AND IMMUNOREGULA TORY LINK OF T-
SYSTEM LYMPHOCYTES. L.P. Titov, LV. Korobko; Medical Institute, Minsk, USSR 
Interferon plays an important role in regulation of many immunological processes. Changes in interferon level are 
characteristic for pathological states which may have an impact on the values of the other links of the immune system. Interrelation 
of humoral, cell immunity values and interferon activity has been studied insuffICiently yet. 115 children, from 7 to 14 years old, have 
been studied for interferon level, common activity and components of clasSical (Cl ·CS) and alternative (B and D factors) of the 
complement system ways of activation, T-Iymphocyte content and regulatory subpopulations (Tmicro· and Ty-cells and their ratio). 
Children were divided into three groups as to interferon activity: I - low level · 2 IU, II - mean level · from 3 to 32 IU and III - high 
level · 32 IU. These groups had the same T-Iymphocte content, the quantity of Tmicro·cells in children of group II I was lower as 
compared to that of the children in group I (p < 0.05), difference in Ty-ceillevel was not significant. Tmicro/Ty ration value in group I 
was lower than in group III, Significant differences were found in complement system of children having different levels of interferon 
by the direction and depth of shifts. Common hemolytic activity of classic and alternative ways, activity of Band D factors were 
higher in the children 01 group Itt; C2, C3, C5 components were higher in the children of the first group, C41evel was essentially the 
same. Thus, the immune status in groups of children with different interferon activity in blood serum is characterized by the 
differences in complement system state, quantitative and functional parameters of T -system lymphocytes. 
T-ACTEMODULIN . AN INDUCTOR FOR INTERFERONS IN THE TREATMENT OF HERPES SIMPLEX VIRUS. M. Trashlieva-
Koilcheva, T. Varadinova, A. Kurparov. Z. Kemileva; Dep\. 01 Dermatology and Venereology, Pleven Medical Institute, Pleven, 
Bulgaria 
T·actemodulin is a product of calf thymus gland with molecular weight of 2,000 - 12,500 D. It closely resembles thymoSin 
fraction (Goldstein) by physico-chemical and biological properties. It stimulates the production of interferon in vitro and also 
suppresses the replication of herpes simplex virus. When it is included into the remedies lor topical application T-actemodulin-gel 
and T·actemodulin-cream forte, provokes analgetic, antiinflammatory and epithelizing effects. These remedies were applied to 111 
non-selected patients with herpes simplex virus infection with different localization and distribution. We achieved curing of the illness 
in 2 - 5 days in patients with primary manifestation. In 24 from 44 patients with herpes recidivans, inspected through 1 year, recidives 
interrupted completely. In 12 of them the attacks occured more rarely, but in 8 no effect was obscured. The good therapeutic result 
probably is due to the stimulating endogenous interferon production and the influence of T·actemodulin on the skin immune system. 
INTERFERONS IN SCLERODERMA: CLINICAL USE. A. Tulli, R. Capizzi, G. Petitti, M. Biele; Dept. of Dermatology, Catholic 
University Rome, Rome, Italy 
The relationship between fibroblasts and Iymphokine/monokine system has been investigated by many authors. As a 
matter of fact, this system seems to operate as a modulator of fibroblast proliferation and collagen synthesis. It is also well known the 
analogy between interferons and UM system, so that it is possible to discuss the modulating effect of interferons on collagen 
synthesis. Five patients affected by progressive systemic sclerosis have been treated with beta-interferon. After a full clinical and 
laboratory evaluation they received beta-interferon at the dosage of 1 x 106 IU i,m. every day for a period of 3 weeks. The cycle was 
repeated 4 times in a year. Authors report clinical and laboratory data before and after the treatment. Broncho·alveolar lavage (BAL) 
has been found the more suitable parameter to follow·up the effects of this treatment. 
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CLINICAL TRIAL OF HUIFN-B ON HERPES ZOSTER IN IMMUNOCOMPROMISED PATIENTS. K. Uyenol. H. Yasun02.J! 
Niimur~; 1 Dept. of Dermatology. The University of Tsukuba, School of Medicine, Tsukuba; 2Dept. of Dermatology, Kyoto 
Prefectural University of Medicine, Kyoto ; 3Dept. of Dermatology, The Jikei University School of MediCine, Tokyo, Japan 
To study the clinical efficacy of HuIFN-B against herpes zoster caused by herpes zoster virus infecbon in the 
immunocompromised patients, a double blind clinical trial was pertormed cooperatively in several hospitals. HuIFN-B (Toray 
Industries, Inc., Tokyo) was administered intravenously by drip infusion, twice a day for five days at a dose of 1 x 106 IU (MIU) for 
the treatment group and 0.2 MIU for the control group. Significanl difference of their efficacy rates was observed, 71 .8 % (27/34) for 
1.0 MIU group and 33.3 % (11/33) for 0.2 MIU group respectively (Po = 0.0236). Although suppression of exanthema, healing pain 
and etc. were observed in the 1 MIU group more than in the 0.2 MIU group (but not significant), the 1 MIU group represented highly 
significant efficacy against suppression of pan-exanthema. Their appearance rates of transaminase activity were not significantly 
different. Therefore, it is concluded that HuIFN-B has the highly clinical benefit against herpes zoster in immunocompromised 
patients. 
INTRALESIONAL INTERFERON ALFA-2B AS ADJUVANT THERAPY TO CARBON DIOXIDE LASER VAPORIZATION OF 
RECALCITRANT ANOGENITAL CONDYLOMATA ACUMINATA. J.C. Vance , Hennepin County Medical Cenler, Minneapolis, MN, 
and The University of Minnesota, Minneapolis, MN, USA 
Twenty five patienls with recalcitrant anogenital warts were treated with carbon dioxide laser vaporization, followed by a 
course of intralesional interferon (IFN) injections. The results were compared with 50 patients who had laser treatment alone. The 
IFN injeclions were begun on the day of laser treatment, and 5 million units were given three times weekly for three weeks, injecting 
the margins of the treated sites. There were two recurrences (18 %) and they were retreated. There were mild to moderate flu-like 
symptoms for the IFN and mild to severe pain from the laser treatment. There was a slight IFN-induced delay in healing of the laser 
treated sites. A marked reduction in recurrences was observed compared fo patients given laser treatment alone. Intralesional IFN 
injections used as an adjuvant to carbon dioxide laser vaporization, add significantly to the treatment of recalcitrant anogenital warts. 
INTERACTION OF INTERFERON WITH OTHER CYTOKINES. J. van Damme, Rega Institute, University of Leuven, Leuven, 
Belgium. 
Human interleukin-l (IL -1) is a monokine isolated in our laboratory by virtue of its antiviral effect on fibroblasts. We have 
been able to show that IL-l exerts this antiviral effect indirectly, Le. through induction of interteron-B (IFN·B) on the fibroblasts. Since 
IL-l is also a potent inducer of IFN-B2 (IL-6) it has been speculaled that this molecule could be the mediator of the antiviral effecl of 
IL -1 and tumor necrosis factor (TNF-ALPHA). However, IL -6 has no antiviral activity and antibody to it cannot abrogate the antiviral 
eflect ot IL-l or TNF-ALPHA, whereas antibody against bona fide IFN-B can. It must thus be concluded that IL-l and TNF-ALPHA 
aCI antivirally via induction of and in synergy with IFN-B. In contrast to its controversial antiviral effect, IL-6 is a potent growth factor 
for B-cell hybridoma and plasmocytoma cells (109 U/mg), is the major acute phase protein inducer and causes fever. IL-6, inducible 
in several cell types (fibroblasts, endothelial cells, monocytes, etc.) by IL-l, shares thus many biological functions with IL-l and can 
act synergistically with it. Furthermore, IL-l was found to induce a granulocyte chemotactic factor (GCP), discovered in our 
laboratory by its capacity to induce skin reaction and granulocytosis upon in vivo administration. GCP, originally isolated from 
monocytes is also produced by fibroblasts and endothelial cells. Since GCP has also chemotactic activity for lymphocytes, the 
molecule is now designated IL-8. In conclusion, interterons are produced in concert with other cytokines in response to infection, and 
interact in a cytokine network. 
IFN-TREATMENT OF HAIRY CELL LEUKEMIA AND SIGNIFICANCE OF ANTI-IFN·ANTIBODIES. P. von Wussow; Dept. of 
Immunology and Transfusion Medicine, Medical School of Hanover, Hanover, FR Germany 
Hairy cell leukemia can be effectively treated with IFN-ALPHA. In different clinical trials up to 80 - 90 % of the patients 
respond with a complete or partial response. The duration of the responses is long-lasting with a median length of more than three 
years. At the present time IFN-ALPHA therapy is the treatment of choice for this disease. Chronic myelogenic leukemia can be cured 
only by bone marrow transplantation. Hydroxyurea or busulphane are effective in the chronic phase of this disease, but do not 
prolong signifi-cantly the survival of the patients. IFN-ALPHA induces haematological remissions in 60 - 70 % of the patients when 
given at adequate doses (10 Mill IU daily). In contrast to the chemotherapeutic agents, IFN-ALPHA is also capable of reducing or 
even abrogating the presence of Philadelphia-chromosome positive cells in the bone marrow in a minority of CML patients. The 
influence of IFN-ALPHA on the survival remains to be established. More than 10 % of both hairy cell leukemia and chronic 
myelogenic leukemia patients develop specific antibodies to the recombinant IFN-ALPHA during rlFN therapy. Such antibody-
positive patients experience sequentially resistance to IFN and a relapse of their disease, if the anti·IFN-ALPHA titer is high enough. 
Further details of the anti-IFN-ALPHA-positive patients will be presented. The existing clinical data clearty demonstrate that patients 
during rIFN-AlPHA therapy could be monitored for rIFN-ALPHA antibodies. 
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INTRALESIONAL INTERFERON-ALPHA THERAPY IN ADVANCED MALIGNANT MELANOMA. P. von Wussow, B. Block, F, 
Hartmann, H. Deicher; Dept. of Dermatology, University of Hanover, Hanover, FR Germany 
Rfty-one evaluabte patients with histologically proven metastatic melanoma and at least one skin metastasis were treated 
intralesionally with interteron-alpha (IFN-ALPHA). Twenty-Six of the patients were given highly purified natural IFN-ALPHA 6 Mill. IU 
three times per week of recombinant IFN-ALPHA2b (rIFN-ALPHA2b). All patients were examined for systemic and local responses 
to this treatment. The systemic response consisted of nine objective remissions, each of which lasted from 2 to 18 or more montfls, 
There were 24 complete or partial local responses. Forty two of 51 patients had at least two skin metastases so that IFN-injected and 
noninjected tumor sites coutd be compared, The difference between systemic and local efficacy was highly significant statistically (p 
= 0,0004) . The results show tflat IFN-ALPHA has clinically observable antitumor activity in malignant melanoma, 
ANTIVIRAUIMMUNOMODULATOR R-837 INDUCES ALPHA INTERFERON IN MICE. C.E. Weeks and M.J. Reiter, 3M Riker, 3M 
Health Care, St. Paul, MN, USA 
R-837 (1-(2-methylpropyl)-IH-imidazo(4,5-c)quinolin-4 amine ; S·26308) is an effective antiviral agent in a guinea pig (gp) 
herpes simplex virus (HSV) model and in arbovirus infected mice. In gp, serum interteron (IFN) levels and mononuclear cells 2',5' 
oligoadenylates are elevated following ip, sc, po or topical R-837. To further understand mechanism(s) of action, we studied R-83Ts 
IFN induction profile in mice. R-837 was given po or ip at levels from 1 to 250 mg/kg. Serum was obtained (pooled, n=4) from 30 min 
to 24 hrs post dose. An active metabolite, S-26704, and an analog devoid of anti-HSV activity in gp were also studied as were the 
effects of multiple R-837 dcse regimens. Poly I:C (100 microg, ip) was used as a reference. IFN levels and type were determined by 
Lee Biomolecuar, San Diego, CA, Peak IFN level (2,000 - 3,000 U/ml) occurred 2 hrs following a single 30 mg/kg dose, Multiple 
doses caused hyporesponsiveness unless the doses were given 3-5 days apart. However, multiple fractionated dosing during day 1 
produced heightened IFN levels even at low R-837 doses. R-837 induced comparable IFN profiles in atflymic mice. S-26704 
provided an IFN profile similar to R-837 whereas the inactive analog did not induce IFN. R-837 induced exclusively alpha (ALPHA) 
interferon in mice. Since ALPHAIFN is an approved agent further comparative studies with R-837 are warranted. 
DIFFERENTIAL EFFECTS OF RECOMBINANT HUMAN INTERFERONS ON CULTURED HUMAN VASCULAR CELLS. B.J, 
Weimann and B. Takacs; F. Hoffmann-La Roche & Co. Ltd., Basle, Switzerland 
Effects of recombinant interterons (rIFN-ALPHA2a, rIFN-B, rIFN-y) on the morphology, proliferation, migration, as well as 
prostacyclin and protein synthesis of human vascular endotflelial (HEC) and smootfl muscle cells (HSMC) were studied. Untreated 
HEC formed monolayers, while HSMC grew in multilayers. The morphology of confluenf and growing HEC changed in the presence 
of rIFN-y. Cells became tflin and elongafed. The change in morphology was reversed after removal of rIFN-y. No effect was seen 
witfl rIFN-ALPHA2a and rIFN-B. Cell growth was dose-dependently inhibited by rIFN-y, but not by rIFN-ALPHA2a or rIFN-B. After 
removal, cell growth resumed. Migration of HEC into the wound was also dcse-dependently inhibited by rlFN-y (half-maximum effect 
at , -2 U/ml). No or only marginal effects were seen with rIFN-ALPHA2a or rIFN-B, Interterons did not induce the synthesis of 
prostacyclin. Secretion of proteins was altered after rlFN-y treatment. Proteins witfl molecular weights (Mw) of 110,000, 95,000 and 
4' ,000 were induced, while otflers witfl apparent Mw of 56,000 and 52,000 disappeared. The nature of these proteins is unknown. 
Chemical cross-linking of 32P-rIFN-y to its receptor and SDS-PAGE analysis of tfle resul ting complex revealed two radiolabeled 
polypeptides witfl Mwof 105,000 and 62,000. The binding of 32P-rIFN-y to these proteins was inhibited by an excess of unlabeled 
rIFN-y. In conclusion, the Iymphokine IFN-y seems to tightly regulate the migration and proliferation of HEC, The newly syntflesized 
proteins suggest a local differentiation of endotflelim exposed to factors of various immune responses. 
IMMUNOLOGICAL OBSERVATIONS DURING TREATMENT OF METASTATIC MALIGNANT MELANOMA WITH ALPHA-
INTERFERON AND INTERLEUKIN 2, H, Welters', U. Keilholz", B. Brado", V. Daniel ''', and W. Tilgen'; 'Dept. of Dermatology, 
"Dept. of Internal Medicine, and '''Inst. of Immunoiogy, University of Heidelberg, Heidelberg, FR Germany 
The treatment of metastatic malignant melanoma remains unsatisfactory. Also the immunotherapy with immunomodulatory 
agents alone have shown limited success. For alpha-interteron a response rate of 15 - 20 % is reported, For interleukin 2 of 25 - 35 
%. New therapeutic strategies include the combination of cytokines. We treated 8 patients with 10 Mill U/m Id interleukin 2 (r IL-2, 
Cetus) as continuous intravenous infusion. The lytic activity of PMC (peripheral blood mononuclear cellS) during tflerapy was 
determined by a 3H-thymidine release assay against various target cell lines (K562, an NK sensitive erytflroblastoma cell line, Daudi, 
and NK resistant Iymphoblastoid cell line, MML-l and SKMel-28 two melanoma cell lines). Parallel to the lytic activity we monitored 
subsets of PMC (T3, T4, T8, la, Ml and Leu' t - positive cells). We observed an increase in cytotOXiC activity against each target line 
during therapy, In the treatment-free interval the level of cytotoxic activity decreased, but exceeded the pretreatment value. With 
each consecutive treatment cycle, the cytotoxic activity showed an increase in excess of the previous level. There was an increase 
of T3 and T4 positive PMC, Other subsets showed no correlation to the observed cytotoxic activity determined by 3H-thymidine 
release assay. Thus our cytotoxicity assay may be a c1inicat relevant monitoring assay for response to immunotherapy with alpha-
interteron and interteukin 2. 
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TREATMENT OF A CASE WITH PERSISTENT EXTENSIVE FLAT WARTS WITH RECOMBINANT INTERFERON-BETA CREAM_ 
S. Weltlriend and R. Friedman-Bimbaum; Dept. 01 Dermatology, Rambam Medical Center, and Faculty of Medicine, Technion-Israel 
Institute of Technology, Haifa, Israel 
A sevenleen-year-old boy developed multiple flat warts at the age of eight. At that time he was tour years in remission from 
Hodgkin's lymphoma of the thymus. During the last eight years the warts became widespread, with innumerable Closely-set lesions 
in a mosaic-like fashion covering the entire surface of the face and, in somewhat milder extent, the extremities. Impairment of cell-
mediated immunity (CMI) was manifested by reduction 01 T -suppressor cells and in vitro tymphocytes response to 
phytohemoagglutinin (PHA), pokeweed mitogen (PWM) and Concanavalin A (Con A). T-helper cells, B-Iymphocytes and 
macrophages were within normal limits. Natural killer (NK) cell activity was normal as well. CO2 laser and other local therapies were 
ineffective. Therapy with Tab. ligason 1 mg/1<g body weight was followed by only a slight and temporary improvement. In view of 
successful studies on the effect of interferon on condylomata acuminata, the patient is now treated with recombinant interferon-beta 
cream 3 times a day. 
EPIDERMAL CALMODULIN (CAM) IN PSORIASIS_ U. Wollina. B. Knopf, R. Klinger. R. Wetzker; Depts. of Dermatology and 
Biochemistry, Faculty of Medicine, Friedrich Schiller University, Jena, GDR 
Because CaM is a mullilunctional Ca;+ receptor involved in cell cycle progression and thought to be a target 01 selected 
anti-psoriatics, we decided to investigate the possible role of CaM, the spreading and in the anthralin-induced regression of psoriatic 
lesions in vivo_ Skin biopsy specimens were taken from uninvolved, perilesional and lesional psoriasiS and from normal skin. Soluble 
epidermal proteins were prepared as described recenlly (Wollina et aI., Arch. Dermatol. Res. 281 :73-74, 1989). The CaM content 
was determined with an assay of Klinger et al. (Cell Calcium 1 :229-240, 1980) using CaM-depleted erythrocyte ghosts. Anthralin-
treated lesions were obtained during the first 3 weeks of treatment before the lesions had cleared. The samples were processed in 
the same manner as described above. The results expressed in microg CaM per mg soluble epidermal protein are shown below: 
Normal epidermis 
Uninvolved psoriasis 
Perilesional psoriasis (margin of ,cm) 
Psoriatic lesions (untreated) 
Psorialic lesions (anthralin-treated) 
CaM (Xt/-SD) 
1.15 +/- 0.25 
1.18 +/-0.12 
6.34 +/- 3.82 
2.04 +/- 0.69 
7.07 +/- 4.57 
Our findings suggest that the perilesional CaM increase is a prerequisite of the development of phenotypic pSOriasis. Moreover, the 
anthralin-induced regression is not due to CaM-inhibition. 
RECOMBINANT INTERFERON ALPHA-2A WITH AND WITHOUT ETRETINATE IN CUTANEOUS T-CELL LYMPHOMA. H. 
Zachariae and K. Thestrup-Pedersen, Dept. of Dermatology, Marselisborg Hospital, University of Aartlus, Aartlus, Denmark 
Eleven patients suffering from cutaneous T-cell lymphoma (mycosis fungoides) were treated with recombinant interferon 
alpha-2a in combination (seven patients) or alone. Two patients, one in combined treatment, went into clinical complete remission, 
while five experienced partial remission. Two patients progressed during therapy and two were non evaluable as they stopped 
treatment eany due to side-effects. Dosages of interferon were from 3 to 36 million units daily for 3 months and thereafter 3 times 
weekly. Etretinate was given 0.7 mg/1<g orally. The study shows that recombinant interferon alpha-2a in combination with etretinate 
or alone can induce remission of cutaneous T-cell lymphoma. 
ANTIPROLIFERATIVE EFFECTS OF VARIOUS CYTOKINES AND THEIR COMBINATIONS ON MELANOMA CELLS IN VITRO. 
Ch.C. Zouboulis, C. Garbe. S. KrOger, K. Krasagakis, K. Schroder, C.E. Orfanos; Dept. of Dermatology, Univ. Medical Center 
Steglitz, The Free University of Benin, Berlin (Wesl), FR Germany 
The purpose of this study was to investigate the antiproli-ferative activities as well as the long-term effects of several 
human interferons (IFNs) and of tumor necrosis factor-alpha (TNF), used as single substances and in combinations, on melanoma 
cells in vitro. Monolayer cultures of the human melanoma cell lines SKMel-28, STML-11 and StML-12 were treated with nIFN-alpha, 
rIFN-alpha-2a, nIFN-beta, rIFN-beta, rIFN-gamma, rTNF and their combinations for 72 hrs in the logarithmic phase of cell growth. 
The antiproliferalive activity was evaluated by cell counting anc by determination of the ratio 3H-thymidine uplakelmicrog DNA. 
Cytostasis was assessed calculating the ratio 3H-thymidine uptake/cell. Cytotoxicity was concluded by the difference between the 
antiproliferative and the cytostatic rates and was measured by the trypan blue-exclusion test. All IFNs tested induced a dose-
dependent inhibition of melanoma cell proliferation. The strongest anti proliferative effects were obtained by treatment with nlFN-beta 
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followed by rIFN·beta. IFNs mainly acted as cytostatic drugs. Additional cytotoxic activity was observed by nlFN·beta in all 
concentrations tested (1-1,000 IU/ml) and by all rlFNs in concentrations 100 IU/ml. rTNF induced a minimal dose·independent 
inhibition of melanoma cell proliferation (abcut 20%), being possibly cytotoxic. The antiproliferative effects of all IFNs tested were 
reversible a few days after drug removal. rlFN·alpha did not influence the cloning efficiency of the cell lines investigated, while all 
other IFNs tested decreased the cloning efficiency rates. Most IFN·combinations induced additive inhibitory effects on melanoma cell 
proliferation in low dose, while combined IFN·alpha and IFN·beta were less than additive. The combination of rTNF with all IFNs 
tested intensified the antiproliferative IFN·activity. In conclusion, the strong inhibitory effect of IFN·beta on human melanoma cell 
proliferation and its enhanced activity by other cytokines in vitro motivate for further exploring the use of IFN·beta in melanoma 
treatment. 
CORRELATION OF THE ANTI PROLIFERATIVE EFFECT OF THE TUMOR NECROSIS FACTOR·ALPHA AND THE PHENOTYPE 
OF MELANOMA CELLS IN VITRO. Ch.C. Zoubculis, K. Schroder, K. Krasagakis, S. KrUger, C. Garbe, C.E. Orfanos; Dept. 01 
Dermatology, Univ. Medical Center Stegl itz, The Free University of Berfin, Berfin (West), FR Germany 
The purpose of this study was to investigate whether the varying sensitivity of melanoma cells to human recombinant 
tumor necrosis factor·alpha (hrTNF·alpha) in vitro previously described correlates to their phenotype. The antiproliferative activity of 
10·10,000 U/ml hrTNF·alpha applied for 72 hrs was tested in monolayer culture systems of the cloned human melanoma cell lines 
SKMeI·28, StML·l1 , StML·12 an StML·14. Cell counting, assessment of the 3H·thymidine uptake and of the DNA·content, trypan 
blue dye-exclusion test and determination of the cloning efficiency after treatment were performed. The phenotype of the cell lines 
was evaluated by following parameters: the in vitro morphology, the population doubling time (PDT), the cloning efficiency (CE) and 
the expression of tissue specific antigens reported as markers of tumor progression in vivo. All experiments were performed in the 
logarithmic phase of cell proliferation. The resistant human melanoma cell lines StML·l1 and StML·12 as well as the slightly 
sensitive cell line SKMeI·28 (26.6 % inhibition by 1,000 Ulrnl hrTNF·alpha; cytotoxiC effect) revealed a high malignant phenotype 
(spindle orland dendritic cells, PDT 22.4 • 23.6 hrs, CE 56.2 • 72.9 %, expression of late markers of tumor progression). On the 
contrary, the sensitive cell line StML·14 (3rd subculture) (59.8 % inhibition by t ,ooo Ulml hrTNF·alpha; cytotoxic and cytostatic 
effects, influence on DNA synthesis) presented less malignant characteristics (epithelial·like cells, PDT 27.6 hrs, CE 18.1 %, 
expression of earty markers of tumor progression). As the cell line StML·14 was consequently subcultivated, a changed phenotype 
was obtained (25th subculture: spindle cells, PDT 20.3 hrs, CE 51 .0 %, expression of late markers of tumor progression); whereas, a 
significant lower sensitivity to hrTNF·alpha occurred (26.7% inhibition by t ,000 Ulml, cytotoxic but no cytostatic effect, no innuence 
on DNA synthesis). Our results evidence that the sensitivity of human melanoma cells to hrTNF·alpha in vitro possibly correlates to 
their malignant potential. 
SYSTEMIC RECOMBtNANT tNTERFERON·GAMMA (rIFN·GAMMA) FOR THE TREATMENT OF CONDYLOMATA ACUM INATA. 
Ch.C. Zoubcutis. R. Stadler, H. Ikenberg', C.E. Orfanos; Dept. of Dermatology, Univ. Medical Center Steglitz, The Free University of 
Bertin, Berlin (West); 'Dept. of Gynecology and Obstetrics, Albert·Ludwig UniverSity, Freiburg, FR Germany 
The efficacy and tolerance of rlFN-gamma were studied in an open pilot trial of 9 patients with resistant genital orland anal 
condytomata acuminata. The patients were men, aged 23-46 (32.7 +1· 7.0) with a disease duration of 5.5 • 58.0 months (20.5 +1· 
15.5) and were all Ireated previousiy with electrocautery orland podophyllin. The diagnosis was confirmed histologically. DNA· 
hybridization detected HPV I t in 5/6 patients; in 116 patient no virus· DNA was found. HPV 16 was not identified. No other venereal 
diseases or immunodeficiency were diagnosed. The patients were treated with 100 microg rlFN-gamma (specific activity 1.5 x 107 
U/mg protein; Bioferon, FRG) administered subcutaneously in the upper leg once daily for 2 treatment cycles of 7 consecutive days 
with a therapy free interval of 3 weeks. The efficacy of the treatment was evaluated by planimetry and volumetry after a standardized 
documentation of the lesions before each IFN cycle and 6 weeks after the 2nd cycle. One out of 9 patients with anal condylomata 
had significant reduction (SR) in lesion size (> 50%), while another one shewed no significant change (NC) and 7/9 patients 
presented a significant change and 719 patients presented a significant progression (SP) (100 % with genital and 67 % with anal 
condylomata) at the end of the Irial. No complete clearance was observed. SR, NC and SP were detected in t19, 5/9 and 319 patients 
correspondingly after the 1st cycte, as well as in 118, 318 and 418 patients correspondingly after the 2nd cycle of treatment. One 
patient did not follow the 2nd cycle due to a rapid progressicn. No serologic changes wre observed during and after therapy. Clinical 
side-effects were more frequent and severe during the tst cycle of treatment and consisted of local erythema (9/9), fatigue (4/9), 
headache (4/9). low fever (3/9). myalgia (219) and nausea (119). All patients wre consequently treated by electrocautery and were 
followed at least over 6 additional months. Three out of 9 patients (33 %) shewed recurrences 3 • 6 months after surgery. Our 
findings suggest that rlFN-gamma does not appear to exert any significant biological effect on the clinical course of condylomata 
acuminata, at least in the treatment schedule employed. 
